var title_f28_61_29648="Optic disc Frisen grade 4";
var content_f28_61_29648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade IV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 338px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFSAcIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxRHDd6mT1qkmDzU8cpU8msGj6CJYIznjFMkXKkZ5oLb1+VsH1p5rM2jqQQYDYNTptGAST71CykNnsanQAAHjFJm0ETKuR7U8rkHGcU1BjFTL2rJs6YkISQOc7dnb1zUqLhfU08rxxSKxJwcVLZfLYQg54py4I54pACDknNKR6VDZSQ4KCOetKBtX1NICDxTnXHRhikyhQwVuRVnIaOqoXOM9DVqPaQR0xUsqLIJVBA45pyAtwMgUZUNsHJz0qdPvnPFDNEjPv0AYE8npz3qvpzbJCa0b6IMA3UCqVvHtJPTnitIvQwnuaFs+4Mc/hSE7GyD1pturZOP0qSSP5sZB/Coe409BsZ/eLk8Hgmq+pxMHwD2qy7Krr1wDTbxw869SuPyprcN0c/Kjox7ADnjrVBxuYntXQXwHlMF/DisiGBsZYcH1reLuc9RdBsbeTbn3pA2/AHftUs6HbsAHHIqbTLTbIXk6fwinfqQk72J7WJlGOtX0QAjPApwURqOOTTVwXy1ZN3NVoOIz24FGwuwxwBTi+Xx2x6U5Cq/ebHrUF3GEA/KOnrTWQZ+fp61KXXtjFV5pBsyxwPWmkRJ2IHCxsckYpgcnjgj1qN3R2JAbAPWnAO3cAVrY55S1JAg6gmqc8oz61PJL5ShV5rPkk3ykBeDQkJy0JfMIGFFCqzH3pY1HG7pU4YIu7I21ZDG+SFXd3pgYoCWIIqO5uwgODnNZc1y7khaaVzOUkizd3CL93BPqKzpGZySc4p+D3ySafHC0mBirWhk7yKqqSc4qZZSvarYtQq+9Ne39OlO4cjRXa4Y1ExdjnmryW6d+cU/ylHIGaLoTizN8lyKTYy+1aRGB7VXdQ3Xii5PKMifjrzUuagaPFP3YGCKAJCc1EzgZoZ/lqsxMh9BQQ2JI+TgVCQT1qwsWBzSOuBx0qkZSVyttPvRUuPeincz5ToPKOcqce1Idw+8v5VbUL0I5oCg5pXO6KKauyHjoasC4wMnrUjRKRgDBqB4tvvUuzNY3HmcMcYOatW5DLgHn0qoiKRhqUxSRfMp4qGjeLaNSNMmpQMDGKoW12CQsnBrSQgjqCPWspJnTBroMPFNC85A5p5TJ4qPcFfa2Q3vUMtMev3cNTsYXNGPpil/h4P4VmzREIcb8HiopZMSgZ4HanSoWJIzUDv5hXIww4qkhSL0TZTmrkA3AMBkis213ZIPNacAZSO2aUkVAQwkOW4BpoJ6YPX0qe4JYcHn2qsjOrruU49KlGrZK6gJ168Gqioy53AcHjFW3+cHApzREkAHqOlNOxlJXC33cEEAVHcMWlXBwKfATt+YDI7U1V8yT0GKDMYc8E/lUMrjduI4HWpHbj6GoLvhB3qkgbsUpp1LE9O2KZGN5O0/L6monUl+eKsxRHAx3rWySMVJyZAse6XLZK1fjIGNqk46CkWEqCWGTT1XcwK8Ed6lu5aViQtkYHXvTFB35yQBUuCSMEcU0KWcg44qbjYm8KcgcnqaRnOMAHJpcjJI5Ip6Bh8/H1oFcqyZQfMx+lRrC8q75OI+wPepZFDOWlZQg556k1m3epsGIj4HSrim9jKclFal67ZQFCgBccCoPOymFwBWX5ztyScVKMhcDmtOWxz8/MyWQiRsK2R3zUgjRV4zu9TTIY/kJYYzTJmz900WG2PkkVRjNVHkeQkLnFSrHnO84NPCZJVOBTWhLuyg0RH3utIIGbAUflWnHbKSd3NWbe2GPlA4/OnzWEqd2ZttYFmBbOKutb7RtjHap5TsIUtj6VYhUBck1LlctRS0RneThDxyKg8rBOTmtCYkk4FU2Rh96i5DRGI9x4AGaa6hDgHJ9qUhyQM4oIGOlMVis+4n0FRupHWrLc9AKiZcuM9Kq5LQeUGGTUDxGri49aa4HShMlxuZ0iY60ijH0q1KgORVZlKnjNUYtWAnmmN04oJIPINH3s0yWM49BRRiimZ2OpCntxSquDyKkpQM9qi52qJGy9TQgG7n8qdjbxT414NS2bRRG9v5hynBqMFoztcVdQYHFEihh059ai5tFFB4S3zJ1p1vcvEQsmcVOUaNsjpSsqyLkjkCi5draotxyBlBBFNI86L5xz6g9KqxAxYDAipg6qPlP4Vm1YuMiqZJbZjvO6PsfSrcE6yLkEc0pKyIdwzWTPG9u5khOVz0pWUiruPob0WGXk4qlqEW0b07dQKrWupI/ysdrDrmtJWWZMcEVNnF3LU4zWhDp8m/acDcDjNbGAUHJwKxkCwTjK4U9MVu25VxkelKfc0g9CNgTH0KntSqu9AxBB9KdOjq+Qcqam2fuQVOCe9QirlMPsJPqO9NaU7QCfm/pVoQeZy3I/nUFxEEBYDKVRLIgnmjceSvccVZhBQcDORzVSBz93t6VZgkVW2n7386bMrjUiImAIOCaLqDLfdUIT1q6FEdwgY5LZ2j1pJl81kRcqM5z/AEoT1FujnLuDDnAqS2bcAO44rQv4P3pK9CaoRxmOYZHfpWt7oxtyyJipwcHg1LHGOeenrUp6gnpThwpbb6496ybNiIJlsAcjtTJAcAAfMeKuRQl23ElTjNRtGcsp6jqaLiKSxsZNijNOlwFJY4UdSP5VbmQrFuU7WAwce9ZGoyiNPIQ5J5Jq4+8RJ2VzN1C6MrnaMD0qnHEznp2qcR73AUc1c8ryhjDMT2Fb35VZHJZzd2U44yAcgcdhUkSguvH1qWRFX5R171PHEGiYZ+c/pU3NFAGeLaFBHIxyagit0BLM3OelXfs6EgIi8DrjrUkNsxfHPHtSuPlK6W+4fwhB+dWIrNSMgZFWI7dZJcMQqjr71pqYo4QkYAx1JpOQramSsGD8wwPTFPKokJCKSx7+lSySL5oywB7DuaWScIMKBk1Ny1Ez57fAywGc9aZEnynceKlnYyMcg5NQmBywLMRx0qkyZRHuy4ODjFVZ9zDC1ZCD0JI707A28DFO4uQzlhA5Y59TSMOMDpVzyiQxJ4quQufancXIVGG0HkYpmBjrzU0ygsADwe9RsmOnNNGbQxcA0hPPFB/lTSeKozZHJ1zUR5PNSSbifambeKoyZXnHHvTVxt5p04OKYgGOaoyYm0e9FOopk2Ot7YNKo9KVlxznikBxgjketZM9BIVkyPenIMLThk9eRQoAqGzeKFAqQJkdKcqAgEdamEe2ocjRQZV2HncOKj8vZ8w6Vb7nI4pGIyRjilcaIFUOPmNVbmNouVGVrQZR1WmFQ4IzzQmU4mdFdKOvB96LnbIm4Dn2qW508EgocNVUwTQPg9P0ppK90K72ZkXKlXz+tXNK1Axvsc5X3qxJb7wQVFZF3EYXxyCK1VpKzOSfNTfMjpJbtSwDcqf0q/YXShMEjOa5KC43x7W5I71dt5emc4NQ6fQ6Kdfm1O7Qq44I4FK4VIwcHb04rM0uf5OF3OR271fBO47RwTkhuoNczVmdidy0gUREkjgZqndcxZH3W5BxUwLBsAYIqVw0loQwwB39aEwMKMlH6BuamgVnkDAbj1oZQFG5CcHgjvU1oPnDHO6rbM7Fz5FjD7fnzj6VOQuUVfvd/wCtJDFuwO+4HJHWrSqA8hIXPQZqLgkQTQx+QwjcGRiW47VgXFu4cls8CugKEQkg8/zNUtSiZoiBggKCTWkGROOhSt0a6aNEUnaME561cS2DTlVXheP8adpEflIw/jcYBHYVfjjKKzg/J09zUy0Y4q6KEvy/dG4nqM9qjlGQWQHYvUelaLw4XcVzkcYqGRV8iNmUrn7w7VKG0Ubv/UlkONqcD1NcvOGSUncM55zzWzqk6mYJGflAxxWaqLLdCPGV9P61vDRXMKiu7Dra2Uw+ZJjLcBT1qdYto2sDuxnr2q7IsECKqYZv7w5xTDFuORz3Jo5hqFkZZhG4tt49f8KVBs46DNX3TLE5FRbMMcjp607kBC5VuuM+1XYnQKeTmqAUluOakDGJST93vSaHckeUId3Bwaa90zn5AKpO5kRimevenxW8rgBCQOrHv9KLC3HxZkl3Pw/r61YaIgbj8xP6VYgiRFUYyT7dKnVCoIICr796mTNYxKBVgQxHTpmgLwTjJParsgVyPKUn1PpUG1RMQTgetTcvlK4iHVjgk0kgVUJP3qklVVbrxUTqOrcAU7icSqzMXUEDb3NQOuWOeFq1IQRwDVdzx17VSZlJWKbqQcjvUcmQM5qd8kcdKicBgfQVojCSICOKTBNSYBpCMA8VaZi0QtTNvp1qRsEUwnqRwapGMircIcEfnVfcRwa0HTcCc1RnXnIqkYyE3CioMn3op2I5juQQRgZPrRnAwBTygJ44J7ik2MuCOlY3PW5QRu3NPU0gwfY08R4PHWoZpEmiJ7CrAckbW6VXjyo5qdGB4rKR0R2BkA5pGU5HAIqcIe/60OuVGOD7VFzTkKuVQ02VCRlQM1O0Z46H2qK7jCjMRKt6dqaZLViL73XrS4wOefY0kQZ0yy4bv70rgAfjVEsrSRgklVwO4rN1K1WSLOOR0rZVTk4/OoZ4gwII61cZWZhKPMrM40q0T56VpWnzgc0l7blZGBFPs12ttwM1u3dHLTi4SsbulF4mUqcAH9K6QoGKyL6c1zVoGDjGA45GehrpbV8oGxweorlqHowdizEyqwD9uvvUmN0YBOUbPP8ASq6t+/wYyGXv61u6bGhALAFCeQayehqjnri2YMc5Crz0qazgRWUt93GRiugltPMSeVYwse7jJzx61XSzZ5ZGjwUUAnjpRcZTEWWTymCsOS3XHtT5EUkAtnGckj1rYSxVZBnb90j05qvLZDzo3IIIBDD19KVw0MiUCEFWBwxBHtVK6O1SMHHbHet25gVvLb5emMH+Gsq6T95sPQYBNXF6ilG6IbP5Uyc59QK0QQAhWPL4+X2z1qC3G2HYvMjE8dgK0IomS1kZiNykYLd6UnqEY2RC5e3tzKFDgfKR3z6iqF4zLACGwgB+UnvWlcSBSBwAR39a5/UroPJtRQy9D7miKuEtEYlwVXLuvXoaZp7qyPIqjeeATViVPMZQQCO4ot4B5zRRKNvUHsRW99DGK1uSSRs3EIy4HI7VetoH8hdygOeD71Y0y1jj3B/vHg5NWpYcMipgkHI9qzcug2ijcW4dMBAgxyx5JNUzZNHEHkP3ugzWrcq8rhMkjHODgCqk8aqipuZgvvQmZOJRWNWlK9Mnp6U64tCHIyCRyO+KkTIBGcsDyKHnbJXHyHqB1p3EkVooArbgQT2FXbddrfMMH1qsOfuqcepNPTduDBj/AI0maRiXhtUM3ftVR3w4MnIJ5FB3BtzDr2NKUDZ5A44HrU3NorQfJcqgKphQRVK5cbvlB+gqQxZGWyQOuagMhGc/dppA9CMnKjI5qB5lIxjOKkmJkBCYUVX2FXBHT3qrGbZIGyORgVWnBUHaOKnd/wC9Ue4F8HoaaM5FQgkcnFRsBjg59atShcnHeoccHmtEzCRXEec880EHHJp7EKBjrTV5bmrRjJohdODUMgwtWpZIVzliT6Cs+eVTwM1aOebQ1pwvHUVHLMrDAVc1BIRnio8Zq7HPKQ7NFNxRVGep3oGDUnX6VAkgP/16eK5We6mP2Angc09VdCMDIpFycGrKZAOahs0jG4gkDcEYqWII+AaSNVcYxk0/ydvK9qhs2SJdsmAB8yjpTgoxyKjXdjKdadGZN5D/ADelZM1iNdDv64+tRSOxwGAx9KtZ3HDdO2ahkhZlPaheYSiUy5jOR09KRmRlzjk85p8ts+3nv0NVlMiNtcbl9a0Ri0TJJGOAcjvRKo6g5X1piLh/unHripkOOMZU96ZLRiarGUkVucHiiC2WVVI4f+dblxaJOmw4Knn6VWt7B9+zcN38Oa0U9DLk1J9NjGSroDjkH0rdEPyAoTgdRWPEjxP864kXqa2rN9znrk4PWsZm0US26AklgA3Q49a17WQ+YI9uARh6pmDnzB8uOfXirkbA7cDtn/eFZt3N0tC3MGjXahAGPmA7imQMFSR0GQV6Z7+lPm4XOcgjAIqvayZtPM+6ndT1XFSWo6FySZZpojtzlsnjgcUSnddyxjI2gMD6ioG8yAH+IjDfgeafNmS4icHhk6imPlKpRYpZQSSBhiTWbdy+bMx2YyuOa15YG3PGmCWxnd3FUha+XklTt+6C1OISRDZQIsfmEkkc7quGQORJJubP3V7CqrRtHbIMFSW5A704ytESWII6D2FEmJLQLmBZS0dwQIicvg1z1y1shYJFgZODWxJdyOH3KDngZ71i3qMjKrEYY9RV0yJopwBZJEMvEZbGOhq9ZR/vt6gqDxuAzgdhVy2sB5aBgPl5BNXLJIftRt5QYx2IHWqchKNkSJBFEsSMu5jyxI6io5bdGctB8iA9QeWrSlfzNscC7AON4GTUU8XkpHEfmZerYrO5DMcQBD82GbHBOSRVWSJ/LJJwucfStK4BaQBEAA6mkVFwQ539wKq5DVzFlTLl1G3sB61XZdpJ7j8q1Z0HzdN2evYD0qkFycn5l6YqkyLECzbMY6dT70JP+8YrSX5XeNuMAdulUlduoIz2p2uUnYvZedsFj6nPYVLAEJIVgzCqUTM2Cw49OlWo3RT8o+tS0aRdySbcfpVRsEYNWWYAFjkk9Kqg4JzxmkhyIAACx5/Goww5zjPvUjgbvWq8p98dsCrRhJ2FyM5xmoi3LHAoL54zxTGIJwapIycgcsenSmMoK08YyBnFNcgDcTwKszZAcFwAKCq5OadMB1UfSm7sAGqMZIryQqcgCqs0XoK0SxwdqjNV5mOORj2FWmYSRkvGA1RMNuauSDmq8grRHPJEWKKb+NFUZ3O424HIp6NkelOAyOKVQAa5Wz3UtSWIkDB6e9WFK+vPpVcDjg1Ls44HPrWbOiJMq8/KcGnGTjkZNRcnoenpUsbqQVZcVmzRIlUIVJB+b0FNjAVzyeeetAj28jrTipVc4yMVBoich87uDjofShPLbAJIbvUCysgHcU9QrsMNyevtUgEgmV+mVx2qJUUsd69P0qeT7vJzj8xVdkZs+ueD61SM5aETgBjg/L6GoiMZIzg9s1IyEOeOaniiyp3DB9/SruZkUWOPn2n6Vat4AJkfJYHOCaaLdGTAI35ypNW4VDAKG2kHjPQ0Ai4sSyKC45+6xPp6002XOY/mxwccECp4yJECkBTjB96uxKPlVWw/Y+1Q5WNYorQzyKihxvRThsenvVtCgGxWCY5Un0qU2i4Zt249Wx3H0qBrZ4WDE7oiOSOQRU6M3iieEsI2QkvIPmUH+L6VW3BQ5QNiTlkPY+lEUpjUJgHB455I9qTcJZwNhx6ehpWNELK0glbe2VIGOfap4yIokVWICn5Qf5VbGnxyQJLO4iUDDIPvEd6zrhkhPyBtinoepHY0DVmWo5GfUlMbYKKd2Rnr0q3dGKJFMjF8nnisiK6MJII+VjncO/1qK9uWkjL7sAdF9aaMqkSTUpVaRHhyUcYIPas0XIkiAbI7HPeqM2JJhIzNnGAM9KbF5kkgwRnBxnvWnKTGWlix5hlZFAyvY+lXbOzFxOFP3W7020ttsY8zAH581oRSmMERBA3QOegpOVtg5Lu5G9jHGZQHZhnGWblabbxRk/vHZmyQH9qnkDSyxsoEgVTv44NWLe2aER4fBYhtrCouU0KE2KqbSvP3ieg/xqOZJJcjGyMHoO/41cuDiTEZB9+5NV595jIIJJ6en50GTRnzN5SMpKrz06k/jVGSZI8k9OxzVqZ1RSgjZnB7cjpUMCoy4ZcMw3AAcirM3Eqj5mJmTp0GetUwWklOMDHp6VPcP5kjfJhemQf51RuGGMqQAB2FNGb0EvxC4+UMv+znrVFRgnpgc1K7MSC3XHSqrscfKP1rRdiLkvmEsAORU8QUld7Y9hVASfMu3k/Tir8YBGAcY5NJqxpFkrOM8DAqOXEp9qmj8sxkkZOehqtdTKrYiBz6CpRTZGU2556djUORg+lMuGm6gAZ7GofNYABsA1okzCTFcbW5FMcDqBUjAsATUYB6YzVIxYhIx05pvH40rYDY6UmRimIa/OBUZb5eRzSyNxgdaYzCqRlIYXBGDmopSoToc+9Oc4HGM1BK5zyK0RzSZExHXJFV5Bk/Spzg9ajOM1aMWQeVRU2feindk2R2CcjmnAVXR84ycc1OpIPSuVo9uLJ0I4BqdcEYzxVYN3ABqQHjnOKhm8dSdQFJwcilG0t6U1Sp5HSlZuhxyeKzZexYR1DAHP8ASnujAYHQ9apDeCOlWFkY9M1DRSkI2I3VSTlugqSNCTkY/OondlIBycd8VNEsbr8rnNDBSFkUn7xBH8qgK4cAZHtmrDK4OCy496jkzsxgE9iDQiZEeN+47TwKkRm4LBqZGpViR+IzUsZO7LAjH45qjImi2u+GTBHQ9M1aSNQVAOwZyc802Al9wY8ew6VeFu7lcAFM9SKVy4oY8RJUqy8+lWYIHK88N6dafFAclJICqjkMp/nWjDbAsGhlA45DCobOiJFatg7jgnHfuKcq7lkZc7AcgA8GnTYMZil7elSWWyNPm4Q8YHapN0upHbWoMrM8anPzqc4/Cp0to1MszEZ4ceg9qYreWjxHA4+Rqqm58xDGSAQMHPtRcdrks8mI2B+Yjleece9Z8kbyHlgD1A/pTvNJCnbubaB1xmpoIlfGXIDfoadyrWMohhEVJLHJOMdvSoDkMEUN9Wrp5dL3sjhhx93I6+1Zt3YlXLyZGDxgU0zOVpaGP9nErA5PB5461btLVornzAm9AoBFW7Wz86JSX6859KtW0biDaSuRn8eaHIaikiKdfPIEQIGc5xjI9KBECWERVc9fSrOCIwAD8voemahdyuMR4brn1qbjLFkfsxMZBHHU0t5MwZckEjuOwNTQFDCzTxs5bgAnnNQ3xhiViwDYHKZxj0oItdiSLvUFPlb1NRmaB4XhikCydM+v4VUk+1sfMdSsIHT0BpHCIQgjLE9h2+tUkQ0DGOH7uQ3Q555qrc3EhQtlEQDg9CadPiAZZdg9QcmqT7XyRuYY6tzVJXMpFK5mChumW7Kc1TVfOjJUoCp5yepqxJaNJKZAMJ0yev0HpTxbCIY25x69KvRGErmTOWaRhkYzxioXToe9XroEMTt9gBVRwUBzVozY3aUUZwM+lOEgIAY8VCRu5zilBj3fMw4HWhjRYeZRH8nWmRoygMxGTzToghXpUdxKVG1Rk9qXkjR7D3CfxE1WuIxIAUwG96iVZXc7i2PSnrA6g8jntVJWMpO5GGbsMmmkTE8rxVtF2KelCtuHIqrmdig0Dkk7qZ5bqeTVyZgH6YAqu7KGPNUiGiBlIbrTCalkKkdearnjIzVIwmMl7VE/3eakY5qNxmtEc8iButRsPyqTFMPpVGLDP0/KikwaKBHURvgdOalVs1XRwy+tSKeawZ60WWox71Mqn8KhjqcZPArKR201oPiOCRTnpilkOe1SbgyEsOfWs2aWurCOrEZ3CljdlcZNVzu/vCoppXjXPBoSuQ9C8ZA+SxIqVDGFLIxz6GsU6gEGGwRSw6lCTgsRk0+RkcyNvzEdSclm9KYEfOV6/wB01BFIj/dYGlZwrE7sH6VKRb1LCA7sjAPsKsFm4CbeDzkVBCGkIOBj1HWrioTyCzUmJIfA21gTkAdeK24Zi6EEcAeuKyINqSDeBx61uW8yY5TAHOQamRcUOUu0JG9hnocg4qeOEGPDZEhGCwOKZbhJVQsAr9cK2QDSmON5WdiwI9T0qDeI90XOJGJAHU85+lQxsIrvy3fMMntwaY5WJB5kx8vOMEZIqa58qeFFjcFscDGNtI2SC6ARTzyvQntVUtuOJI8nHPGAack6vE0Erjzk9e9JlzFukXGenfigtFaZliDMqkRd8dqntpPKnXPK+o75qs0q42HOG4z/AEpkYO3YxICnHuRTGdIt8UiRZFByOw6CtRoo72ILHtyBnpzXL25duHJCV02hEG1ZS+7OcZ7Umjmqrl1Rzd5G9l5gjbaFywXGcH/CoFdmVAjHnnPTPvV/VEdZ8kMCTwD6VRAeORmVAY8d6ZpGV0XrIGVzEmWZuPan3tobfCnJ+YYIPWorWYwkMMcdKlSOeZnlZigPCgjOKQdRkhiTDMSCOODzWdcRXE8xZEDbjgHH86vGJHkJB+YcA+hq8lqxcSSYwOQi8Ae+KaYtjO+w3oTEwzj5fvYFNmsLmGPzA4RcckdWroPMjdiWdN0Z4Gc4ptzMkieWvBbocZoUvIzcmcpN5cW5WV3V+rN/jVGVfl2QDapHUDiumvdPiMQ3FOeg65rDltg6AA+WckbfpVpkNJmSFkYrvIVAOPemXEZkQBJCSO46VptbndlmBAHQ1Ru1BDCIjjriqRnJGTINoD5Zqp3DZOTx6CrMoIByM+1VZMkdK1RzyKkjnBwaprKxl2hd2atS/K2WHU0BDztABrS9iLNly33CIFgPoD0qZSmRkjNV4lO0etTLEOcdayZomxxw0mFpGzkhh0oANKqk5BzTQncibGeOlReW2ScipWG1qjc56cGqRmypcRMxOTiqZTa2Oa0HPXJqtIuSatGMyv5XpTZMgDAFT4GOlMkGeKtHNIqMSDTWPPtTmqJqsxYj+1Qk9ae/Tg0xuhqjNjc0UnNFMi7OjEWM4OKUSNGfmBNWAOM4owGGGHOKwbPXSLVs6uMg5NWFz2ODWUmYpCYz06itCOYOnHBrGSOynLQnfscg0IT3qNQTkGn/AHT+FZs0T1JsLjBX5vXFRXBhTb5ifeOOBS+dxtTrUsduWAL5JqdtzRq60KrWkRY7VUg1BJZQq2NgU1pNAMnHFRSQvk45AqlLzIdPyIlgjU4X9Kco3uAMkD1qPypmcgfKOlXYbdYsl2GcUNiSFiYo5AIHHBNW0uDgLvDP3FUmC8lScn8qamWbgDNK1wbsa8bFvrVyBmjGSU2+prLhMq8sg/CrsELTEfMV5yMjApNFRZfE0rEeWxjUc7gP5VKGnfc8bbnPrj9KW2te0sgcY9eauQxQKcBRuxx2IrN2Nk+xSSJ3J3yKHYZOaU2rr85fgHnaM5FaIiKEsoUseOajaQ+cIwgBxnjpSbNosyXtWVyNw59ajmubmJQoG5QOnWtC6U/xAg+lQuCD0wcdKLmiMx7kt9+IjPWpY7mLy1Ur8xHU+taioV6orE9Ce1NkNlHEftAXcOwHei6C4R3KGJjGRwMZptprAj43d8ZB6Vzl9fRIHFtuXDcn1FZsMk9zcKIgSc1pGFzCpJbHo7E3SI+7LKM/N3+lRSqwjPQE8HJ7VW00yRwpHIN8m3Bx1FXV3AYIDKvqORWbVhRHrGkAXC5PoD0pzTS+WFQRhT1JbmoJZVCHbGCQM4PenLI5iAdAh7qBip1LSLEAi8wFtxPUuD+lXme3YERKyZ53buv1NY0m5lY4Y8cAHrSqQzBZPnIGdo5xSuDhfU0mmjKFY1j3P1PTFZ+0PM6xPu5wcfrUUsiq/wAm1I+M560CRnj8yGMyEDaNhxQhNWQt0JIlZSxkjAzgdVNY8Uv2m0DFwwyRg8YNaqQzjdvI2N2z0qFIpGiaS1tWe3jba7qnyhj0GelaIybsUGVQcMXUdwVzn6GmXGwEiP5QOyrVmRn25dwT/dFU3lDsV5IHf0qjKRh3PEjcMAT3qlIrHIAOK27mOI8bgeKypV+b73HTrWkWYNFGSA8Hqaa/y4J4q60ecY4FJJHGy7XGarmBIpJIhwFcEe1WI8g7QTg0gsosZj+Ue1RvFLGQQdwo9BpFkAZAHJpGHHWq4nx1Uj607zUc8tzQkxNkjYxioHUdeMUrbezcVHK6hOTVIxkyCXmoGBGfale5QfdGaqyTsx4FapHLNjz1+tI+B1OKrlXJzk4ppjbHJNWkYNjnKgEiq7MoodGB9qa0JPWrRkyKSQDpUBYnNWGj64GTUZGKpGUmRYailOc9TRTIudiSDwDxUibcdKrmJj0p6q6g8muZnuRRaAHtzTHj24KfeFRK7L2/OpUnBHNZs3QpuxEFMwIycD61KZS5wF5qNirYDqDjkZqaJ1qWkVG9xYo5FZXUbueSe1Xw8m0c8elV43XPBIq1GNw6jNZSN4aCEyuOmaUbh1xSjcpyP0pr5PQ4qTbQUpGTkZ3etCKMbmbp2pqgjg9aRpCPvU0ZyViRj/dYEY5qJf8AWZR8HHQCmSOj4AVj3zikikI5GR9atIxlqaERkJHUnv2rWt1k2hWUY65PNY0O51BJBbOOK1IBOsR2TE57AVLRcEaKzKhyzjbnH41cM6yYOeB3PFZUYjBUNGA3+11qwADHwxAP61DRskWGkPlbZCZhu+UtwRUYuWAZQGHtilhkBkCovCn5i3AqaWVHyEUkZz1zU2NVoVDMxBbD7v8AdqvLcSH5R177hirU77SA+VrOucu5KdOlCRfMkVbxrlFLQyHfnO1azBJLeSMkJcyE/MW4rYjSeUbYhle59KdIbeNRGseHB5x3NaK0QScmR2OgQJG0t7IZQOW2nCr7Z71VutUt7RttnbpGBxkdTReai7o0CHbGvbPescWj3UyhBkmrjruZVLrSJ02h6g9zdpg7D3IrqZP3swyOQOveuR0eBrCdC64x1JrpRfIH3Q9emaxqtN6BCEkrsn+zhucONvU5qO5RwP3cmSBwD3/GlN006gHqR0PemxmQNgjAz35rFmmvUzI9SRbkJceajdPn+6Kv4dgCkmFPPy9DUpto9RY24tZJ5VBY7EJYYGSeOwFVNF0fUNR1D7LoCz3L/wAUYXIUepPQD3NOzlsNzik3J2sOkEqYKKXBODtrU0LStS1e7Ftp1rLNIPvbFIVf949B+Nb40bRfDCmTxRfjUb9f+Yfp54B/6aSdvcDB+tZOq/EC+vITZ2cMWnaWcgWtqCoI/wBphy3v6+lbKmo/G/kcUq8qulFad3t8ur/LzNmbRPDnh0btduxqd+pz9gs5MID6SSf0HP1rB8SeMb/WLEWkcMVlpKN8tnbR7U46Enqf5e1YcN025ljjIUcrjn8KhurmYE8Mecc1XO9o6Iz9gk1Ko+Z+fT0XT8/MpzJEV3g5PtWexAyQzAVbuMAkOM+mKz7hkVT3WkimOk+dDkjgdqzJVwDuBFTNcGQHacDpTJCxXDN+FWlYzIQcnrxQWG0ginKvtxT2UAg5H1obKSGYIGCKaD+VK8qshPHB5prOrYwKLg4kbYJOVyPWqksIyCDirUjc8VXfLNx0960i2Yz0K5t367v1qJrd+MtkVcYnJA6CoZpMD1q02YSZUMSK2DyaRgAMYFPZskngConPvVo5ZMGXcOoFJtQDLZb05wKZz1HSkLZHSrRi2Ml55RQv0qCQnpmpScMc8VDIVx8pyapGTZA2QTiomOae7Ef1qMn86tGLY2ikyPSimRc7YEinAHPNN27e9Oycda5GfRIVsenNR4GcYFLgsalRAPvCpZSHRoCoBqRYFOSOtMUY428VNFwcGs2zaI37Pk8NjFSJCyMPmpXYIM5+tKkm4dOO1TqUmkXIZFAw1WHhQruCkE96ox7iOhNPNw6fJ+hqbGnMOMbZZQOPWqc0TwjzJG3L9Oa0IrjfGAwANV7ydnVcKMdKa3Jk7lJWLsMkpx0qRBhwOSevNIFGSc5qzDKI23MBnpu9KszbLtpvUqQDuPQYrWiyV3bwGPXJ/lVCwkQFvk37hgknH61ZmIAVgsUYXoqtkmpZUWTBdzKGkwuevqamiCRthSWkbjLHpVAXAKhlJ8zpk9qfG8kh5I+bgYHSlys1Ui3PJJHJGiFG5+YZ6DuaBdKskmBz2x2+tVtvkzKCDIe4qsEk8+RFUrk9zS5UaKXYuiQszFiWJGTUsNuSC7jbGemaLeJYiA43NxyDU9/LstnkIMjDgKO9S30RaXcrzTCJCsZCgenpWLfTeS7ugIZhjdjkitK4PzLuQjI+6exrE1q5mbblQoX7oJ6U4K7LlKyuVo2WSbGOW5wRzXVaRZpDBvcDzG6e1cxoSM7hgglmBzknAFdSHDL8xw3Tk4Ap1NNCYO6uTz48va249wD0zTbZo5EEb5XHPTrUMhGAUYkgYNQxzqjDfwO5rOxobJt0f5OcbcZFa/hvRLvWLuKxs1aSU8l26KvqT2rmEu48AQyMAevORW3p3i3VNJtDbWNyLaNz8zRAK7/VsZ/XilFK/vbGVZVOV+ztfzPoDwn4Y07wpp7EtG1zIB59zJgZ9hnovt+deYfEHWntLyXR9Cu7S10jAZV04hfMJHIdlPXOcj0xmuGm1ObUJN13czTTsMBpJC7A/jVeON44xHJI0ynqxFb1K/NHkgrI8zDZa6dV1q0+Zvy0/pdCMwyeYsbEbXyAw6g06G3ltztJDAd8U5gDCGfiMco/Rh70+SWWW3AnO2T+FuhI9/esFc9KbKV3I+CscgU88jtVZ5WKgFsjGP8A69TPHGWIeIhm6iq8sYRcRkEDgc1aMJMo3ML/AHlfOB1rJud7t8/BrXk3AYJbiqk4BXLAE1adjGRllWVuDyKlj2sMEnPenNgZ4+nrTJQVUOoxjrVN3BIfHw2AOvSmXKNuCkflUX2jewEQJx3qfYxIMh+Y/wAqnYoqyIo5HBFRFmXOPmFWbpPLOCDiqh46VS1M5uwjSHGSKga4GeQc0SEqTz1qLPNapHNOY43Gfeoy3GPWlkAYH2qBWI471aRzykS44PSomxnk04ncOTzTG2jnAJ+tUjGTInYZ4phGc84p+U/55jr61HI+MhatGDYyQDj5j+IqB1IPHNT5/vcVFIfeqRDK7hvwqFmJ4xVhzwcVXbk1SM5DM/WijP1oqiDtjIGHekVweBn8aOR1FJj5uK5D6C5MuODT1b0qIDtT1OD0qGjRMlU571KpHPeq7MB3AqNryNB1FRa5akkWiQeDxSpIijrWLcXpYkxjpVdTcXDYGcHpVqn3IlV10N641VIwAWwB2FV01YSyBY0ZiapRaS7czSYz2HNa9nYxW/8Aqkyw7mk1CI4uo32LUM7BeU59KbI5ZyWIIPYdqnC4wWBz6U1l+Us4AHTFZG9tCsCAcE9OlLHMI2JIHB700lCTnHtiqw+Z+Oa0SMpM011ARE7Bncc8DpSLLNLLwMbuuaWytQxBl5HpW7a23Tau7noOtJyURxi3uULaCbsp45PvWpbxKCS7EMP4akaFopSBu5+8R6Uy3jALMHP0PYVm53N4wSHwSqjnGNxOCeppZIi0p28ZHJPJpggAYyKu5u2B+taCZaTLoEAXnHSpNr2IikawFcM20/kfrTG83hmYAnpgcCtCKJ2RP4Y/vDI6VDJbIyvcMwcHO0k1IKZgakQrS+YWPBJIrHkQSQF3ViPTPeuh1O3Khcpu3dMd6pCJYrTaFOD13HvWkdNRuVw8O6eEtjI3BbnI65q1PGv2hgmGQHqecmrWn2Yithl2VGG5h7+1Sy24iZQAQgHJA61Mnd3LXuqxnOhAzHlDnHyccfSiRAVBIPPWrTIXiLsoUZyM9cdqfcxBSnl4bcOQexqR3ILBArNk5HUVbj2STjptCchh0qkuY22KV4HPpU67ZEjO35t2Oe1JrqO5Yks4ZHUqdrryGWpUeVsRzSs8i9AwAzUqRBW+f5fcdaklZM7G2iQfdYjrSRk5kdpa+a8izSfMRjBGPyqO9SSMFCAUA7HmpV8u5eFbjcPLbcCtR6uYyxycr2I9feqMXJtmbI/m4V2KkdBVK4keJ8MVOO4q03IAmA3Z4x6VRuoTj73A6GrREmRtcYYBuc96YZUdTj5h7jpVaVNmSeh6+1VhIynbkgdR71ViLlkhRJnaM+majdd2emaVJVdSr8E9DTAfQUrFRYRRY5wOuTimTtlgc8ipwSueetRSqAMnGaSepTWhWuXYgbuaqMxUZAq6Qv8AHmq0mzdgZx71cTmqIrKnmv1Cg+tRSxFWxwallXGKhY4zjNbI5JDGBHU1Axy2TUhBbOTxTHxtwRVoxZGXHXnNNfpkHmlO0Z2jikJ6ccVRjIiIPc1GcqanZj2qBi1UjNjS7d6icknnpTmJzjJqMtiqRm2NJx1qJzjpTnJqNj2qkZtjciijNFMk7Vwd53GhWI6CnyHzH4pdvy8EVys99JihgBk4FQTXUaZ2nJpwgHO9iRT/ALJFkEjNToXZ9DKmmllf5ATUkVlJL98FfrWysSL91Rn2qYKCOlJztsNU+5nR2ccY5GauxQxjBUc0EHO0YpVJUhRyaltspJImVfnwRj3q1EwQc81XIcJnqaSOTAy4K1G5otC65GwuOp71mXNwGY/NUtxclwFU/KPSoYrYu2QOv504xtuU3fRFcMTLjoKsRgLg9D9Kl+zbDjqfT1q3FCwjJK7f1zTchqHcdZ5TB6kn61rQ3DkqWzkHpWZCCDjGFznryTV5ZUR41OAT91PWsmXyms85lVRI3I546AVDsMxIj4AOSTVWRmZx8wLsemelXbcAEIjcnqTU7GkVYlgZkZWGc/dx61dnUhAuRuYgt9KggZndVijBdR3PB96RyROQ8gYgbmwOh9KVwLoJnkkQELGOM9MCq5CGEsciFTwB3FOjKxW+SeCPmyaiaZCjBgNoPAzQCRn3t1FIojiLh+gBPAFV9geMKQcD0NMdRuJY5x365qfTIvOmbccxIpc47mtVogvqbbwGOO2DMHjUblA6tTLhRLIXcbdo+6p4/Gs4zSkIAxLHBAHYelTsXRWG4F24+lZs0ZG+CpdSzdgDSiAPECmAuMnnsKWRkQhCMhR/k1XNyLcs0DAgrhgexpWFd9Bt1gLH5S7SeFzwMUkZDqu5gpRt2VNRvHNLbmVyPLRuvoD3qU2xVFe3O5COvrVBcvea864yu8dATT54Z5bF2SPdIvG0nofrWWpQkRksjjkOp5FaK3MnllWZjgfe6Z+tK1iJeQ6L5I02794wGVhkg1WvwWJkaGTevBQ8ZpryyqxLruRhgsGximy3E3lhZX+hPOaZm0RP5BT5WZD1Oc1SuwqAshyvfHNSNKTjcc5HaoJEUAZJwfTpTIZWLKycqRj1rOmA3deKuzkwSZY5jYZ465qrMA/I5HX6VSMyKFcDJzjoKlVhv61X3eUfn+7Uh2yIOx7EU2VEsPyODxSNjaASTVWOXAKP1HNTs3yjBz9KhqxrcpalK9tbCWCIzNuwRTiBIill2Erkj0qV32DCk4qpJJnkk81aOee9yOcDcBVVwM8dqsyeg71EY3OD61rE5Zq5ArKvBqN2BbpxU7pg5NQlVzzWiOeSsRnAHQYqNmBOOKfJ3zyKiqkYyGyHHSoGY9KlYj6VG31qkZMgZu1MJ4p7j5uaik4FWjJjGPWo2NOJphPNUZCbvaik4opiO7VSpIJ5HWlDYPNLJgcg5Y+lMPfFcjPoI7D1O6pVHGKhQECpEYnjvUM1iWEIFJI3GRTFPPzVKDlcACoLuRhW6k4xQhJfgZHqaSRsAgVn3FywO1Dgd8VSVzNysac1x5YxnJ7Yqm8skrYLEe1VYS0jgLlmPetW2gEbDeu407KJUW5jrS1kdd23JFa8EaqORyBzTI9qoNh5ParChFXc3J9KxlK51QhYiZAASF57VVSaRphjG0dferM0m9dsQzk8+1LHAsQPTPapvbc2UbibtpyPvE4zjpTmUkF12rtGN7D5j9KkRR5fKkDtnvTJnHlonryRntSTHylnTQiJkcsRwT1NXYmG8KBkgZbFZsZMaE8AE8AdatwffJbcF6E0mOxsrIEjQIu1PXPOahdyZwoUb26n0qEzRkqNuQOAO1CjBbyxzwoqUFiWaKSRVbgrnrnoKrXSpDbvjG5zxz2qw0hkCxpkRqcMenPpWRqlyrXQiGMDqRVxV2TJ2RDcZMAVW7/Mc9vQVtWS/Z7VEVeZ1/Sse3IuLiNFGUB7d66C3ESzhmcBkG1VPpVzfQiPcaI/KuSF+6qZP1pI0EsO/PzkjPsKJWZQ5IbDEDOOtMl3bwQpCkZrM0WuhFMgjldZWba2OfUVEYYUbCZIYck9qSd1+bzjnA+VTzmrVrEpEbH5Qy4x70xPQsWsP7llGNuAOPSlIW2VVU7426Zq7CLeMEvuVSMDBxzVYiKN2VmLRHkA9qkjcxrhFEjFBjc2eaheRlmBQkBhyCatXyn5ngUZzwD2qBYHbJkI3N3A4q0xk6zIsZON/qp/pUEzgZ8sMAeSDVO6V0VhgnaeeeRVF72UfKX47Z6imo32IkaTyA9gQex7VC7gbguQPeqq3cUikZKN/OmCY9XbcOnTpTszNkMrktyQV7U9NoX0OMD0NQuc5+X8acg45xnvTYkguY1dCvc9xVII8TcduxrSj2OMjg+ppHi5+fFK9tC7GfvExzjDL1FSg4TnNOmCqcrg8dagZwyADqe1MliOSwz0FQvjNSueMVERxyaaMZajSwApnmY5FMPHuaaTxzWiRzyY137HpULHBPFDkZNMyK0RzSY2TnoKiI9qm3KD1pjlSD3q0YSKzZ/ComJ9KnYj1qGQgd6pGTIJO/rUTH16099zewzUboepNWjFkTEk8U0rxzUhAFMbNMgZgUUuKKYjuSGK+1JuJqVmyMdKiKg9/wAK5T31oPQ59qnCkHio1GBz2qVSNvWoZtBCbwDyRmmtMADluKr3UiLwDlvSqoG8jcefShRuKUrE085k+VM4pLe2aU96s2lqWwxGBWtGkaIFUfMetDko6II03LVlaztRFgKMtV+OMLx3qSJAoA7etI08SHAYfSsHJs6qcLALdmfcXwop7ICNiMR6mkSUS7cdKlDgN90sfaoZskJDE8cgzgg84qebazAnr6UxnbcCV59B2poIUFpjz6etJmqGSzNxxvOeg7Co4gwkBYHBPp0FPgYyT7YlUxjktjpVliVzu6CjYoeuCqDoevNOUsyqo+Y96i3gKMke9EL7mbBIUcZpBYuIxQbyMEcAClilb7q53HOT6Cq5kGSSTwMDHrTo4ztO+Q7s/MRx+FBLFvrwWsGFbBH3VH9a5rzyztIepqfV7kPMyKcKpxVO0jMsoX+HPNdEI2VzlnNylyo6Tw3HJJ84TI5Gc4xXRIuGAfDMowOKwtNZo5I/KIHpnnFb0ccrIDuR25+7xmsZO7ubctlYrXm5rjAONmOlQvGXHLNkjGPar10jIFdgA+cMAM4qvCuZI8SEFskhh39qQ/MzJWTzFXb0HPFW7eVi52LvjXHTgiqt8Ns5DffzyaIg0DZB4PWnuirXNUsGRlznP8J7Gq7FTHskOMdsVIGMkYLfgRUO1iTu2k4xUk2GzKGVVQlVOAee9NkzCqqW3DAzjvR1Uo+QP4cdjVe4LLGEPLAf99UwsEqhnG7JUfnWbcW6OxG3IPQ9KuI+U4P3uxprxnkbcg+vaqWhmzn7i32gmN92DjB6io7dzIrI3GOvvWlcoC3GeP1rO8oicc9eK1TujGSs7olZirAA5FWbZchg2OB17VUkG1gG5NTRTAKY2HFS1cpEn+r4XDD2qOeVmAXFNNwiJt4HemC4Qtnqxo5R30FeIbB/eqm4dCcr09K0BKMc1BPIS3QYNCIkVMZXvTJAdoxTpJSM5xioXkLAAg4q0jCTGMQAdvNQSZI4BHrU/Hao5Wz0rRHNMg24FMPU1I1J1HTNWczIig/GoZeOlWtoIPaq7RnJxzVIykVmPWq5+c8dBU8/XaOtNYAAAVaMpEZ471Ex61I47dKiYcc00ZsYfyph5PFOb0FIRVEEePeinYooFY7pUwvJz9aaeGPrT2KBfmOTVWaVUxzXPY9u5YVwByar3N0NoCdaqvcE/cqFQzP3JNHKV7ToiUZY56sa0LSAghpO3am2kAUbiPmq9Go3Zeok+xrTj1ZagG4gdB2q4GREGBwaomVI03elQ/bDIeRxWDi2daaRbuC0i/Kdo6VEixxj5z83vUMspAGTSxxNOwLDC07WLjuXIZRKxVFP1HetCGPZHknn+VNt7bbGDnao6ip1Ic4Uce9ZSfY2iiCSURruUZ7VTed2JxzV66gDqMnb34qpHDvlZQMqvekrGiWhsaOkaRDzflJHWqt+cylFJ256iq5lcBUyQFHAFIf3hGW5HYGjqNIlZQ3HU4ojAVPl7npUkQHpg9KdISCOmB60rjtciabyY9zgjtUTSvJucZAA4HrU/LoQBk+uKg8lhvAJxjoOKaZMkYNw7NNyBk9a0bCKQRbkB3E7c1nzA+cRjHPSteylWO3+U/P1INbz+E4aStN3NOE7MY4xW7bTOCCB8q/xEda5yORFEZ4BPGK1Fnby+CPf1rBnXa5uvJHcKjc5JySfpVWVQWQLg8/lTNPlRlbccDGADT5SBNthQDavynPepDlsU7y2dvO2r847npVFiVIDgggcjtW8krGMxuRx371Dcwpt2jDg9OOlNMop2M+FKH5vT2qbK7srtySQVzz0rOl3RkgcY60Sy4ZWBBOOcU2gsW7iCRI0dl+U8YzVWZPMTA4xVq1uv3ewvvI7Gp3MIG9R1X8M0rkmQQzLsCj1pjMNhRmZWPXB6itFY2zuIxkZxVa+iCncMbT6VVzNmTOqE9GB7f41TaBmf5fzqzcRySSfu87PWiGORcCTBPfFWnYzauZ7xOj/AD5FPEZxk9B3rQlRNmTg1Gg+XC4KmnzEWMy7tTINy9u9UYn2PtcH61sBdznAPFZmpwMoLqOKpO+jE11LaDOG7VFcHLADgVXsLxWXyn+96mrM6jbup211Ik9NCF1Uds5qFyGG2pSCRwahcMM8ZppGDZXZCh+XmmM+D83BqQkgVG+G5bmtEYSY1RTtnNNI28qab5nY8VRg0KxkU4B49xUMs0mPmOBVnzflw65HqOtQ3WETcOV7GqRm0ZrHdKSeaGxn0FPUDaSeppjDPSrMWiMjPNRPUr59KhYZOaaM2RhecmmtweKkbrxTDVGbI6KdkUUCOh86R+mRTfmZuSSanSE5yTip0jH41m2erFN7laOIscdBVyGJI1yRzTyFUZ71ESWb1qG7msY2LH2gdFpI5Cz8c01YdwHOKlzFAxI++eKzZ0QbBo5HOWPHoasW0fr1pkJaVvu/L61fjj2qd2BiobsdMUMVFDDeAT2FX4k24JFVUHOR19ashuAKybN4osM7SbR0X0qVCEHUbqrRE7sc89TTyuDkc+prNmsR5JYguflqSMKB8oxmoXHzDn6CpVYkfSoZtEa8as5CjikSNFYsMZpDLtO0DrUoT7uepoTsU0OQMxBGAo65pXUuzEc+i09RgYp6x4Uknmp5iooEjXAzwfr3qGeJtpbHzDnNTKDnk0+Igtz+tNMHEwL+3ziRO9VoiwHIHHr2rZmQrMykd+KoTRiPcWGB71vGelmc1SjrzIfak71HAIPfvWrbuYp8YBjPOaybfoNoB9K0EyWLY+Yj8qUkKL6MuFwzZiBII6DtVpmIVXBAZeo9azkkKHcCRVkS+ZEQeHHIOetZM2sacM6SFHPKHr2qO+uAsbBc7SciqcJ8zajnnuBUsiCNVWPJC9zS6hYp37l8OrcnrVB3CYZ8ZPcGrkskbNgBQR6d6o3KqegAYelaJ9BNDo5GxuyM54NWradw4DjOe3as2CZomw4yM9O1aDS52lSCvWm0ZtF5blpAVbC7TioZHbDfLnHY0sSB48gkO3c9qdGzZZJAp7AjvSJaKU6+WoaIHYeSPelkZZIw0a4PtSuphZlXJHoeagWQqflHHdaozZTckkhux6iiSMI2V+7jmpZQu5iCQTVZ8sO+B3FUQ0PCjbhSPeq1yGI2uMgVZ4jBUDIIyCaqzlihJPToKEJvQwb6AJIGi+96UxLuRSFlrQCBhuI5PWori3WReB81bJ9Gckl2ESQsM5odnYYqrETE5V+lXVIIBGOKdrEblcq3emEH0qy+d5NRtx9apMylEiAwOeBUTFW61KzDOPXtUZAPPSqRi0QE7SVzkVDP+8YAHgVJIxc7VwfemNGI1BzyetWjKQ0xqBzIOlREKP4ifwpxKk88ZpCB60zJoifABJP6VAQoHXrU7AE9eBUEhH5VSMpIjPBqNj1zStlunFMK5PJqjFibh60U7ZRQB14FKDzTm4+lHHrWJ7KEPJqVCi9RTAKa0eepxmoZpFCS3DE7IBz60W9q28NI2aeiqvCj8asRqepqW7G0Ia3ZZhkEYwnWn7i33qgXr04qwhAxjk1kzshqTIdqngYp8bFiT2qIDd1qVMdBWTN0iwrYGAMZp4UrjB5oiXGN3XtTiM9+PSouaJWHp2zRJIFGPSo8lQd1QFvMkz2FKxpBEsO5m3n8KsQkls+lEITGDUn3QcDiokzZIlU5BNSK25ccVWEmGzzj0qVWBGRUF8pKoA606NCz8dKRTyOalD7OlFx8pXlX943GTVW7tvOiwePY1pqq7t+0bj1NSSoGTGKqMupEomDBbhEwV6VMfujGciroRWXDDBHSqbEbipyT9K2i7nLOHKwWc/JyMk9+lWw4dAygKR1xVFdm7BXI64ParcIRfmXgnqO1JmkNS6NvyMVDAc5p1zJGcOqg46ioYWJOwgbe1JOhT7o4PNZl2M67VnlEiKqgDnFKItx4BPHQ1ZaQRDGMg+tVzOm/A/PtVp3REolS5tWVTwOOeD1qGOVoV25zzxmtSYhhuXp6Cs2aNixYfMvbtVp33M2iaO4fPyk7c9D2qzHcc56HvWeCAQRkNirUNypUBlG71oZmy1KQ+MAkn17U5rbyyhzgHkioo2O7crZU/pSz3Mi5AoJaIpUBdvlBPaqeGjcjb8x61YWcmXI696ddEzj5B8wGDVGUjPuJm3nC4FVbh8ryMZqeQFF+bk1SncnpyDVxMWxVVdtRSjng0rM20EjB9KGc4GapEMz71OjAU2NCUyTgVdnKvGapo5Ax2rRGMlZjWVx0amt5i89amyADyCKYxzjnimjNormUk/d5pjF5OMYFWGx+dRscHrVJmMkRBQowB+NRSAk1I5zUb85PQCqTMJEbINo3dahdccA1OeR14qJjhsVRmyHOAQag6kmp5WBGO5qMqQO1UjGREaQ05hzTRn0qjJibaKXJooEdh2OabkCkeXnCihELc5rE9iOoB+ePzqZE3DJNIIsYwalUccdKhs6YIVFxUoANIvzDFKelZM3ihegqRODUOCeualXoRzn+VQzeHcsRkk4qaIZbPaq0XA5q1DjtWbOqOpdjIPXrTWKqcimZwM1XnnGMd6zSuzVj5GLnbkYqSGMdqr2qlvmIxV7O0CiT6FxXUkRQvUU9S2cAVGjknIP51KrgDnk+9ZM2iRn72OlSxMc4PSoxjrilBweeKTNlEsAg8g/X2qUcjrUCYNSBtvUVFx2J0Yrx2qUHjbmqu7KdKGmUICxAxTRMoj5goXjisy6YhxtbBFOurwEfJ+OazLq4IOR83sK6aUX1OSta2hpb1OxmG498VcjCyJ8tY9jOrphuM1dtZCkgznbmqmjOkzUijcRlSA3cUwSuh2yDIq9bMrAcmi4h3ncBn8KxNr62M6VEdSU6+hqpPbxjJXdk+/StC6jURsE4fHGKopi4jKO2xh/F71SEyqTsUgZDe9LnegGB+FOIzuWQYdelQCQIQCcA1RmxZ7dUhLdx3zVUnCh1II7itCEiTdGxBVv0rOurZombyycE9atMyZat7hHIGNpq5OQwBCnjvWLbqqOWLH8TWmsiyQgBvmHUUNGbZXlYb/lGB/Wo2eWPBJ4PcVMYgTw+D9KJFAhw3NNIwm7lK5zgMX3A1W2h1PIxVuQhowrLjFVGbaSFXIFaJGLfcilbI5IqFsnBPWkmZQ2SOtMMgB9jV2M3ICCx4zgVXkjBGQeTVgsQCARg00dOMZ9KaM3qUmR+maiZZAM5NXnB5Hb1pjDA9au5DRREzqRkcU/zVapXQNyRxVSaAg5Q1SsYyuiYbTnd+FQO0ecFj+AqEs4O1jxS4AHFVYwkxJHC9CCPaojIMmnsoNRlR6VSMmR43NntQeBT2xt6Uw80zNjD6U005sUw0zJiZopN30opknYIgHWpE600jinICKxZ7EES4xSqRSY5yaUKBWTOqKJBwOOtLTAfm56VIOeBUM6I6kkYzUmOtNjTHWpByetZM64rQbg9KniIXqaYeB70gqWaJ2J2cBDk1UBEkuO1Fw+AFB606GMhd2OaSViuYvJhV4PvSgknJqrvPHpU6EY71DRpGVyZH5xUu7I6VVJ5qSNjuqWjeEiyiZp+3AyaYrjAFTNgr8prFtnVoOjG7mnMQDiqwfYcZpwYuQcilYXUl3lQc9Pesy4n3N7dhUuoTbFwDyaoQZkbnkCt4KyuZVHd8qJY7RpH3SMcHtU7WiBMKBUyfKBmpGwcEGjmbYnBJGBLutZj12daljuiZFO/5a0L6zWaNmHJxXPEtBIUat4vnRxzTpu/Q7iyuR8rKe1aaSgjII9647TLvjBNbsE+F7FTWM42Zompak95hX3L361iXbMj7o1Oc1tuVeImqbqMYYZpJ2KaM3Hnh23HzcdKrhcsOOB1FaaxBWLKpqNlV3BA2itEzOXmRQRhgGQ4HWp5h+6O7BUio4wI2Oeh7VJI8bEgfdPUUGUjInjwxOajt5hBLkrkHirlzHtbAHHvVSSJ2H7oEgckmtYs55FmU5fdyAe9OimKnbJg+hqKCfChHQ5PeiRfnJOePWnaxi9SSdW3g5BFUrgrkhWxUu8luuRVeZdxPBzTRlNlKYjzFJFDhfLb06090IU8ULhh0rQxKkZ+b2pd3JOeaWTAYgdTTeFGSKZOwm49DTHag880nHNMlsY5zUXc+lPbJ5qMiqRjLUjnTcue9Vd22rnWq8gw/tVpmMkREg88UmeelSNGMcVCyEHrTMmgYk5zimEDuMfSl2kd6a27FMzaEKcYXvUTAjINDMwPIpGk3H5qpGLG4HvRRuFFMVjsvSpV+6KKKwZ7NPceKd2oorNnXEZ/FU8fUfWiipkaU9ywOppR0FFFYnchxo7UUVIyrIf3n41oJ/qloopS2KEIG9aki6GiioLhuNPQVLH900UUmbR3JV7VYTpRRWUjqiNloX7tFFC2GZmrE/LyaNN+4frRRW32DJfxDRXqakWiisy2Nc9a57WAA6kAZoorWluc2I+AisyQwwTXSWBPlnnvRRV1DGiXkJwOTTm5BzRRWHQ6JCfwGqj9D9aKK0WxhMguP9WPrVZCd5+tFFNGU9iW65hbNJa/6k/WiitEc72G/wAT/U02+4hOPSiiqIRn2xPmNzUkn3TRRVo55lUfcNRj71FFMzZRm/1xpx+5+FFFV0I6kZ6CmS8dKKKZDIjTKKKpGTDuKrXH3qKKpGUthifdpjdD9aKKpGQh7Uw/0oopkMhaq79TRRVIwkR0UUUyT//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade IV showing obscuration of a major vessel on the optic disc (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29648=[""].join("\n");
var outline_f28_61_29648=null;
var title_f28_61_29649="Patient information: Photokeratitis (Arc eye) (The Basics)";
var content_f28_61_29649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/27/5553\">",
"         Patient information: Allergic conjunctivitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Photokeratitis (Arc eye) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/photokeratitis-arc-eye-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H17016855\">",
"      <span class=\"h1\">",
"       What is photokeratitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Photokeratitis is an eye condition caused by an invisible kind of light called &ldquo;ultraviolet&rdquo; (UV) light. Photokeratitis causes eye pain, redness, and other symptoms. This condition is also called &ldquo;arc eye&rdquo; or &ldquo;snow blindness.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      People get photokeratitis from being around bright UV light without eye protection. UV light comes from the sun and some types of lamps and tools, such as sunlamps and welding torches. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016870\">",
"      <span class=\"h1\">",
"       What are the symptoms of photokeratitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms usually happen 6 to 12 hours after being around UV light without eye protection. Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eye pain that makes it hard to work, drive, or sleep &ndash; Some people pace or rock back and forth because the pain is so strong.",
"       </li>",
"       <li>",
"        Red, watery eyes, sometimes with swollen eyelids",
"       </li>",
"       <li>",
"        Being very uncomfortable around bright lights",
"       </li>",
"       <li>",
"        Not being able to open the eyes",
"       </li>",
"       <li>",
"        Feeling like there is sand in the eyes",
"       </li>",
"       <li>",
"        Red, swollen face",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016885\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have any of the symptoms above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016900\">",
"      <span class=\"h1\">",
"       Is there a test for photokeratitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016915\">",
"      <span class=\"h1\">",
"       How is photokeratitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Photokeratitis almost always goes away on its own. It does not usually cause lasting problems. But it takes 1 to 3 days to get better, and is very painful. The doctor or nurse can give treatments to help with symptoms. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to control pain &ndash; Some of these medicines can help you sleep. Sleep can help the eyes heal. &nbsp;",
"       </li>",
"       <li>",
"        Antibiotic ointment to put in the eyes &ndash; This can make the eyes feel better and keep them from getting infected.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your doctor or nurse says you have photokeratitis, go back for another visit in 1 or 2 days. Your doctor or nurse will check to make sure your eyes are healing. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016930\">",
"      <span class=\"h1\">",
"       Can photokeratitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can lower your chances of getting it by wearing sunglasses when you are outdoors. Make sure the sunglasses fit well and block UVA and UVB rays. The label on the sunglasses will say what type of rays they block. If you wear prescription sunglasses, make sure they block both types of UV rays. &nbsp;",
"     </p>",
"     <p>",
"      If you work around UV light from welding, high voltage electric lines, or certain types of lamps, wear safety goggles that block UV light. Sunglasses or contact lenses do not give enough protection from these types of light. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H17016945\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=see_link\">",
"       Patient information: Allergic conjunctivitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/61/29649?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82946 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29649=[""].join("\n");
var outline_f28_61_29649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016855\">",
"      What is photokeratitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016870\">",
"      What are the symptoms of photokeratitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016885\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016900\">",
"      Is there a test for photokeratitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016915\">",
"      How is photokeratitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016930\">",
"      Can photokeratitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17016945\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/27/5553?source=related_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29650="Technetium Tc-99m succimer: Drug information";
var content_f28_61_29650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m succimer: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42754?source=see_link\">",
"    see \"Technetium Tc-99m succimer: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13210341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DMSA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13210343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13214966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Brain imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 15-20 mCi (555-740 MBq)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal imaging:",
"     </b>",
"     I.V. (based on 70 kg patient): 10-15 mCi (370-555 MBq)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13210344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Scintigraphic evaluation of renal parenchymal disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13214979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Dermatologic: Dermal hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13210349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"     <b>",
"      Note:",
"     </b>",
"     Contents of kit are not radioactive; however, adequate shielding is required after addition of radioactive material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Patients with renal disease may have delayed elimination, therefore decreasing quality of images.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Patients should be adequately hydrated prior to dosing; instruct patients to void frequently for 4-6 hours following administration to decrease radiation exposure to the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13214958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13214959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13214960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Technetium Tc 99m succimer is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16817 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29650=[""].join("\n");
var outline_f28_61_29650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210341\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210343\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13214966\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210344\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255279\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13214979\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210349\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13214958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13214959\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13214960\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916860\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/48/42754?source=related_link\">",
"      Technetium Tc-99m succimer: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29651="Polycarbophil: Drug information";
var content_f28_61_29651=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polycarbophil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/36/11844?source=see_link\">",
"    see \"Polycarbophil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Equalactin&reg; [OTC];",
"     </li>",
"     <li>",
"      Fiber-Lax [OTC];",
"     </li>",
"     <li>",
"      Fiber-Tabs&trade; [OTC];",
"     </li>",
"     <li>",
"      FiberCon&reg; [OTC];",
"     </li>",
"     <li>",
"      Fibertab [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Fiber [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal;",
"     </li>",
"     <li>",
"      Fiber Supplement;",
"     </li>",
"     <li>",
"      Laxative, Bulk-Producing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Constipation or diarrhea:",
"     </b>",
"     General dosing guidelines (OTC labeling): Oral: 1250 mg calcium polycarbophil 1-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Constipation or diarrhea: General dosing guidelines (OTC labeling): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: 625 mg calcium polycarbophil 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: Calcium polycarbophil 625 mg [equivalent to polycarbophil 500 mg], Calcium polycarbophil 625 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FiberCon&reg;: Calcium polycarbophil 625 mg [scored; contains calcium 140 mg/caplet, magnesium 10 mg/caplet; equivalent to polycarbophil 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Fiber: Calcium polycarbophil 625 mg [sugar free; contains calcium 125 mg/caplet; equivalent to polycarbophil 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fiber-Lax: Calcium polycarbophil 625 mg [contains calcium 170 mg/caplet; equivalent to polycarbophil 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fiber-Tabs&trade;: Calcium polycarbophil 625 mg [scored; equivalent to polycarbophil 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibertab: Calcium polycarbophil 625 mg [equivalent to polycarbophil 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Equalactin&reg;: Calcium polycarbophil 625 mg [citrus flavor; equivalent to polycarbophil 500 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F144785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient should drink adequate fluids (8 oz of water or other fluids) with each dose.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of constipation or diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Abdominal fullness",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Taking products without adequate fluid may cause it to swell and block throat or esophagus; use with caution in patients who have difficulty swallowing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14446370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F144787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain calcium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Equalactin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg (24): $3.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (FiberCon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg (90): $11.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (FiberGen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg (90): $4.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Konsyl Fiber Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg (90): $8.70",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fibercon (GR);",
"     </li>",
"     <li>",
"      Fiberphil (TW);",
"     </li>",
"     <li>",
"      Mitrolan (TW);",
"     </li>",
"     <li>",
"      Sylcon (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Restoring a more normal moisture level and providing bulk in the patient's intestinal tract",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29651/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10065 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29651=[""].join("\n");
var outline_f28_61_29651=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144803\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144794\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144800\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144795\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144783\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144770\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144785\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144784\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144801\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144774\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299897\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144778\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446370\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144787\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323036\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961916\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144773\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10065\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10065|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/36/11844?source=related_link\">",
"      Polycarbophil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29652="Clotrimazole (topical): Drug information";
var content_f28_61_29652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clotrimazole (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41556?source=see_link\">",
"    see \"Clotrimazole (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/28/13763?source=see_link\">",
"    see \"Clotrimazole (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8011625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Fungal&trade; [OTC];",
"     </li>",
"     <li>",
"      Cruex&reg; [OTC];",
"     </li>",
"     <li>",
"      Gyne-Lotrimin&reg; 3 [OTC];",
"     </li>",
"     <li>",
"      Gyne-Lotrimin&reg; 7 [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF Athlete's Foot [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF for Her [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF Jock Itch [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8011626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Canesten&reg; Topical;",
"     </li>",
"     <li>",
"      Canesten&reg; Vaginal;",
"     </li>",
"     <li>",
"      Clotrimaderm;",
"     </li>",
"     <li>",
"      Trivagizole-3&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8011744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical;",
"     </li>",
"     <li>",
"      Antifungal Agent, Vaginal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8011683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatophytosis, cutaneous candidiasis:",
"     </b>",
"     Topical (cream, solution): Apply twice daily; if no improvement occurs after 4 weeks of therapy, re-evaluate diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvovaginal candidiasis:",
"     </b>",
"     Intravaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream (1%):",
"     </i>",
"     Insert 1 applicatorful of 1% vaginal cream daily (preferably at bedtime) for 7 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream (2%):",
"     </i>",
"     Insert 1 applicatorful of 2% vaginal cream daily (preferably at bedtime) for 3 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatologic infection (superficial):",
"     </b>",
"     Topical (cream, solution): Apply to affected area twice daily (morning and evening) for 7 consecutive days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8011682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/28/13763?source=see_link\">",
"      see \"Clotrimazole (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Vaginal, topical infections:",
"     </b>",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8011704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8011717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1% (15 g, 30 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Fungal&trade;: 1% (113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cruex&reg;: 1% (15 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin&reg; AF Athlete's Foot: 1% (12 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin&reg; AF for Her: 1% (24 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin&reg; AF Jock Itch: 1% (12 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal: 1% (45 g); 2% (21 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gyne-Lotrimin&reg; 7: 1% (45 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gyne-Lotrimin&reg; 3: 2% (21 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 1% (10 mL, 30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8011627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8011705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Topical: Avoid contact with eyes. For external use only. Apply sparingly. Protect hands with latex gloves. Do not use occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8011628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible fungal infections, including dermatophytoses, superficial mycoses, and cutaneous candidiasis, as well as vulvovaginal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8011624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clotrimazole may be confused with co-trimoxazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lotrimin&reg; may be confused with Lotrisone&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cloderm: Brand name for clotrimazole [Germany], but also brand name for alclomethasone [Indonesia]; clobetasol [China, India, Malaysia, Singapore, Thailand]; clocortolone [U.S., Canada]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Canesten: Brand name for clotrimazole [multiple international markets] may be confused with Canesten Bifonazol Comp brand name for bifonazole/urea [Austria]; Canesten Extra brand name for bifonazole [China, Germany]; Canesten Extra Nagelset brand name for bifonazole/urea [Denmark]; Canesten Fluconazole brand name for fluconazole [New Zealand]; Canesten Oasis brand name for sodium citrate [Great Britain]; Canesten Once Daily brand name for bifonazole [Australia]; Canesten Oral brand name for fluconazole [United Kingdom]; Cenestin&reg; brand name for estrogens (conjugated A/synthetic) [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8011665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Genitourinary: Vulvar/vaginal burning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Burning or itching of penis of sexual partner; polyuria; vulvar itching, soreness, edema, or discharge",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8011630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clotrimazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8011631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical:  When using topical formulation, avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8011736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9775535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal reproduction studies, adverse events were not observed with vaginal administration of clotrimazole. Following topical and vaginal administration, clotrimazole is poorly absorbed systemically. Adverse events have not been reported following vaginal use during the second and third trimesters of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9775536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9775537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following topical and vaginal administration, clotrimazole is poorly absorbed systemically.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8011719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Clotrimazole External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $8.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Clotrimazole Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (45 g): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Desenex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $7.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Gyne-Lotrimin 3 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (21 g): $9.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Gyne-Lotrimin Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (45 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lotrimin AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (12 g): $6.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lotrimin AF For Her External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (24 g): $9.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Clotrimazole External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $7.40",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agisten (IL);",
"     </li>",
"     <li>",
"      Apocanda (DE);",
"     </li>",
"     <li>",
"      Aristen (HK);",
"     </li>",
"     <li>",
"      Axasol (CN);",
"     </li>",
"     <li>",
"      Baby Agisten (IL);",
"     </li>",
"     <li>",
"      Canazol (TH);",
"     </li>",
"     <li>",
"      Candazole (MY, SG, TH);",
"     </li>",
"     <li>",
"      Candibene (CZ);",
"     </li>",
"     <li>",
"      Candid (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Candiva (PH);",
"     </li>",
"     <li>",
"      Candizole (ZA);",
"     </li>",
"     <li>",
"      Canesten (AE, AT, AU, BF, BG, BH, BJ, BO, BR, CH, CI, CL, CN, CO, CY, CZ, DK, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, HK, ID, IE, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Canesten 1 (KP);",
"     </li>",
"     <li>",
"      Canestene (BE);",
"     </li>",
"     <li>",
"      Canifug (DE);",
"     </li>",
"     <li>",
"      Canison (PH);",
"     </li>",
"     <li>",
"      Chingazol (TH);",
"     </li>",
"     <li>",
"      Cloderm (DE);",
"     </li>",
"     <li>",
"      Clomazol (EC, NZ);",
"     </li>",
"     <li>",
"      Clonea (AU);",
"     </li>",
"     <li>",
"      Clothree (IL);",
"     </li>",
"     <li>",
"      Clotrasone (CL);",
"     </li>",
"     <li>",
"      Clotrex (DO);",
"     </li>",
"     <li>",
"      Clotrimaderm (IL, NZ);",
"     </li>",
"     <li>",
"      Cotren (TH);",
"     </li>",
"     <li>",
"      Covospor (ZA);",
"     </li>",
"     <li>",
"      Dermatin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dermizole (TH);",
"     </li>",
"     <li>",
"      Empecid (AR, PY);",
"     </li>",
"     <li>",
"      Epicort (CO);",
"     </li>",
"     <li>",
"      Factodin (GR);",
"     </li>",
"     <li>",
"      Fungicare (IL);",
"     </li>",
"     <li>",
"      Fungicide (TW);",
"     </li>",
"     <li>",
"      Ginet (PE);",
"     </li>",
"     <li>",
"      Hydrozole (AU);",
"     </li>",
"     <li>",
"      Imazol (DE, EE, VE);",
"     </li>",
"     <li>",
"      Kamicin (HK);",
"     </li>",
"     <li>",
"      Klotrimasool (EE);",
"     </li>",
"     <li>",
"      Krema-Rosa (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lotramina (PE);",
"     </li>",
"     <li>",
"      Lotremin (MY);",
"     </li>",
"     <li>",
"      Myco-Hermal (IL);",
"     </li>",
"     <li>",
"      Mycocid (IN);",
"     </li>",
"     <li>",
"      Mycoril (SG, TW);",
"     </li>",
"     <li>",
"      Mycozole (TH);",
"     </li>",
"     <li>",
"      Pan-Fungex (PT);",
"     </li>",
"     <li>",
"      Panmicol (AR);",
"     </li>",
"     <li>",
"      SD-Hermal (DE);",
"     </li>",
"     <li>",
"      Taraten (TH);",
"     </li>",
"     <li>",
"      Trimaze (ZA);",
"     </li>",
"     <li>",
"      Vagimen (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Vagizol (PH);",
"     </li>",
"     <li>",
"      Vanesten (TH);",
"     </li>",
"     <li>",
"      Yeastazol (PH);",
"     </li>",
"     <li>",
"      Zema (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8011674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to phospholipids in the fungal cell membrane altering cell wall permeability resulting in loss of essential intracellular elements",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8011676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Negligible through intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Vaginal cream: ~24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29652/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duhm B, Medenwald H, Puetter J, et al, &ldquo;The Pharmacokinetics of Clotrimazole 14C,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1974, 50(Suppl 1):13-6.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9072 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29652=[""].join("\n");
var outline_f28_61_29652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011625\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011626\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011744\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011683\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011682\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011717\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011627\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011705\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011628\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011624\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011665\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011630\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011631\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299069\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770106\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011736\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775535\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775536\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9775537\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011719\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961963\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011674\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011676\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=related_link\">",
"      Clotrimazole (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/44/5828?source=related_link\">",
"      Clotrimazole (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/6/15460?source=related_link\">",
"      Clotrimazole (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/37/41556?source=related_link\">",
"      Clotrimazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/28/13763?source=related_link\">",
"      Clotrimazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29653="Hydroxyurea: Patient drug information";
var content_f28_61_29653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydroxyurea: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     see \"Hydroxyurea: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/53/25431?source=see_link\">",
"     see \"Hydroxyurea: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Droxia&reg;;",
"     </li>",
"     <li>",
"      Hydrea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydroxyurea&reg;;",
"     </li>",
"     <li>",
"      Gen-Hydroxyurea;",
"     </li>",
"     <li>",
"      Hydrea&reg;;",
"     </li>",
"     <li>",
"      Mylan-Hydroxyurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hydroxyurea may cause changes in cells and may raise the chance of getting cancer when used to treat blood problems. It may also cause very bad side effects. Talk with your doctor about the good and bad effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat blood problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sickle cell anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydroxyurea or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Anemia (other than sickle cell anemia) or bone marrow disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have irritation of the mucous membranes (for example, lining of the mouth, throat, nostrils, stomach, bowel), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ever had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have HIV and are taking didanosine and/or stavudine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698972",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear gloves when touching this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2860099",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A liquid may be made if you cannot swallow capsules.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You must handle and throw away this drug the right way. If powder from the capsule is spilled, wipe it up with a damp, throw away towel right away. Throw away the towel in a closed holder, such as a plastic bag. Wash your hands fully.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10747 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29653=[""].join("\n");
var outline_f28_61_29653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181021\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181022\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022264\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022266\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022265\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022270\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022271\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022273\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022268\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022269\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022274\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022275\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=related_link\">",
"      Hydroxyurea: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/53/25431?source=related_link\">",
"      Hydroxyurea: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29654="Laryngeal anatomy sagittal";
var content_f28_61_29654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Diagrammatic representation of laryngeal anatomy in the sagittal plane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29654=[""].join("\n");
var outline_f28_61_29654=null;
var title_f28_61_29655="Famotidine: Pediatric drug information";
var content_f28_61_29655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Famotidine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"    see \"Famotidine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16549?source=see_link\">",
"    see \"Famotidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Heartburn Relief Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Heartburn Relief [OTC];",
"     </li>",
"     <li>",
"      Pepcid&reg;;",
"     </li>",
"     <li>",
"      Pepcid&reg; AC Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Pepcid&reg; AC [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acid Control;",
"     </li>",
"     <li>",
"      Apo-Famotidine&reg;;",
"     </li>",
"     <li>",
"      Apo-Famotidine&reg; Injectable;",
"     </li>",
"     <li>",
"      Famotidine Omega;",
"     </li>",
"     <li>",
"      Mylan-Famotidine;",
"     </li>",
"     <li>",
"      Novo-Famotidine;",
"     </li>",
"     <li>",
"      Nu-Famotidine;",
"     </li>",
"     <li>",
"      Pepcid&reg;;",
"     </li>",
"     <li>",
"      Pepcid&reg; AC;",
"     </li>",
"     <li>",
"      Pepcid&reg; I.V.;",
"     </li>",
"     <li>",
"      Ulcidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Histamine H",
"       <sub>",
"        2",
"       </sub>",
"       Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric acid suppression, GERD:",
"     </b>",
"     Oral: 0.5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress ulcer prophylaxis, gastric acid suppression:",
"     </b>",
"     I.V.: 0.5 mg/kg/dose once daily (Crill, 1999; James, 1998; Wenning, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"      see \"Famotidine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children and Adolescent &le;16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      GERD, esophagitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 1-3 months: 0.5 mg/kg/dose once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &ge;3 months to 1 year: 0.5 mg/kg/dose twice daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 1-16 years: 0.5 mg/kg/dose twice daily (maximum dose: 40 mg/dose); doses up to 1 mg/kg/dose twice daily have been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients unable to take oral medication:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 0.25-0.5 mg/kg/dose once daily (Crill, 1999; James, 1998; Wenning, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 1-16 years: Initial: 0.25 mg/kg/dose every 12 hours (maximum dose: 20 mg/dose); doses up to 0.5 mg/kg/dose every 12 hours have been reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peptic ulcer disease:",
"     </b>",
"     Oral: Children and Adolescents 1-16 years: 0.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     once daily at bedtime or divided twice daily (maximum daily dose: 40 mg/day); doses up to 1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Stress ulcer prophylaxis, gastric acid suppression:",
"     </b>",
"     I.V.: 0.5-1 mg/kg/dose every 12 hours (maximum dose: 20 mg/dose) (Crill, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypersecretory conditions:",
"     </b>",
"     Oral: Adolescents: Initial: 20 mg every 6 hours, may increase up to 160 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heartburn, acid indigestion, or sour stomach",
"     </b>",
"     (OTC use): Oral: Adolescents: 10-20 mg 15-60 minutes before eating; not more than 2 tablets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Duodenal ulcer:",
"     </b>",
"     Oral: Acute therapy: 40 mg/day at bedtime (or 20 mg twice daily) for 4-8 weeks; maintenance therapy: 20 mg/day at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gastric ulcer:",
"     </b>",
"     Oral: Acute therapy: 40 mg/day at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypersecretory conditions:",
"     </b>",
"     Oral: Initial: 20 mg every 6 hours, may increase in increments up to 160 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      GERD:",
"     </b>",
"     Oral: 20 mg twice daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Esophagitis and accompanying symptoms due to GERD:",
"     </b>",
"     Oral: 20 mg or 40 mg twice daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Patients unable to take oral medication:",
"     </b>",
"     I.V.: 20 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heartburn, indigestion, sour stomach:",
"     </b>",
"     OTC labeling: Oral: 10-20 mg every 12 hours; dose may be taken 15-60 minutes before eating foods known to cause heartburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Manufacturer recommendation: Administer 50% of dose or increase the dosing interval to every 36-48 hours (to limit potential CNS adverse effects)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [preservative free]: 20 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (4 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 40 mg/5 mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg;: 40 mg/5 mL (50 mL) [contains sodium benzoate; cherry-banana-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heartburn Relief: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heartburn Relief Maximum Strength: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg [berries 'n' cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepcid&reg; AC Maximum Strength: 20 mg [cool mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Infusion, Injection, oral suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food and antacids; shake suspension vigorously for 10-15 seconds prior to each use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: May be administered at a maximum concentration of 4 mg/mL at a rate of &le;10 mg/minute over at least 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: Dilute to 0.2 mg/mL in an appropriate diluent, infuse over 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F169985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, fat emulsion 10%, NS, sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, aminophylline, amiodarone, ampicillin, ampicillin/sulbactam, amsacrine, anakinra, anidulafungin, atropine, aztreonam, bivalirudin, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cisatracurium, cisplatin, cladribine, clindamycin, cyanocobalamin, cyclosporine, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, dextran 40, digoxin, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin lactobionate, esmolol, etoposide phosphate, fenoldopam, filgrastim, fluconazole, fludarabine, folic acid, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, insulin (regular), isoproterenol, labetalol, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methotrexate, methylprednisolone sodium succinate, metoclopramide, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pemetrexed, phenylephrine, phytonadione, phenytoin, piperacillin, potassium chloride, potassium phosphate, procainamide, propofol, remifentanil, sargramostim, sodium bicarbonate, telavancin,  teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate potassium, tirofiban, verapamil, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, azithromycin, cefepime, piperacillin/tazobactam, sulfamethoxazole/trimethoprim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, dexamethasone sodium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder for oral suspension: Prior to mixing, dry powder should be stored at controlled room temperature of 25&deg;C (77&deg;F). Reconstituted oral suspension is stable for 30 days at room temperature; do not freeze",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Store controlled room temperature. Protect from moisture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Solution for injection: Prior to use, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). If solution freezes, allow to solubilize at controlled room temperature. May be stored at room temperature for up to 3 months [data on file (Bedford Laboratories, 2011)].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. push: Following preparation, solutions for I.V. push should be used immediately or may be stored in refrigerator and used within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infusion: Following preparation, the manufacturer states may be stored for up to 48 hours under refrigeration; however, solutions for infusion have been found to be physically and chemically stable for 7 days at room temperature; injection is compatible with D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR injection, 5% bicarbonate injection, and standard parenteral nutrition solutions with electrolytes, multivitamins, and trace minerals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Solution for injection, premixed bags: Store at controlled room temperature of 25&deg;C (77&deg;F); avoid excessive heat; stable at room temperature for 15 months",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term therapy and treatment of duodenal ulcer, active benign gastric ulcer, gastroesophageal reflux disease (GERD) (FDA approved in ages 1-16 and adults); pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas) (FDA approved in adults); OTC formulation for use in the relief of heartburn, acid indigestion, and sour stomach (FDA approved in children &gt;12 years and adults); has also been used for stress ulcer prophylaxis and gastric acid suppression in critically ill patients, and symptomatic relief in gastritis.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7305905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Famotidine may be confused with FLUoxetine, furosemide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, necrotizing enterocolitis (VLBW neonates; Guillet, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal discomfort, acne, agitation, agranulocytosis, allergic reaction, alopecia, anaphylaxis, angioedema, anorexia, anxiety, arrhythmia, arthralgia, AV block, bronchospasm, cholestatic jaundice, confusion, conjunctival injection, depression, dry skin, facial edema, fatigue, fever, flushing, hallucinations, hepatitis, injection site reactions, insomnia, interstitial pneumonia, leukopenia, libido decreased, liver function tests increased, muscle cramps, nausea, palpitation, pancytopenia, paresthesia, pruritus, QT-interval prolongation, rash, seizure, somnolence, Stevens-Johnson syndrome, taste disorder, tinnitus, thrombocytopenia, torsade de pointes, toxic epidermal necrolysis, urticaria, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to famotidine, any component, or other H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in renal impairment; seizures have been reported; dosage modification necessary. Relief of symptoms does not preclude the presence of a gastric malignancy. Reversible confusional states, usually clearing within 3-4 days after discontinuation, have been linked to use;  increased age (&gt;50 years) and renal or hepatic impairment are thought to be associated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools and not to extend use &gt;14 days without consulting their physician.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     QT prolongation has been reported in patients with renal dysfunction. Use of gastric acid inhibitors, including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H",
"     <sub>",
"      2",
"     </sub>",
"     receptor antagonists; however, a causal relationship has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H",
"     <sub>",
"      2",
"     </sub>",
"     blocker use and an increased incidence of NEC in VLBW neonates (Guillet, 2006).  An approximate sixfold  increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving an H",
"     <sub>",
"      2",
"     </sub>",
"     blocker (ranitidine) in a cohort analysis of 274 VLBW neonates (Terrin, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Multidose injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of the multidose injection in neonates. The oral suspension contains sodium benzoate;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: H2-Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: H2-Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: H2-Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: H2-Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: H2-Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: H2-Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: H2-Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: H2-Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: H2-Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: H2-Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: H2-Antagonists may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: H2-Antagonists may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: H2-Antagonists may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: H2-Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): H2-Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: H2-Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: H2-Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): H2-Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: H2-Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: H2-Antagonists may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: H2-Antagonists may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: H2-Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use whenever possible.  Monitor patients closely for decreased antifungal effects if this combination is used.  Consider using a noninteracting antifungal as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: H2-Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: H2-Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: H2-Antagonists may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: H2-Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: H2-Antagonists may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit xanthine-containing foods and beverages",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, famotidine is classified as pregnancy category B. Famotidine crosses the placenta. An increased risk of congenital malformations or adverse events in the newborn has generally not been observed following maternal use of famotidine during pregnancy. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD), as well as gastric and duodenal ulcers, during pregnancy. Although if needed, famotidine is not the agent of choice. Histamine H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists may be used for aspiration prophylaxis prior to cesarean delivery.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibition of histamine at H",
"     <sub>",
"      2",
"     </sub>",
"     -receptors of the gastric parietal cells, which results in inhibition of gastric acid secretion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Antisecretory effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: I.V.; Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Incompletely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-3 months: 1.4-1.8 &plusmn; 0.3-0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 to 12 months: 2.3 &plusmn; 0.7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2 &plusmn; 1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 1.5 &plusmn; 0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.94-1.33 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 30% to 35%; minimal first-pass metabolism; forms one metabolite (S-oxide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 40% to 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-3 months: 8.1-10.5 &plusmn; 3.5-5.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 to 12 months: 4.5 &plusmn; 1.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 3.3 &plusmn; 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: 2.3 &plusmn; 0.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-3.5 hours; increases with renal impairment; if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute, half-life &ge;20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuria: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1-3 hours; orally disintegrating tablet: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 65% to 70% unchanged drug in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     0-3 months: 0.13-0.21 &plusmn; 0.06 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;3-12 months: 0.49 &plusmn; 0.17 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-11 years: 0.54 &plusmn; 0.34 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 0.48 &plusmn; 0.14 L/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.39 &plusmn; 0.14 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16549?source=see_link\">",
"      see \"Famotidine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     OTC: Do not use for more than 14 days unless recommended by prescriber. May cause drowsiness, dizziness, constipation, or diarrhea. Report acute headache, unresolved constipation or diarrhea, palpitations, black tarry stools, abdominal pain, rash, worsening of condition being treated, or recurrence of symptoms after therapy is completed.  Avoid excessive amounts of coffee and aspirin; when self medicating, if the symptoms of heartburn, acid indigestion, or sour stomach persist after 2 weeks of continuous use of the drug, consult a clinician.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11368091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An 8 mg/mL oral suspension may be made with tablets. Crush seventy 40 mg tablets in a mortar and reduce to a fine powder. Add small portions of sterile water and mix to a uniform paste. Mix while adding a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg; in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     350 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 350 mL. Label \"shake well\". Stable for 95 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Dentinger PJ, Swenson CF, and Anaizi NH, \"Stability of Famotidine in an Extemporaneously Compounded Oral Liquid,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2000, 57(14):1340-2.",
"     <span class=\"pubmed-id\">",
"      10918924",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crill CM and Hak EB, \"Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(2):162-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/10030767/pubmed\" id=\"10030767\" target=\"_blank\">",
"        10030767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guillet R, Stoll BJ, Cotten CM, et al, \"Association of H",
"      <sub>",
"       2",
"      </sub>",
"      -Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):137-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/16390920/pubmed\" id=\"16390920\" target=\"_blank\">",
"        16390920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James LP and Kearns GL, &ldquo;Pharmacokinetics and Pharmacodynamics of Famotidine in Paediatric Patients,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(2):103-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/8853932/pubmed\" id=\"8853932\" target=\"_blank\">",
"        8853932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James LP, Marotti T, Stowe CD, et al, \"Pharmacokinetics and Pharmacodynamics of Famotidine in Infants,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1998, 38(12):1089-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/11301560/pubmed\" id=\"11301560\" target=\"_blank\">",
"        11301560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rudolph CD, Mazur LJ, Liptak GS, et al, \"Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2001, 32(Suppl 2):1-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/11525610/pubmed\" id=\"11525610\" target=\"_blank\">",
"        11525610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terrin G, Passariello A, De Curtis M, et al, \"Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2012, 129(1):40-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/22157140/pubmed\" id=\"22157140\" target=\"_blank\">",
"        22157140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treem WR, Davis PM, and Hyams JS, &ldquo;Suppression of Gastric Acid Secretion by Intravenous Administration of Famotidine in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(5):812-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/ 2019939 /pubmed\" id=\" 2019939 \" target=\"_blank\">",
"        2019939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wenning LA, Murphy MG, James LP, et al, \"Pharmacokinetics of Famotidine in Infants,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2005, 44(4):395-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/61/29655/abstract-text/15828852/pubmed\" id=\"15828852\" target=\"_blank\">",
"        15828852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13295 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29655=[""].join("\n");
var outline_f28_61_29655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169927\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169928\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058659\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442486\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058653\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169901\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169887\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058663\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169985\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058656\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058662\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7305905\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169983\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058668\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058652\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058651\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299312\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169896\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058670\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169898\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169910\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058650\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058666\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058667\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058658\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368091\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13295|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=related_link\">",
"      Famotidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/10/16549?source=related_link\">",
"      Famotidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29656="Oxygen monitoring and therapy in the newborn";
var content_f28_61_29656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygen monitoring and therapy in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29656/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29656/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29656/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/61/29656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen supplementation is an important component of intensive care of the newborn. Careful monitoring is required to avoid pulmonary toxicity or the consequences of hypoxemia or hyperoxia. The two main complications of excessive oxygen are lung injury and retinopathy. They are caused by different factors, from lung injury to high inspired oxygen concentration, and retinopathy to high arterial oxygen tension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link\">",
"     \"Retinopathy of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen administration, monitoring, and target levels for the neonate including the premature infant will be reviewed here. Oxygen administration during neonatal resuscitation in the delivery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H85370822#H85370822\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Supplemental oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OXYGEN TRANSPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal cellular function depends upon a continuous supply of oxygen. Inhaled oxygen diffuses across the alveolar-capillary membrane and into the pulmonary capillary blood. The partial pressure for oxygen in the alveoli (approximately 150 mmHg breathing room air at sea level) is greater than in mixed venous blood (40 mmHg) and in the mitochondria (&lt;10 mmHg). This gradient maintains the arterial oxygen tension (PaO2) and is the driving force for oxygen delivery to cells.",
"   </p>",
"   <p>",
"    Oxygen diffuses into the blood where it is predominantly bound to hemoglobin in red blood cells, with a small proportion being dissolved in plasma. The relationship between PaO2 and hemoglobin is described by the S-shaped oxyhemoglobin dissociation curve (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ). At a PaO2 above 90 mmHg, the curve is nearly flat, and hemoglobin is almost completely saturated. At lower values of PaO2, the curve falls steeply, promoting release of oxygen to the tissues.",
"   </p>",
"   <p>",
"    Oxygen affinity, which refers to the ability of hemoglobin to bind or release oxygen, is modulated by pH, CO2 (in part independent of pH), 2,3-diphosphoglycerate (DPG), temperature, and fetal hemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ). Lower pH, higher CO2, increased temperature, and a decreased proportion of fetal hemoglobin reduce oxygen affinity. These shifts in affinity promote oxygen uptake in the pulmonary capillaries and release into the tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen content and delivery must exceed oxygen consumption to ensure sufficient tissue oxygenation. Adequate oxygen content depends upon normal hemoglobin concentration and PaO2. Delivery of oxygen to the tissues requires appropriate blood volume, heart rate, and cardiac function. Circulatory failure can result in tissue ischemia and hypoxia, even if oxygen content is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oxygen content",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arterial oxygen content (CaO2) is the sum of the quantity of oxygen bound to hemoglobin plus the amount of free oxygen dissolved in the blood, according to the equation:",
"   </p>",
"   <p>",
"    CaO2 (mL",
"    <span class=\"nowrap\">",
"     O2/dL)",
"    </span>",
"    = (1.34 x hemoglobin concentration x SaO2) + (0.0031 x PaO2)",
"   </p>",
"   <p>",
"    where PaO2 is the partial pressure of oxygen in the arterial blood and SaO2 is the arterial oxyhemoglobin saturation.",
"   </p>",
"   <p>",
"    Each gram of fully saturated hemoglobin carries 1.34 mL of oxygen. Oxygen dissolves in plasma proportionally to the PaO2, with 0.0031 mL dissolved per deciliter of blood per mmHg PaO2.",
"   </p>",
"   <p>",
"    Normal CaO2 is approximately 20 mL",
"    <span class=\"nowrap\">",
"     O2/dL,",
"    </span>",
"    depending upon the site from which the blood is sampled. It is much greater than the 5",
"    <span class=\"nowrap\">",
"     mL/dL",
"    </span>",
"    of oxygen that is normally extracted during each pass of the circulation at steady state, and provides a substantial reserve if blood flow is reduced or demands for oxygen increase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen delivery (DO2) is the amount of oxygen transported from the lungs to the microcirculation. Oxygen delivery depends upon the cardiac output (Q) and CaO2:",
"   </p>",
"   <p>",
"    DO2",
"    <span class=\"nowrap\">",
"     (mL/kg",
"    </span>",
"    per min) = Q x CaO2",
"   </p>",
"   <p>",
"    Cardiac output in newborns is approximately 250",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min. Thus, DO2 is 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    when CaO2 is 20",
"    <span class=\"nowrap\">",
"     mL/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oxygen consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen consumption (VO2) can be calculated as a function of the cardiac output (Q) and arteriovenous content difference. Practical techniques for clinical measurements in newborns are unavailable.",
"   </p>",
"   <p>",
"    Oxygen consumption can be indirectly calculated from the Fick equation:",
"   </p>",
"   <p>",
"    VO2",
"    <span class=\"nowrap\">",
"     (mL/kg",
"    </span>",
"    per min) = Q x (CaO2 - CvO2)",
"   </p>",
"   <p>",
"    where the arteriovenous content difference, CaO2 - CvO2, represents the quantity of O2 extracted by the peripheral tissues. This method assumes that all unused oxygen is transferred from the arterial to the venous circulation. VO2 is approximately 4.5 to 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min during the first month after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OXYGEN ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neonatal resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of supplemental oxygen and its administration and monitoring are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H85370822#H85370822\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Supplemental oxygen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Postresuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the need for supplemental oxygen persists after resuscitation, the gas should be warmed, humidified, and delivered using a system in which the concentration can be regulated. The inspired oxygen concentration should be measured with an oxygen analyzer, continuously if possible, or at a minimum of every hour. Comparison of the oxygen concentration needed to maintain adequate oxygenation in the patient is an important measure of the efficiency of gas exchange in cardiorespiratory disease.",
"   </p>",
"   <p>",
"    Delivery devices include a hood, facemask, nasal cannula, nasal continuous positive airway pressure (CPAP), or endotracheal tube if the infant requires assisted ventilation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Continuous flow nasal cannula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delivery of oxygen by nasal cannula poses a unique clinical challenge, because inspired oxygen concentration cannot be directly determined. The inspired oxygen concentration is a mixture of room air (which enters through the infant's mouth and nose) and oxygen delivered by nasal cannula.",
"   </p>",
"   <p>",
"    There are established formulas to estimate the effective delivered oxygen concentration based upon the size of the patient and the concentration of oxygen and flow rates delivered through the nasal cannula [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these formulas are not routinely used in practice because they are cumbersome to perform during clinical care. As a result, the effective inspired oxygen concentration is often lower than prescribed and, in some cases, equivalent to the oxygen concentration of room air [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited humidification by the standard nasal cannula therapy results in drying of the upper airway mucosa, which can contribute to nasal mucosal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     High flow nasal cannula",
"    </span>",
"    &nbsp;&mdash;&nbsp;High flow nasal cannulas (HFNC) are increasingly being used to provide positive distending pressure with or without oxygen instead of traditional continuous positive airway pressure (CPAP) devices [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, a major issue with HFNC is regulating the delivered pressure, because airflow is directly applied to the infant, and the generated pressure is primarily determined by the",
"    <span class=\"nowrap\">",
"     open/close",
"    </span>",
"    status of the infant's mouth.",
"   </p>",
"   <p>",
"    This was illustrated in one study that measured the oral cavity pressure, which was used to estimate airway pressure, at varying flow rates in 27 infants who were being treated with HFNC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/8\">",
"     8",
"    </a>",
"    ]. With the mouth open, there was no generated pressure regardless of the flow rate in any size infant. With the mouth closed, oral cavity pressure rose with increasing flow rates and decreasing size of the patient. Pressures of 4.5 cm H2O were generated in infants with fully closed mouths who weighed less than 1500 g and received a flow rate of 4",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    In larger infants (greater than 2000 g), the maximum pressure generated at a flow rate of 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    was less than 3 cm H2O.",
"   </p>",
"   <p>",
"    A crossover over study comparing the effect of CPAP (adjusted to 6 cm H2O) and HFNC on the cardiorespiratory status of 15 preterm infants (gestational age less than 30 weeks) also noted the variability of airway pressure of HFNC at different flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/9\">",
"     9",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The end-expiratory esophageal pressure (EEEP) generally increased with increasing flow rates with HFNC. However, there was great variability in the EEEP value at different tested flow rates so that it was not possible to predict EEEP for a given flow rate.",
"     </li>",
"     <li>",
"      There were no differences in heart rate, arterial oxygen saturation, and respiratory distress syndrome score between CPAP and HFNC. The respiratory rate of the infants increased as the HFNC flow rate decreased from 6",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      to 2",
"      <span class=\"nowrap\">",
"       L/min,",
"      </span>",
"      and comparable respiratory rates to nasal CPAP were observed when the flow rate was &ge;4",
"      <span class=\"nowrap\">",
"       L/min.",
"      </span>",
"     </li>",
"     <li>",
"      In vitro testing demonstrated that pressure-limiting valve (PLV) was effective in limiting pressure to the set maximum pressure in a system without leaks when the flow was increased to 6",
"      <span class=\"nowrap\">",
"       L/minute.",
"      </span>",
"      With leaks of 30 percent, the delivered pressure was always below 3 cm H20 at a flow rate of 6",
"      <span class=\"nowrap\">",
"       L/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this study suggests that HFNC may be useful in providing distending pressure, it showed that it is not possible to predict the delivered pressure to the infant based upon flow rates. It also demonstrated that it is feasible to include a PLV within the system; however, studies are needed to confirm that PLV will work in the clinical setting and be able to prevent delivery of excessive pressure to preterm infants.",
"   </p>",
"   <p>",
"    It is also unclear whether the work of breathing is greater using HFNC versus the conventional lower flow nasal CPAP delivery system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability to detect dangerously high or ineffectively low levels of continuous distending pressure during HFNC use remains problematic in clinical practice. Further data regarding the efficacy and safety of HFNC are needed before the technique can be recommended for routine use as a noninvasive mechanical support for preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF OXYGENATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygenation should be monitored in any infant who receives supplemental oxygen therapy to prevent episodes of hypoxemia and hyperoxia, and avoid the use of excessive supplemental oxygen. In premature infants, high concentrations of supplemental oxygen are associated with increased risk of bronchopulmonary dysplasia and retinopathy of prematurity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H3#H3\">",
"     \"Retinopathy of prematurity\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H8#H8\">",
"     \"Retinopathy of prematurity\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Oxygen toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The level of oxygenation can be assessed in several ways. Each method provides unique information and has potential limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arterial blood gas measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of arterial oxygen tension (PaO2) measures the partial pressure of the small amount of oxygen that is dissolved in plasma, and has been considered the \"gold standard\" for the measurement of oxygenation. The PaO2, along with the accompanying measurements of PaCO2 and pH, are used to evaluate effective pulmonary gas exchange in acute cardiopulmonary disease. However, intermittent sampling of arterial blood may not reflect the fluctuations in oxygenation that typically occur in infants with cardiopulmonary disease. In addition, although PaO2 measurements can be used to estimate oxyhemoglobin saturation, changes in pH, temperature, or other factors may render this estimate unreliable. Capillary samples do",
"    <strong>",
"     not",
"    </strong>",
"    provide reliable measurements of PaO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Specimen collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood usually is obtained by percutaneous needle puncture of a palpable artery. The radial artery usually is used; the posterior tibial artery is a good alternate site. The brachial and femoral arteries should be avoided if possible. Percutaneous puncture frequently causes agitation, and the resultant PaO2 measurement may be lower than in steady state conditions.",
"   </p>",
"   <p>",
"    Catheterization of the arterial system can be performed when frequent arterial blood gases are required. Sampling from a catheter also avoids the agitation associated with percutaneous puncture. Preferred locations in newborns are the umbilical or radial arteries; an alternate site is the dorsalis pedis. Common clinical settings in which an indwelling arterial catheter is useful include patients with tenuous gas exchange (eg, severe respiratory distress syndrome or persistent pulmonary hypertension) or shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of arterial blood gases (PaO2 and PaCO2) can be affected by the presence of air bubbles, the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    as an anticoagulant, and the type of syringe used for collection. Air bubbles occupying more than 1 to 2 percent of the blood volume in the syringe may introduce error, leading to an artifactual high arterial PO2 and an underestimation of the true arterial PC02 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The error can be decreased by gentle removal of bubbles without agitation and by rapid sample analysis.",
"   </p>",
"   <p>",
"    Acidic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    causes only a small change in pH, but the dilutional effect of the heparin solution can produce significant reductions in PCO2, depending directly on the amount of heparin solution relative to the amount of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, the amount of heparin solution should be kept to a minimum, or syringes prepared with dry heparin should be used.",
"   </p>",
"   <p>",
"    Gas diffusion through plastic syringes may introduce error. This error generally is not significant if the sample is analyzed within 15 minutes and the specimen is placed on ice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulse oximetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry measures hemoglobin saturation (SpO2) and reflects the 98 percent of arterial oxygen content that is carried normally by hemoglobin. This monitoring technique provides data that are immediate, continuous, and noninvasive, and, therefore, avoids some limitations of intermittent arterial blood sampling. As a result, in most neonatal intensive care units, pulse oximetry is the accepted standard for routine monitoring, and SpO2 has been called the \"fifth vital sign\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulse oximeter values of SpO2 between 70 and 100 percent in healthy adults are reported to be accurate within &plusmn;2 percent of the true value measured by co-oximetry. Measurements have also been compared in sick newborns with blood sampling from arterial catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. As an example, pulse oximetry values were highly correlated with measured SaO2; values of 92 &plusmn;3 percent were always associated with PaO2 values of 45 to 100 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'SpO2 correlation with PaO2 values'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to determine the target pulse oximetry saturation range that adequately meets metabolic demands of the neonate, yet limits the need for high concentrations of supplemental oxygen that might cause lung injury or retinopathy of prematurity (ROP). Normal pulse oximetry values in healthy term infants average 97 percent on room air [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and in healthy preterm infants 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to maintain SpO2 values greater than 95 percent using supplemental oxygen may result in excess oxygen exposure and hyperoxia. Determination of SaO2 target levels is discussed below. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Oxygen target levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most NICUs currently establish guidelines for target pulse oximetry saturation levels, patients are often outside the intended targeted range. This was illustrated in a multicenter study of 84 preterm infants of less than 28 weeks gestation who received oxygen therapy and were monitored by pulse oximetry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/21\">",
"     21",
"    </a>",
"    ]. Infants spent 16, 48, and 36 percent of monitored time below, within, and above their NICU targeted oximeter range, respectively. The successful maintenance of intended oximetry saturation levels varied among centers. It appeared that centers that set oximeter alarm closer to the target range limits had better target range compliance, but this leads to a higher number of monitor alarms. In another study, although the lower alarm limit was usually set correctly, the upper alarm limit was set correctly only 23 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional measures including increased surveillance and heightened awareness by medical personnel at the bedside may be helpful to reduce the time periods of either too low or too high oxygen saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulse oximetry is easy to use and does not require calibration. However, interpretation of pulse oximetry readings must account for a variety of technical and clinical factors that may artifactually influence the results. The best defense against these potential sources of error is a high index of suspicion.",
"   </p>",
"   <p>",
"    Technical sources of error include motion artifact, improper probe placement, and ambient light [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"     24",
"    </a>",
"    ]. Pulse oximeters are sensitive to changes in background signal that result from body movement. Low amplitude arterial pulsations in small preterm infants are particularly difficult for oximeters to detect and differentiate from venous pulsations and other movement artifacts.",
"   </p>",
"   <p>",
"    Examination of the displayed waveform is recommended to validate the oximeter signal. An alternate check is comparison of the pulse rate from the oximeter with the heart rate from the electrocardiograph monitor; the two values should be identical.",
"   </p>",
"   <p>",
"    Erroneous data will result if light that has not passed through the tissue is received by the oximeter probe, which can occur if the probe is improperly placed on the extremity or if it is exposed to ambient light. These problems can be avoided by proper placement and shielding of the probe.",
"   </p>",
"   <p>",
"    Measurements may differ by approximately 2 percent among various instruments, because different algorithms are used to derive SpO2 or to exclude motion artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"     24",
"    </a>",
"    ]. False desaturation events are common in small preterm infants during SpO2 monitoring. Such events could contribute to excess oxygen administration. New signal extraction technology may improve the accuracy of monitoring during movement or poor perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical factors that contribute to error include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoperfusion &mdash; Pulse oximetry readings can be falsely low because of signal failure in the setting of hemodynamic instability or poor limb perfusion caused by vasoconstriction. Placement of a blood pressure cuff and oximeter probe on the same extremity should be avoided.",
"     </li>",
"     <li>",
"      Abnormal hemoglobins and severe anemia &mdash; Abnormal hemoglobins or hemoglobin variants can interfere with pulse oximetry if their absorption properties are similar to those of oxyhemoglobin or deoxyhemoglobin. Fetal hemoglobin does",
"      <strong>",
"       not",
"      </strong>",
"      interfere with oximetry measurements unless levels exceed 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/26\">",
"       26",
"      </a>",
"      ]. Although pulse oximetry values are falsely lowered only when anemia is very severe, clinicians must be aware that low hemoglobin concentrations decrease oxygen content and delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"       \"Genetic disorders of hemoglobin oxygen affinity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperoxia or severe hypoxemia &mdash; Pulse oximeters are not ideally suited to detect hyperoxia or severe hypoxemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"       24",
"      </a>",
"      ]. Because of the shape of the oxyhemoglobin dissociation curve, large changes in PaO2 may result in no change in O2 saturation if the saturation is already near 100 percent. Thus, in newborns at risk for hyperoxia or profound hypoxemia, SpO2 should be verified by periodic arterial blood gas analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Transcutaneous oxygen monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous oxygen monitors measure oxygen tension (TcPO2) with a blood gas electrode applied to the skin surface. The technique depends upon heating the skin at the sensor site to 43.5 to 44.0&ordm;C to increase skin perfusion and diffusion of oxygen into the sensor.",
"   </p>",
"   <p>",
"    In stable preterm infants, TcPO2 correlates well with PaO2 measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, this technique underestimates PaO2 when skin perfusion is decreased, as occurs with hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"     24",
"    </a>",
"    ]. Increasing skin thickness with maturation also decreases accuracy.",
"   </p>",
"   <p>",
"    Detection of hyperoxia or hypoxemia may be unreliable with these devices. In an analysis of published studies, TcPO2 monitoring missed approximately 15 percent of these episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"     24",
"    </a>",
"    ]. TcO2 monitoring also may be unreliable in older infants with bronchopulmonary dysplasia (BPD). In one study of infants more than 10 weeks of age with BPD, TcPO2 significantly underestimated PaO2 by 16 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calibration is required, and accuracy of monitoring is dependent upon user expertise. Because the sensor is heated, the application site must be changed every four hours to avoid thermal injury, and the sensor must be calibrated before each application. These procedures take time and interrupt monitoring. Because of these technical limitations, TcO2 monitoring is rarely used in the NICU environment today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OXYGEN TARGET LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal values for PaO2 in term newborns and healthy premature infants are approximately 50 to 60 mmHg in the first hours after birth, and stabilize at values greater than 70 mmHg after 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. During oxygen therapy, the target PaO2 is selected to achieve acceptable tissue oxygenation. Tissue oxygenation will also depend upon circulatory function and the hemoglobin concentration.",
"   </p>",
"   <p>",
"    In general, PaO2 values of 50 to 80 mmHg are adequate to meet metabolic demands and limit the need for high concentrations of supplemental oxygen that might cause lung injury. In some circumstances (eg, congenital heart disease and preterm infants), lower target levels (40 to 50 mmHg) may be acceptable. High PaO2 levels must also be avoided in premature infants to avoid the risk of retinal vasoconstriction and retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H8#H8\">",
"     \"Retinopathy of prematurity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     SpO2 correlation with PaO2 values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most NICUs, current monitoring strategies employ target pulse oxygen saturation values rather than targeted PaO2 levels.",
"   </p>",
"   <p>",
"    In general, SpO2 values from 85 to 95 percent provide a PaO2 range that avoids hyperoxia as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 98 consecutive infants born at less than 29 weeks gestation that compared paired SpO2 and PaO2 measurements, the mean PaO2 at 85 percent SpO2 was 40 mmHg (range of 29 to 51 mmHg), and at 95 percent SpO2, the mean PaO2 was mean 54 mmHg (range 41 to 67 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective multicenter study of 122 neonates that compared 976 paired SpO2 and PaO2 measurements, when SpO2 values were between 85 and 93 percent, the mean PaO2 was 56 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/33\">",
"       33",
"      </a>",
"      ]. About 87 percent of the PaO2 values were between 40 and 80 mmHg, 9 percent were below 40 mmHg, and 5 percent were greater than 80 mmHg. When SpO2 was greater than 93 percent, the mean PaO2 was 107 mmHg. About 60 percent of the PaO2 values were greater than 80 mmHg.",
"     </li>",
"     <li>",
"      Similar results were reported from an earlier study that reported a mean cord blood PaO2 of 41 mmHg in 10 preterm infants who were less than 30 weeks gestation and who had an SpO2 of 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, the high affinity of fetal hemoglobin (Hb F) results in high oxygen saturation at PaO2 levels below 50 mmHg, and increasing PaO2 above 50 mmHg may achieve little further increase in oxygen content. The proportion of HbF increases with decreasing gestational age so that the concentration of HbF in an infant born at 28 weeks gestation is approximately 90 percent. The increased concentration of HbF and its increased affinity for oxygen is another factor to consider in establishing target SpO2 values, which can be lower in premature infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H8#H8\">",
"     \"Anemia of prematurity\", section on 'Oxygen delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     High versus low SpO2 target",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to determine the target pulse oximetry saturation range that adequately meets metabolic demands of the premature neonate yet limits the need for high concentrations of supplemental oxygen that might increase the risk of bronchopulmonary dysplasia (BPD) or retinopathy of prematurity (ROP). However, the optimal SpO2 for premature infants has not been fully established.",
"   </p>",
"   <p>",
"    Clinical trials have demonstrated higher oxygen target goals were associated with greater morbidity in premature infants. However, as oxygen target goals decrease, it remains unclear whether or not there is an increase in mortality in extremely premature infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the STOP-ROP trial, 649 infants (mean gestational age 25.4 weeks) with prethreshold ROP were randomly assigned to maintain SpO2 at 96 to 99 (high SpO2) or 89 to 94 (control SpO2) percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/35\">",
"       35",
"      </a>",
"      ]. Infants in the high SpO2 group compared with those in the control SpO2 group were more likely to remain hospitalized (13 versus 7 percent), on oxygen (47 versus 37 percent), receive diuretic therapy (36 versus 24 percent), and have pneumonia or chronic lung disease (13 versus 9 percent) at 50 weeks postmenstrual age (PMA). Mortality rate and progression of retinal disease was similar in the two groups.",
"     </li>",
"     <li>",
"      In the Benefits of Oxygen Saturation Targeting (BOOST) Trial, 358 infants born at less than 30 weeks PMA were randomly assigned to maintain SpO2 at 95 to 99 (high SpO2) or 91 to 94 percent (control SpO2) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/36\">",
"       36",
"      </a>",
"      ]. Infants in the high SpO2 group received longer oxygen therapy (median of 40 versus 18 days), and were more likely to receive supplemental oxygen at 36 weeks PMA and at home. There were no differences between the two groups in growth or rate of major disabilities. Although there were six deaths due to pulmonary causes in the high SpO2 group and only one in the control group, the difference was not statistically significant.",
"      <br/>",
"      <br/>",
"      Enrollment of a subsequent trial (BOOST II trial) of infants born at less than 28 weeks gestational age was closed early after a safety analysis demonstrated a higher survival rate in the group that was randomly assigned to a high target SpO2 of 91 to 95 percent versus those in the low target SpO2 group of 85 to 89 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the SUPPORT (Surfactant, positive pressure, and pulse oximetry randomized) trial, 1316 premature infants (mean gestational age 26 weeks) were randomly assigned to maintain SpO2 at 91 to 95 (high SpO2) or 85 to 89 percent (low SpO2) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/38\">",
"       38",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In this study, infants were also randomly assigned to intubation and surfactant therapy, or nasal continuous positive airway pressure (CPAP) alone within the first hour of life. Infants in the low SpO2 were less likely to have severe ROP (8.6 versus 17.9 percent, relative risk [RR] 0.52, 95% CI 0.37-0.73) but had a higher mortality rate before discharge (19.9 versus 16.2 percent, RR 1.27, 95% CI 1.01 to 1.6). There were no differences in the rates of intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, pneumothorax or other air leaks, late sepsis, and patent ductus arteriosus. The rate of BPD was similar in the two groups based upon a physiologic definition, which determines whether supplemental oxygen is required by a trial of reducing oxygen concentration. However, the rate of supplemental oxygen administration was lower in the low SpO2. The effect of the initial ventilation management on SpO2 target range was uncertain, as the study did not directly compare the results of the four study groups",
"      <span class=\"nowrap\">",
"       (CPAP/high",
"      </span>",
"      SpO2,",
"      <span class=\"nowrap\">",
"       CPAP/low",
"      </span>",
"      SpO2,",
"      <span class=\"nowrap\">",
"       surfactant/high",
"      </span>",
"      SpO2, and",
"      <span class=\"nowrap\">",
"       surfactant/high",
"      </span>",
"      SpO2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up study of 94 percent of enrolled infants (n = 1234) demonstrated no difference in the composite outcome of death or neurodevelopmental outcome at 18 to 22 months corrected age between low and high SpO2 groups (30.2 versus 27.5 percent; relative risk [RR] 1.12, 95% CI 0.94-1.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/39\">",
"     39",
"    </a>",
"    ]. However, mortality was increased in the low SpO2 group (22.1 versus 18.2 percent; RR 1.25, 95% CI 1-1.5). Impaired neurodevelopmental outcome was defined as a predefined poor score on cognitive testing, moderate or severe cerebral palsy, hearing impairment, or bilateral visual impairment.",
"   </p>",
"   <p>",
"    A subcohort analysis of 115 patients monitored by high resolution oximetry reported that patients assigned to the low SpO2 group were more likely to experience intermittent episodes of hypoxemia (defined as SpO2 &le;80 percent for &ge;10 seconds and &le;3 minutes) prior to 12 days and beyond 59 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/40\">",
"     40",
"    </a>",
"    ]. Higher rates of intermittent hypoxemia events were associated with lower gestational age. In both high and low SpO2 groups, increasing postnatal age was associated with a shorter duration of episodes but increased severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pooled data of premature infants (gestational age &lt;28 weeks) at 36 postmenstrual age from the SUPPORT trial and the BOOST II trial appeared to show a higher survival rate in patients randomly assigned to the high SpO2 target of 91 to 95 percent compared with the low SpO2 group of 85 to 89 percent (85.6 versus 82.7 percent, RR 1.21, 95% CI 0.96-1.52) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29656/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    Because these studies used different target SpO2 ranges, the optimal SpO2 remains uncertain, particularly the upper and lower limits.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The STOP-ROP study suggests 89 to 94 percent is a better target range than 95 to 99 percent",
"     </li>",
"     <li>",
"      The BOOST study suggests that 91 to 94 percent is a better target range than 95 to 99 percent",
"     </li>",
"     <li>",
"      The SUPPORT study suggests that 91 to 95 percent is a better target range then 85 to 89 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, the results suggest that values at the extreme (ie, above 95 percent and below 89 percent) are associated with poorer outcome, particularly mortality, in very premature infants. However, universal application of these results are limited by the uncertainty of how precisely targeted SpO2 levels are adhered to compared with research settings. As discussed above, SpO2 levels are often outside the intended targeted range, and the variability among NICUs in maintaining targeted SpO2 ranges must also be considered as universal guidelines are established. In addition, because these studies were conducted primarily in very premature infants (ie, less than 30 weeks postmenstrual age), results are not applicable to more mature infants, in whom higher SpO2 target may be desirable. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Pulse oximetry'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;At our center, based upon the results of the studies discussed in the previous section, our current Sp02 targeted levels are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preterm infants &ndash; 90 to 95 percent",
"     </li>",
"     <li>",
"      Infants greater than 40 weeks postmenstrual age with acute respiratory distress &ndash; 90 to 95 percent",
"     </li>",
"     <li>",
"      The targeted SpO2 levels of infants with congenital heart disease, bronchopulmonary dysplasia, or pulmonary hypertension are individualized based upon the clinical status of the neonate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal cellular function requires an adequate continuous supply of oxygen that is determined by the arterial blood oxygen content that depends upon oxygen exchange across the alveolar-capillary membrane, oxygen transport and delivery, and oxygen consumption. Supplemental oxygen may be needed to meet the metabolic demands of the neonate because of cardiopulmonary disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Oxygen transport'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The requirement for supplemental oxygen and its administration for infants who require neonatal resuscitation in the delivery room are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H85370822#H85370822\">",
"       \"Neonatal resuscitation in the delivery room\", section on 'Supplemental oxygen'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In infants who have a persistent need for oxygen after resuscitation, oxygen should be warmed, humidified, and delivered using a system in which the concentration can be regulated. The inspired oxygen concentration should be measured with an oxygen analyzer, continuously if possible, or at a minimum of every hour. Delivery devices include a hood, facemask, nasal cannula, nasal continuous positive airway pressure (CPAP), or endotracheal tube if the infant requires assisted ventilation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Oxygen administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that oxygenation be measured in any infant who receives supplemental oxygen to prevent episodes of hypoxemia and hyperoxia, and avoid the use of excessive supplemental oxygen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In premature infants, high concentrations of supplemental oxygen are associated with increased risk of bronchopulmonary dysplasia and retinopathy of prematurity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H3#H3\">",
"       \"Retinopathy of prematurity\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=see_link&amp;anchor=H8#H8\">",
"       \"Retinopathy of prematurity\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Oxygen toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The level of oxygenation can be assessed by arterial blood gas measurement, pulse oximetry, and transcutaneous oxygen monitoring. We do not recommend the use of transcutaneous oxygen monitoring, as it is not as accurate and more limited in it use than the other two methods (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend targeting oxygen saturation based upon pulse oximetry (SpO2) and postmenstrual age (PMA) to avoid hypoxia and exposure to excess oxygen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). During hospitalization, oxygen saturation is monitored continuously by pulse oximetry to maintain SpO2 in a targeted range. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Oxygen target levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, targeted oxygen saturation goals are as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preterm infants &ndash; 90 to 95 percent",
"     </li>",
"     <li>",
"      Infants greater than 40 weeks PMA with acute respiratory distress &ndash; 90 to 95 percent",
"     </li>",
"     <li>",
"      Infants with congenital heart disease, established BPD, or pulmonary hypertension represent a special category, and each patient must be individualized.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nunn JF. Nunn's Applied Respiratory Physiology, Butterworth-Heinemann, Oxford 1993. p.282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/2\">",
"      Hill JR, Rahimtulla KA. Heat balance and the metabolic rate of new-born babies in relation to environmental temperature; and the effect of age and of weight on basal metabolic rate. J Physiol 1965; 180:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/3\">",
"      Marks KH, Nardis EE, Momin MN. Energy metabolism and substrate utilization in low birth weight neonates under radiant warmers. Pediatrics 1986; 78:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/4\">",
"      Benaron DA, Benitz WE. Maximizing the stability of oxygen delivered via nasal cannula. Arch Pediatr Adolesc Med 1994; 148:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/5\">",
"      Walsh M, Engle W, Laptook A, et al. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved? Pediatrics 2005; 116:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/6\">",
"      Finer NN, Mannino FL. High-flow nasal cannula: a kinder, gentler CPAP? J Pediatr 2009; 154:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/7\">",
"      Shoemaker MT, Pierce MR, Yoder BA, DiGeronimo RJ. High flow nasal cannula versus nasal CPAP for neonatal respiratory disease: a retrospective study. J Perinatol 2007; 27:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/8\">",
"      Kubicka ZJ, Limauro J, Darnall RA. Heated, humidified high-flow nasal cannula therapy: yet another way to deliver continuous positive airway pressure? Pediatrics 2008; 121:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/9\">",
"      Lampland AL, Plumm B, Meyers PA, et al. Observational study of humidified high-flow nasal cannula compared with nasal continuous positive airway pressure. J Pediatr 2009; 154:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/10\">",
"      Courtney SE, Pyon KH, Saslow JG, et al. Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants: an evaluation of three devices. Pediatrics 2001; 107:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/11\">",
"      Saslow JG, Aghai ZH, Nakhla TA, et al. Work of breathing using high-flow nasal cannula in preterm infants. J Perinatol 2006; 26:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/12\">",
"      Williams AJ. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. BMJ 1998; 317:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/13\">",
"      Harsten A, Berg B, Inerot S, Muth L. Importance of correct handling of samples for the results of blood gas analysis. Acta Anaesthesiol Scand 1988; 32:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/14\">",
"      Hansen JE, Simmons DH. A systematic error in the determination of blood PCO2. Am Rev Respir Dis 1977; 115:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/15\">",
"      Neff TA. Routine oximetry. A fifth vital sign? Chest 1988; 94:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/16\">",
"      Hay WW Jr, Brockway JM, Eyzaguirre M. Neonatal pulse oximetry: accuracy and reliability. Pediatrics 1989; 83:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/17\">",
"      Durand M, Ramanathan R. Pulse oximetry for continuous oxygen monitoring in sick newborn infants. J Pediatr 1986; 109:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/18\">",
"      Levesque BM, Pollack P, Griffin BE, Nielsen HC. Pulse oximetry: what's normal in the newborn nursery? Pediatr Pulmonol 2000; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/19\">",
"      Brockmann PE, Poets A, Urschitz MS, et al. Reference values for pulse oximetry recordings in healthy term neonates during their first 5 days of life. Arch Dis Child Fetal Neonatal Ed 2011; 96:F335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/20\">",
"      Harigopal S, Satish HP, Taktak AF, et al. Oxygen saturation profile in healthy preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96:F339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/21\">",
"      Hagadorn JI, Furey AM, Nghiem TH, et al. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks' gestation: the AVIOx study. Pediatrics 2006; 118:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/22\">",
"      Clucas L, Doyle LW, Dawson J, et al. Compliance with alarm limits for pulse oximetry in very preterm infants. Pediatrics 2007; 119:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/23\">",
"      Greenspan JS, Goldsmith JP. Oxygen therapy in preterm infants: hitting the target. Pediatrics 2006; 118:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/24\">",
"      Poets CF, Southall DP. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. Pediatrics 1994; 93:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/25\">",
"      Next-generation pulse oximetry. Focusing on Masimo's signal extraction technology. Health Devices 2000; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/26\">",
"      Jennis MS, Peabody JL. Pulse oximetry: an alternative method for the assessment of oxygenation in newborn infants. Pediatrics 1987; 79:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/27\">",
"      Peabody JL, Willis MM, Gregory GA, et al. Clinical limitations and advantages of transcutaneous oxygen electrodes. Acta Anaesthesiol Scand Suppl 1978; 68:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/28\">",
"      Sandberg KL, Brynjarsson H, Hjalmarson O. Transcutaneous blood gas monitoring during neonatal intensive care. Acta Paediatr 2011; 100:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/29\">",
"      Rome ES, Stork EK, Carlo WA, Martin RJ. Limitations of transcutaneous PO2 and PCO2 monitoring in infants with bronchopulmonary dysplasia. Pediatrics 1984; 74:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/30\">",
"      Koch G, Wendel H. Adjustment of arterial blood gases and acid base balance in the normal newborn infant during the first week of life. Biol Neonat 1968; 12:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/31\">",
"      Orzalesi MM, Mendicini M, Bucci G, et al. Arterial oxygen studies in premature newborns with and without mild respiratory disorders. Arch Dis Child 1967; 42:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/32\">",
"      Quine D, Stenson BJ. Arterial oxygen tension (Pao2) values in infants &lt;29 weeks of gestation at currently targeted saturations. Arch Dis Child Fetal Neonatal Ed 2009; 94:F51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/33\">",
"      Castillo A, Sola A, Baquero H, et al. Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range? Pediatrics 2008; 121:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/34\">",
"      Emond D, Lachance C, Gagnon J, Bard H. Arterial partial pressure of oxygen required to achieve 90% saturation of hemoglobin in very low birth weight newborns. Pediatrics 1993; 91:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/35\">",
"      Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/36\">",
"      Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/37\">",
"      Stenson B, Brocklehurst P, Tarnow-Mordi W, et al. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med 2011; 364:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/38\">",
"      SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/39\">",
"      Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012; 367:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29656/abstract/40\">",
"      Di Fiore JM, Walsh M, Wrage L, et al. Low oxygen saturation target range is associated with increased incidence of intermittent hypoxemia. J Pediatr 2012; 161:1047.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5067 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29656=[""].join("\n");
var outline_f28_61_29656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OXYGEN TRANSPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oxygen content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oxygen consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OXYGEN ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neonatal resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Postresuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Continuous flow nasal cannula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - High flow nasal cannula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEASUREMENT OF OXYGENATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arterial blood gas measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Specimen collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sources of error",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sources of error",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Transcutaneous oxygen monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OXYGEN TARGET LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SpO2 correlation with PaO2 values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      High versus low SpO2 target",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5067|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10762?source=related_link\">",
"      Retinopathy of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29657="Dermatoses of pregnancy";
var content_f28_61_29657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatoses of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Miriam Keltz Pomeranz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29657/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/61/29657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal skin and appendages undergo normal physiological changes during pregnancy, as do other organ systems (",
"    <a class=\"graphic graphic_table graphicRef78973 \" href=\"UTD.htm?3/41/3740\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=see_link\">",
"     \"The skin, hair, nails, and mucous membranes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous diseases that are specific to the gravid state may also occur. Dermatoses of pregnancy are defined as skin disorders that are limited to pregnant and puerperal women. These include the following conditions, which are described below [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pemphigoid gestationis",
"     </li>",
"     <li>",
"      Pruritic urticarial papules and plaques of pregnancy",
"     </li>",
"     <li>",
"      Atopic eruption of pregnancy (eczema in pregnancy, prurigo of pregnancy, pruritic folliculitis of pregnancy)",
"     </li>",
"     <li>",
"      Pustular psoriasis of pregnancy",
"     </li>",
"     <li>",
"      Intrahepatic cholestasis of pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"       \"Intrahepatic cholestasis of pregnancy\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dermatoses occurring in the nonpregnant population that may flare or remit during pregnancy are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/4\">",
"     4",
"    </a>",
"    ]. (See individual topic reviews on specific dermatoses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PEMPHIGOID GESTATIONIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigoid gestationis (or herpes gestationis) refers to a blistering disease that is clearly associated with pregnancy and increased fetal risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pemphigoid gestationis is",
"    <span class=\"nowrap\">",
"     1/1700",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/50,000",
"    </span>",
"    pregnancies. It only occurs during pregnancy or with trophoblastic tumors, although rarely it may persist for years postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. HLA-DR3 and HLA-DR4 are more common among women with this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus may precede onset of visible skin lesions, which erupt during the second or third trimester or postpartum; first trimester eruptions have been described in isolated case reports. The rash typically begins on the trunk as urticarial plaques or papules surrounding the umbilicus (",
"    <a class=\"graphic graphic_picture graphicRef78383 graphicRef63947 graphicRef72928 \" href=\"UTD.htm?1/21/1369\">",
"     picture 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]; vesicles may also be present (",
"    <a class=\"graphic graphic_picture graphicRef65231 \" href=\"UTD.htm?13/48/14095\">",
"     picture 2",
"    </a>",
"    ). Lesions may be seen on the palms and soles, but rarely on the face or mucous membranes. The eruption spreads rapidly and forms bullae (",
"    <a class=\"graphic graphic_picture graphicRef72690 graphicRef52776 \" href=\"UTD.htm?14/41/14999\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mucosal lesions are present in less than 20 percent of cases. However, there is one case report of a patient with pemphigoid gestationis-like lesions, as well as mucosal lesions, as seen in cicatricial pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no scarring and no recurrence after pregnancy. The immunofluorescence showed IgA against the C terminus of the BP180 antigen, different from that seen in classic pemphigoid gestationis (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathology'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigoid gestationis may remit prior to delivery. However, 75 percent of patients flare postpartum and at least 25 percent subsequently flare with use of oral contraceptive pills or during menses. Most cases spontaneously resolve in the weeks to months following delivery. The disease usually recurs with subsequent pregnancies and is often worse [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"     6",
"    </a>",
"    ], but may also skip pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two skin biopsies should be obtained to make the diagnosis of pemphigoid gestationis. Routine histology is performed on one specimen and direct immunofluorescence is performed on the other (this specimen should be placed in Michel's medium [ie, ammonium sulfate, N-ethylmaleimide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    in citrate buffer], not in formalin) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy of a vesiculating lesion (using routine histologic processing) reveals a subepidermal vesicle with a perivascular lymphocytic and eosinophilic infiltrate. Eosinophils may appear at the dermoepidermal junction and filling the vesicle. Basal cell necrosis and edema of the dermal papillae are usually noted.",
"   </p>",
"   <p>",
"    Skin biopsies taken from lesional or perilesional skin for immunofluorescent examination show complement 3 (C3) in a homogeneous, linear band at the basement membrane zone (BMZ) (",
"    <a class=\"graphic graphic_picture graphicRef65548 \" href=\"UTD.htm?11/13/11476\">",
"     picture 4",
"    </a>",
"    ). The presence of this C3 band is pathognomonic for pemphigoid gestationis in a pregnant patient. IgG is also present in 30 to 40 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests are not necessary for diagnosis. Antithyroid antibodies are often present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"     6",
"    </a>",
"    ]. The degree of peripheral eosinophilia may correlate with disease severity, whereas anti-basement membrane zone (BMZ) antibodies measured by indirect immunofluorescence do not.",
"   </p>",
"   <p>",
"    Blood studies with indirect immunofluorescence may reveal the \"herpes gestationis factor,\" an IgG1 antibody that can fix complement at the BMZ. However, indirect immunofluorescent studies are positive in only about 20 to 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/7\">",
"     7",
"    </a>",
"    ]. Monoclonal antibody studies reveal IgG1 against the BMZ in almost all patients with pemphigoid gestationis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,7,12\">",
"     6,7,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although conventional indirect immunofluorescence yields only 25 percent positive results, indirect complement-added immunofluorescence provides much higher sensitivity. A new immunoblotting test shows 90 percent sensitivity with excellent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one study, this ELISA to BP180NC16A identified 38 of 44 patients with pemphigoid gestationis, and was normal in all 44 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/14\">",
"     14",
"    </a>",
"    ]. This test may be used for confirmation of the diagnosis and also appears to be useful for monitoring of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic IgG antibody (BP180) in patients with pemphigoid gestationis binds to an 180 kilodalton (kd) antigen in the BMZ of skin, which is known as bullous pemphigoid antigen 2 (BP-AG2). BP-AG2 is a transcellular glycoprotein in the hemidesmosome (a structure that connects the basal cell of the epidermis to the basement membrane, thus helping to keep the epidermis attached to the dermis), with both cytoplasmic and extracellular domain. The majority of patients' sera bind to the extracellular NC16A epitope, but some bind to other epitopes on BP180, both intracellular and extracellular [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/15\">",
"     15",
"    </a>",
"    ]. IgG triggers the classic complement pathway, eosinophils are recruited, and proteolytic enzymes separate the epidermis from the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is not known why some patients form these antibodies. It has been theorized that paternal MHC class II antigens found in the placenta induce maternal antibodies to the amniotic basement membrane. These antibodies can then cross-react with skin and cause maternal (and sometimes newborn) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,7,13\">",
"     6,7,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigoid gestationis can mimic papular urticarial papules and plaques of pregnancy (PUPPP), especially in the early stages of disease. A clinical clue to help differentiate the two disorders is that PUPPP often begins in the striae, while pemphigoid gestationis is truly periumbilical. Immunofluorescent studies can definitively differentiate these two entities.",
"   </p>",
"   <p>",
"    Dermatitis herpetiformis, a very pruritic, vesicular skin eruption is also part of the differential diagnosis. Erythema multiforme, whether due to pregnancy, infection, or drug can mimic pemphigoid gestationis clinically, but routine histology should distinguish between these disorders. Contact dermatitis and drug reactions can also appear similar on physical examination; thus, a careful history regarding use of medications and exposure to environmental agents may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is relief of symptoms. We suggest mid to high potency (group two to four) topical corticosteroids for initial therapy of localized disease. Vehicles for topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef60921 \" href=\"UTD.htm?5/11/5308\">",
"     table 2",
"    </a>",
"    ) and choices and doses are illustrated in the tables (",
"    <a class=\"graphic graphic_table graphicRef76586 graphicRef62402 \" href=\"UTD.htm?19/6/19554\">",
"     table 3A-B",
"    </a>",
"    ). Ointments tend to cause less stinging and may be more effective than other topical preparations, but are more cumbersome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Use during pregnancy or lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsedating oral antihistamines are an acceptable alternative. Topical antihistamines are not recommended because they are not effective and may induce an allergic response. There is little information on use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    (topical or oral) during pregnancy. Although it does not appear to be teratogenic, systemic use or significant systemic absorption may lead to neonatal withdrawal since it is a tricyclic antidepressant as well as an antihistamine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Antihistamines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these drugs do not control symptoms, which is common, then systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) are usually effective. The dose may be tapered, and even discontinued, in some pregnancies. However, reinstatement of treatment postpartum will likely be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild placental insufficiency may result from an immune response between placental antigens and the antibodies targeted against the skin antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/17\">",
"     17",
"    </a>",
"    ]. Fetuses are at risk for growth restriction and prematurity. Antepartum fetal assessment is indicated.",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 61 pregnancies complicated by pemphigus gestationis, 20 out of 58 live deliveries (34 percent) were classified as preterm births and 19 out of 56 neonates with available birthweight data (34 percent) were small for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/18\">",
"     18",
"    </a>",
"    ]. Poor prognostic factors included disease onset in the first or second trimester and the presence of blisters on the mother's skin.",
"   </p>",
"   <p>",
"    Few newborns actually present with an eruption (2.8 to 10 percent); those with neonatal pemphigoid gestationis have a mild course that resolves within weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. There is minimal risk of adrenal suppression, even if the mother has been maintained on high dose glucocorticoids.",
"   </p>",
"   <p>",
"    The mother is at high risk of recurrent pemphigoid gestationis with subsequent pregnancies and at an increased lifetime risk of Grave's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRURITIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritic urticarial papules and plaques of pregnancy (PUPPP) is also called polymorphic eruption of pregnancy (PEP), which is the preferred term in the United Kingdom. Toxic erythema of pregnancy, Bourne's toxemic rash of pregnancy, linear IgM dermatosis of pregnancy, and Nurse's late onset prurigo are older terms felt to represent this same entity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1,6,22,23\">",
"     1,6,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUPPP is the most common specific dermatosis of pregnancy. The incidence is",
"    <span class=\"nowrap\">",
"     1/160",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/300",
"    </span>",
"    pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Three-quarters of patients with the classic type of PUPPP are nulliparous [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ]. PUPPP is 8- to 12-fold more common in women with multiple gestations, possibly due to increased abdominal distension (see below) or higher hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PUPPP is clinical, based on characteristic findings on history and physical examination.",
"   </p>",
"   <p>",
"    PUPPP typically presents as erythematous papules within striae (",
"    <a class=\"graphic graphic_picture graphicRef81605 \" href=\"UTD.htm?1/20/1345\">",
"     picture 5",
"    </a>",
"    ). Abdominal striae are the most common initial site (with periumbilical sparing) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ] and may be the only initial site [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/26\">",
"     26",
"    </a>",
"    ]. The lesions then spread to the extremities and coalesce to form urticarial plaques (",
"    <a class=\"graphic graphic_picture graphicRef56116 graphicRef75861 \" href=\"UTD.htm?18/27/18872\">",
"     picture 6A-B",
"    </a>",
"    ). The face, palms, and soles are usually spared. White halos often surround the erythematous papules in patients with fair skin (",
"    <a class=\"graphic graphic_picture graphicRef68906 \" href=\"UTD.htm?15/30/15842\">",
"     picture 7",
"    </a>",
"    ). Lesions may also be target-like, usually exhibiting three distinct",
"    <span class=\"nowrap\">",
"     rings/color",
"    </span>",
"    changes instead of a halo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. All patients have extreme pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One proposed classification system categorizes PUPPP into subtypes that help to demonstrate the variability of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I is the classical clinical presentation of papules and plaques with no involvement of the face, palms, or soles.",
"     </li>",
"     <li>",
"      Type II is referred to as the maculopapular type and is characterized by erythematous patches with overlying papules and vesicles.",
"     </li>",
"     <li>",
"      Type III is an overlap disease with features of types I and II.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PUPPP usually begins late in the third trimester (mean onset 35 weeks), but may develop postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22,26,27\">",
"     22,26,27",
"    </a>",
"    ]. There are also rare case reports of first and second trimester disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus may worsen immediately after delivery, but generally resolves by 15 days postpartum, although it may last longer. However, in one series, the process resolved prior to delivery in 6 of 15 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory abnormalities related to PUPPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is not necessary for diagnosis, but may be performed in cases of diagnostic uncertainty. Histopathologic examination of skin biopsies reveals nonspecific findings, such as spongiosis and parakeratosis in the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. The dermis contains a perivascular lymphocytic infiltrate primarily composed of T-helper cells; eosinophils or neutrophils are occasionally present. There may also be dermal edema.",
"   </p>",
"   <p>",
"    Immunofluorescent studies demonstrate C3 and IgM or IgA deposits at the dermoepidermal junction (DEJ) or around blood vessels in 31 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ]. These deposits are granular, not linear. (Linear deposits of C3 at the DEJ are considered pathognomonic for pemphigoid gestationis). Cases presenting in the first or second trimester have a higher rate of positivity on direct immunofluorescence. Indirect immunofluorescence is always negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of PUPPP is unknown and may be heterogeneous [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. The degree of stretching of the abdominal skin may play a role; PUPPP is more common with excessive stretching [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. It has been hypothesized that stretching may cause damage to connective tissue, which results in exposure of antigens that trigger an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possibility is that it represents an immunologic response to circulating fetal antigens. As an example, one study demonstrated fetal DNA in maternal skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early, urticarial phase of pemphigoid gestationis can mimic PUPPP. The two disorders can be distinguished by direct immunofluorescence of a biopsy specimen (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Pemphigoid gestationis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The target-like lesions of PUPPP may appear similar to erythema multiforme. Drug reactions, viral syndromes, and infestations (scabies) may also present with erythematous papules similar to PUPPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. The clinical history helps to differentiate among these entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"     \"Drug eruptions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is relief of symptoms. We suggest low to mid potency (group four to six) topical corticosteroids as initial therapy for relief of symptoms. Vehicles for topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef60921 \" href=\"UTD.htm?5/11/5308\">",
"     table 2",
"    </a>",
"    ) and choices and doses are illustrated in the tables (",
"    <a class=\"graphic graphic_table graphicRef62402 graphicRef76586 \" href=\"UTD.htm?18/59/19378\">",
"     table 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsedating oral antihistamines are an acceptable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) are occasionally required because of extreme pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"     6",
"    </a>",
"    ]. Early delivery to end symptoms is rarely, if ever, necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUPPP poses no increased risk of fetal or maternal morbidity (other than maternal pruritus) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6,26\">",
"     6,26",
"    </a>",
"    ]. The rate of recurrence has not been defined. In one series, there were no recurrences among 19 patients followed long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/26\">",
"     26",
"    </a>",
"    ], while in another report, 3 of 57 patients had a recurrence with subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"     22",
"    </a>",
"    ]. Recurrence is also uncommon with menses or oral contraceptives. Several studies have reported a preponderance of male fetuses in women with PUPPP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,26,32\">",
"     2,26,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ATOPIC ERUPTION OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema in pregnancy, prurigo of pregnancy, and pruritic folliculitis of pregnancy have been grouped under the unifying term atopic eruption of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"     3",
"    </a>",
"    ]. This classification scheme is based upon the presence of shared clinical features, including a possible association with atopy. All three disorders may present with inflammatory papules as a primary feature. None of the disorders classified within this group are associated with adverse effects on the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Eczema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema is the most common pruritic skin disorder occurring in pregnancy, and women with clinical findings consistent with eczema account for the vast majority of patients with atopic eruption of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eczema in pregnancy is strongly associated with a personal history of atopy (seasonal rhinitis, asthma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atopic dermatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Only 20 percent of affected women have a preceding history of atopic dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder often begins during the first or second trimester. Symptoms frequently present in a flexural distribution, similar to classic atopic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef57982 graphicRef68215 \" href=\"UTD.htm?42/39/43640\">",
"     picture 8A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"     3",
"    </a>",
"    ]. However, any area of the skin may be affected. Lesions may be eczematous patches or intact or excoriated papules. Papules can be follicularly-based, grouped, or scattered (",
"    <a class=\"graphic graphic_picture graphicRef55424 \" href=\"UTD.htm?6/17/6418\">",
"     picture 9",
"    </a>",
"    ). The diagnosis is based upon the recognition of clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is not necessary in most cases, and findings are non-specific. Spongiosis and a perivascular mononuclear infiltrate are common features [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ]. Epidermal hyperkeratosis or parakeratosis may also be present. Direct and indirect immunofluorescence studies are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laboratory testing is not indicated, up to 70 percent of patients may have elevated serum IgE levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is postulated that the enhancement of Th2 cytokine production known to occur during pregnancy may contribute to the development of eczema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earlier onset, predilection for involvement of skin flexures, and the absence of urticarial plaques in abdominal striae help to distinguish this disorder from PUPPP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to non-pregnant patients with eczema, these patients should be encouraged to maintain adequate skin hydration through the use of topical emollients. Low to mid-potency topical corticosteroids (group four to six) are useful for controlling symptoms. &nbsp;Vehicles for topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef60921 \" href=\"UTD.htm?5/11/5308\">",
"     table 2",
"    </a>",
"    ) and choices and doses are illustrated in the tables (",
"    <a class=\"graphic graphic_table graphicRef62402 graphicRef76586 \" href=\"UTD.htm?18/59/19378\">",
"     table 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link\">",
"     \"Treatment of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eczema in pregnancy has not been associated with adverse effects on the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Prurigo of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prurigo of pregnancy has also been classified as a form of atopic eruption of pregnancy. Other terms that have been used to describe prurigo of pregnancy include prurigo gestationis of Besnier, Nurse's early onset prurigo of pregnancy, Spangler's papular dermatitis of pregnancy, and linear IgM disease of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,5,6,34\">",
"     2,5,6,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of prurigo of pregnancy is approximately 1 in 300 to 1 in 450 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5,34,35\">",
"     5,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of prurigo of pregnancy is clinical, based on characteristic findings on history and physical examination.",
"   </p>",
"   <p>",
"    Prurigo of pregnancy usually begins in the second or third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,6\">",
"     2,6",
"    </a>",
"    ], but has been reported in all trimesters. Clinical diagnostic criteria consist of erythematous, excoriated nodules, or papules on the extensor surfaces of the limbs and trunk (",
"    <a class=\"graphic graphic_picture graphicRef72147 \" href=\"UTD.htm?21/39/22132\">",
"     picture 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,5,6,34\">",
"     2,5,6,34",
"    </a>",
"    ]. Lesions are grouped and may be crusted or appear eczematous. In one series, all 12 patients had abdominal involvement, with some also having the legs, wrists, and hands affected [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eruption usually resolves in the immediate postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ], although it can persist for up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is unnecessary. There are no consistent laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"     6",
"    </a>",
"    ]. Two studies noted an elevated IgE concentration in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,34\">",
"     2,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is not necessary for diagnosis, but may be helpful if there is diagnostic uncertainty and the specimen is diagnostic of another pathology (eg, pemphigoid gestationis).",
"   </p>",
"   <p>",
"    Skin biopsies of lesions are nonspecific. There is a dermal perivascular mononuclear cell infiltrate without eosinophils. The epidermis may show acanthosis, hyperkeratosis, and parakeratosis. Both direct and indirect immunofluorescent studies are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology is unknown. A relationship with a history of atopy has been proposed, but remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUPPP, pruritic folliculitis of pregnancy, and prurigo of pregnancy may be similar in appearance. Cholestasis and eruptions not associated with pregnancy (eg, scabies, drug reactions) should be excluded by history and laboratory testing (eg, bile acids), as indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is initiated for relief of symptoms. We suggest low to mid potency (group four to six) topical corticosteroids as initial therapy for relief of symptoms. Vehicles for topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef60921 \" href=\"UTD.htm?5/11/5308\">",
"     table 2",
"    </a>",
"    ) and choices and doses are illustrated in the tables (",
"    <a class=\"graphic graphic_table graphicRef62402 graphicRef76586 \" href=\"UTD.htm?18/59/19378\">",
"     table 3A-B",
"    </a>",
"    ). Topical corticosteroids are usually effective so systemic glucocorticoid therapy is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsedating oral antihistamines are an acceptable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no fetal effects, nor is there long-term maternal risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ]. Prurigo of pregnancy may recur with subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pruritic folliculitis of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritic folliculitis of pregnancy also has been classified as a manifestation of atopic eruption of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"     3",
"    </a>",
"    ]. Pruritic folliculitis refers to a sterile eruption of pruritic, follicular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence is unknown. In one prospective series, one case was identified among 3192 pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pruritic folliculitis is clinical, based on a characteristic history and physical examination. A pustule should be cultured to rule out bacterial or candidal folliculitis.",
"   </p>",
"   <p>",
"    Pruritic folliculitis of pregnancy usually presents in the second or third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,37\">",
"     2,37",
"    </a>",
"    ]. In one series, 12 of 14 patients were in their third trimester and one-half of the cases occurred in primigravidas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The eruption consists of follicularly-based papules and pustules, primarily on the trunk, but sometimes spreading to the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,37\">",
"     2,37",
"    </a>",
"    ]. The appearance is similar to that of steroid induced acne (",
"    <a class=\"graphic graphic_picture graphicRef74310 \" href=\"UTD.htm?16/27/16820\">",
"     picture 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eruption typically clears within two weeks of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/1,36\">",
"     1,36",
"    </a>",
"    ]. However, one report described a case with persistent symptoms for six weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/37\">",
"     37",
"    </a>",
"    ], and another series noted all 14 of the cases resolved prior to delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests are unnecessary other than to exclude infection. Laboratory values are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is not necessary for confirmation of the clinical diagnosis. Histopathology shows a perivascular or interstitial lymphohistiocytic infiltrate and excoriation of the epidermis, similar to polymorphic eruption of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ]. An acute suppurative sterile folliculitis is diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,36,37\">",
"     2,36,37",
"    </a>",
"    ]. Immunofluorescent studies are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2,37\">",
"     2,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis is unknown. Pruritic folliculitis of pregnancy is classified under atopic eruption of pregnancy, but the strength of the relationship of this disorder to atopy remains unclear. In one case series, the single patient with histopathologically confirmed pruritic folliculitis of pregnancy reported a personal history of childhood eczema and a family history of atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to distinguish pruritic folliculitis of pregnancy from prurigo of pregnancy or PUPPP. Infectious folliculitis must also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest low to mid potency (group four to six) topical corticosteroids as initial therapy for relief of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral glucocorticoids are rarely needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsedating oral antihistamines are an acceptable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H13#H13\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Antihistamines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been tried, but was ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal and fetal outcome appear to be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. One study reported a slightly reduced birth weight and an elevated",
"    <span class=\"nowrap\">",
"     male/female",
"    </span>",
"    birth ratio of 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"     2",
"    </a>",
"    ]. There are no data on recurrence with subsequent pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     PUSTULAR PSORIASIS OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pustular psoriasis of pregnancy is a newer name for impetigo herpetiformis. The former is more descriptive and avoids the implication of bacterial or viral infection, neither of which plays a role in this disease. It is debated whether pustular psoriasis of pregnancy is truly specific to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. We favor a true association as these women rarely have a history of psoriasis and the eruption resolves postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophilic dermatoses\", section on 'Generalized pustular psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pustular psoriasis of pregnancy is exceedingly rare. As of the year 2000, there were only about 350 cases in the European and United States literature, although it was originally described in 1872 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can be made clinically, based on characteristic findings on history and physical examination (",
"    <a class=\"graphic graphic_picture graphicRef79167 graphicRef56769 \" href=\"UTD.htm?5/1/5145\">",
"     picture 12A-B",
"    </a>",
"    ); however, we suggest confirmation by histological evaluation of a biopsy specimen, given the potential consequences of the disease and its treatment to maternal and child health (eg, side effects of systemic glucocorticoids, preterm delivery).",
"   </p>",
"   <p>",
"    The disease can occur anytime during pregnancy. Lesions begin as erythematous plaques with rings of pustules. The plaques then enlarge from the periphery as the center becomes eroded and crusted. There may be concentric rings of pustules. The nails may become onycholytic (lifting of the nail plate from the nail bed) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; pitting has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lesions often first manifest in intertriginous regions. The trunk and extremities are affected, while the hands, feet, and face are usually spared, although the soles were affected in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/42\">",
"     42",
"    </a>",
"    ]. Oral and esophageal erosions may occur.",
"   </p>",
"   <p>",
"    Pustular psoriasis of pregnancy is usually not pruritic. However, the patient feels ill with symptoms such as malaise, anorexia, nausea, vomiting, diarrhea, fever, and chills [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Post-inflammatory pigmentation occurs when plaques and pustules resolve; however, scarring does not result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pustular psoriasis of pregnancy usually remits quickly postpartum, but may also flare after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. It recurs with subsequent pregnancies and may also recur with menses or use of oral contraceptive pills. The disease tends to be more severe and have an earlier onset with subsequent pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39,45\">",
"     38,39,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a complete blood count, calcium level, electrolytes, and urinalysis. Leukocytosis and an elevated erythrocyte sedimentation rate are common. Hypocalcemia may be present, possibly related to hypoparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38\">",
"     38",
"    </a>",
"    ], and can lead to tetany, delirium, and seizures. Albuminuria, pyuria, and hematuria occasionally occur. Pustules are sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest biopsy for confirmation of the diagnosis. The pathology is the same as in pustular psoriasis in the nonpregnant patient. Spongiform pustules with neutrophils are observed in the epidermis. Psoriasiform hyperplasia and, possibly, parakeratosis also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology is poorly understood. It may relate to hormonal changes of pregnancy, particularly progesterone. Hypocalcemia and hypoparathyroidism may also be inciting factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious etiologies of pustules, such as candidiasis and impetigo, should be excluded by appropriate cultures. Subcorneal pustular dermatosis, dermatitis herpetiformis, and pustular drug eruptions (ie, acute generalized exanthematous pustulosis) are vesicular or pustular eruptions unrelated to pregnancy that should also be considered. Pruritic folliculitis of pregnancy is pruritic and exclusively perifollicular, neither of which is true of pustular psoriasis of pregnancy. Pemphigoid gestationis can present with rings of vesicles or pustules, but the histopathology is different [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest systemic glucocorticoids for initial therapy. Administration of high dose systemic glucocorticoids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (80 mg per day), results in a modest response. Glucocorticoids are slowly tapered as symptoms improve, with monitoring in case a flare occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In single case reports, pustular psoriasis of pregnancy has also been successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/46-48\">",
"     46-48",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and etretinate (only postpartum; etretinate is highly teratogenic and should be avoided during pregnancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophilic dermatoses\", section on 'Generalized pustular psoriasis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocalcemia must be corrected, when present, and fluid and electrolyte balance should be maintained.",
"   </p>",
"   <p>",
"    These patients sometimes require early delivery for relief of symptoms and for fetal safety [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/38,39,41\">",
"     38,39,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental insufficiency with sequelae such as miscarriage, fetal growth restriction, or stillbirth may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29657/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Therefore, antepartum fetal monitoring with nonstress tests or biophysical profiles and ultrasound assessment of fetal growth are indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h1\">",
"     INTRAHEPATIC CHOLESTASIS OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrahepatic cholestasis of pregnancy (obstetric cholestasis) is the only pregnancy dermatosis without primary skin changes. Patients experience severe, generalized pruritus. Like pustular psoriasis, this disorder can be associated with serious consequences for mother and fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"     \"Intrahepatic cholestasis of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general guide, we suggest that patients with suspected pemphigoid gestationis or pustular psoriasis be referred immediately to a dermatologist. Patients with a skin eruption and also systemic symptoms should probably also be referred to a dermatologist. Patients who are otherwise well except for some localized itching or eruption should be referred if the initial treatment approach fails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary of the evaluation of pregnant women with dermatoses is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef69237 \" href=\"UTD.htm?10/34/10795\">",
"     table 4",
"    </a>",
"    ). Treatment recommendations depend on the specific disorder, as described above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients suspected of pemphigoid gestationis or pustular psoriasis should undergo biopsy with histopathological assessment to confirm the clinical diagnosis. Pruritic urticarial papules and plaques of pregnancy (PUPPP), prurigo of pregnancy, and pruritic folliculitis can be diagnosed based on characteristic findings on history and physical examination alone. Bile acids should be checked in patients with extensive pruritus and no primary skin lesions. (See Clinical manifestations and diagnosis sections above).",
"     </li>",
"     <li>",
"      Treatment is indicated for relief of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with PUPPP, prurigo of pregnancy, and pruritic folliculitis of pregnancy, we suggest low to medium potency (group four to six (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 3B",
"      </a>",
"      )) topical corticosteroid ointments rather than oral antihistamines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See treatment sections above).",
"     </li>",
"     <li>",
"      For patients with pemphigoid gestationis, we suggest medium to high potency (group two to four (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 3B",
"      </a>",
"      )) topical corticosteroid ointments (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is most effective for mild, localized disease. We administer oral glucocorticoids to refractory cases. (See treatment sections above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pustular psoriasis is treated with high dose oral glucocorticoids. Patients should be evaluated for hypocalcemia, which can be symptomatic. (See",
"      <a class=\"local\" href=\"#H52\">",
"       'Pustular psoriasis of pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pemphigoid gestationis and pustular psoriasis can be associated with adverse fetal effects; antepartum fetal monitoring is indicated. PUPPP, prurigo of pregnancy, and pruritic folliculitis have no adverse fetal effects. (See Prognosis sections above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/1\">",
"      Vaughan Jones SA, Black MM. Pregnancy dermatoses. J Am Acad Dermatol 1999; 40:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/2\">",
"      Vaughan Jones SA, Hern S, Nelson-Piercy C, et al. A prospective study of 200 women with dermatoses of pregnancy correlating clinical findings with hormonal and immunopathological profiles. Br J Dermatol 1999; 141:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/3\">",
"      Ambros-Rudolph CM, M&uuml;llegger RR, Vaughan-Jones SA, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/4\">",
"      Kroumpouzos G, Cohen LM. Dermatoses of pregnancy. J Am Acad Dermatol 2001; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/5\">",
"      Roger D, Vaillant L, Fignon A, et al. Specific pruritic diseases of pregnancy. A prospective study of 3192 pregnant women. Arch Dermatol 1994; 130:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/6\">",
"      Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg 1998; 17:172.",
"     </a>",
"    </li>",
"    <li>",
"     Katz SI. Herpes gestationis (pemphigoid gestationis). In: Fitzpatrick's Dermatology in General Medicine, 5th ed, Freedberg I, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, 1999. p.686.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/8\">",
"      Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol 1999; 24:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/9\">",
"      Jenkins RE, Jones SA, Black MM. Conversion of pemphigoid gestationis to bullous pemphigoid--two refractory cases highlighting this association. Br J Dermatol 1996; 135:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/10\">",
"      Shimanovich I, Skrobek C, Rose C, et al. Pemphigoid gestationis with predominant involvement of oral mucous membranes and IgA autoantibodies targeting the C-terminus of BP180. J Am Acad Dermatol 2002; 47:780.",
"     </a>",
"    </li>",
"    <li>",
"     Elenitsas R, Van Belle P, Elder D. Laboratory Methods. In: Lever's Histopathology of the Skin, 8th ed, Elder D, Elenitsas R, Jaworsky C, Johnsons B (Eds), Lippincott-Raven, Philadelphia 1997. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/12\">",
"      Kelly SE, Cerio R, Bhogal BS, Black MM. The distribution of IgG subclasses in pemphigoid gestationis: PG factor is an IgG1 autoantibody. J Invest Dermatol 1989; 92:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/13\">",
"      Shimanovich I, Br&ouml;cker EB, Zillikens D. Pemphigoid gestationis: new insights into the pathogenesis lead to novel diagnostic tools. BJOG 2002; 109:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/14\">",
"      Sitaru C, Powell J, Messer G, et al. Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol 2004; 103:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/15\">",
"      Di Zenzo G, Calabresi V, Grosso F, et al. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 2007; 127:864.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org. (Accessed on May 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/17\">",
"      Jenkins, RE, Shornick, JK, Black, BL. Pemphigoid gestationis. J Eur Acad Dermatol Venereol 1993; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/18\">",
"      Chi CC, Wang SH, Charles-Holmes R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol 2009; 160:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/19\">",
"      Aoyama Y, Asai K, Hioki K, et al. Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol 2007; 143:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/20\">",
"      Chorzelski TP, Jablonska S, Beutner EH, et al. Herpes gestations with identical lesions in the newborn. Passive transfer of the disease? Arch Dermatol 1976; 112:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/21\">",
"      Katz A, Minto JO, Toole JW, Medwidsky W. Immunopathologic study of herpes gestationis in mother and infant. Arch Dermatol 1977; 113:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/22\">",
"      Aronson IK, Bond S, Fiedler VC, et al. Pruritic urticarial papules and plaques of pregnancy: clinical and immunopathologic observations in 57 patients. J Am Acad Dermatol 1998; 39:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/23\">",
"      Alcalay J, Ingber A, Hazaz B, et al. Linear IgM dermatosis of pregnancy. J Am Acad Dermatol 1988; 18:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/24\">",
"      Elling SV, McKenna P, Powell FC. Pruritic urticarial papules and plaques of pregnancy in twin and triplet pregnancies. J Eur Acad Dermatol Venereol 2000; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/25\">",
"      Kroumpouzos G, Cohen LM. Specific dermatoses of pregnancy: an evidence-based systematic review. Am J Obstet Gynecol 2003; 188:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/26\">",
"      Yancey KB, Hall RP, Lawley TJ. Pruritic urticarial papules and plaques of pregnancy. Clinical experience in twenty-five patients. J Am Acad Dermatol 1984; 10:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/27\">",
"      Lawley TJ, Hertz KC, Wade TR, et al. Pruritic urticarial papules and plaques of pregnancy. JAMA 1979; 241:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/28\">",
"      Cohen LM, Capeless EL, Krusinski PA, Maloney ME. Pruritic urticarial papules and plaques of pregnancy and its relationship to maternal-fetal weight gain and twin pregnancy. Arch Dermatol 1989; 125:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/29\">",
"      Beckett MA, Goldberg NS. Pruritic urticarial plaques and papules of pregnancy and skin distention. Arch Dermatol 1991; 127:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/30\">",
"      Aractingi S, Berkane N, Bertheau P, et al. Fetal DNA in skin of polymorphic eruptions of pregnancy. Lancet 1998; 352:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/31\">",
"      Beltrani VP, Beltrani VS. Pruritic urticarial papules and plaques of pregnancy: a severe case requiring early delivery for relief of symptoms. J Am Acad Dermatol 1992; 26:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/32\">",
"      Regnier S, Fermand V, Levy P, et al. A case-control study of polymorphic eruption of pregnancy. J Am Acad Dermatol 2008; 58:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/33\">",
"      Wilder RL. Hormones, pregnancy, and autoimmune diseases. Ann N Y Acad Sci 1998; 840:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/34\">",
"      Holmes RC, Black MM. The specific dermatoses of pregnancy. J Am Acad Dermatol 1983; 8:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/35\">",
"      Nurse DS. Prurigo of pregnancy. Australas J Dermatol 1968; 9:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/36\">",
"      Zoberman E, Farmer ER. Pruritic folliculitis of pregnancy. Arch Dermatol 1981; 117:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/37\">",
"      Kroumpouzos G, Cohen LM. Pruritic folliculitis of pregnancy. J Am Acad Dermatol 2000; 43:132.",
"     </a>",
"    </li>",
"    <li>",
"     Bellman B, Berman B. Skin diseases seriously affecting fetal outcome and matemal health. In: Skin changes and diseases in pregnancy, Harahap K, Wallach RC (Eds), Marcel Dekker, Inc, New York 1996. p.129.",
"    </li>",
"    <li>",
"     Charles-Holmes R. Skin diseases specifically associated with pregnancy. In: Skin changes and diseases in pregnancy, Harahap M, Wallach RC (Eds), Marcel Dekker, Inc, New York 1996. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/40\">",
"      Chang SE, Kim HH, Choi JH, et al. Impetigo herpetiformis followed by generalized pustular psoriasis: more evidence of same disease entity. Int J Dermatol 2003; 42:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/41\">",
"      Henson TH, Tuli M, Bushore D, Talanin NY. Recurrent pustular rash in a pregnant woman. Arch Dermatol 2000; 136:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/42\">",
"      Breier-Maly J, Ortel B, Breier F, et al. Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology 1999; 198:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/43\">",
"      Arslanpence I, Dede FS, Gokcu M, Gelisen O. Impetigo herpetiformis unresponsive to therapy in a pregnant adolescent. J Pediatr Adolesc Gynecol 2003; 16:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/44\">",
"      Katsambas A, Stavropoulos PG, Katsiboulas V, et al. Impetigo herpetiformis during the puerperium. Dermatology 1999; 198:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/45\">",
"      Sahin HG, Sahin HA, Metin A, et al. Recurrent impetigo herpetiformis in a pregnant adolescent: case report. Eur J Obstet Gynecol Reprod Biol 2002; 101:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/46\">",
"      Imai N, Watanabe R, Fujiwara H, et al. Successful treatment of impetigo herpetiformis with oral cyclosporine during pregnancy. Arch Dermatol 2002; 138:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/47\">",
"      Hazarika D. Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine. Indian J Dermatol Venereol Leprol 2009; 75:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/48\">",
"      Kapoor R, Kapoor JR. Cyclosporine resolves generalized pustular psoriasis of pregnancy. Arch Dermatol 2006; 142:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/49\">",
"      Sheth N, Greenblatt DT, Acland K, et al. Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol 2009; 34:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/50\">",
"      Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology 2010; 220:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/51\">",
"      Bukhari IA. Impetigo herpetiformis in a primigravida: successful treatment with etretinate. J Drugs Dermatol 2004; 3:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29657/abstract/52\">",
"      Oumeish OY, Parish JL. Impetigo herpetiformis. Clin Dermatol 2006; 24:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5564 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29657=[""].join("\n");
var outline_f28_61_29657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H64\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PEMPHIGOID GESTATIONIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRURITIC URTICARIAL PAPULES AND PLAQUES OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ATOPIC ERUPTION OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Eczema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Prurigo of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Laboratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pruritic folliculitis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Laboratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      PUSTULAR PSORIASIS OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      INTRAHEPATIC CHOLESTASIS OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5564|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/56/20353\" title=\"picture 1A\">",
"      Pemphigoid gestationis umb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/50/25376\" title=\"picture 1B\">",
"      Pemphigoid gestationis abd",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30385\" title=\"picture 1C\">",
"      Pemphigoid gestationis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/48/14095\" title=\"picture 2\">",
"      Pemphigoid gestationis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/49/18195\" title=\"picture 3A\">",
"      Pemphigoid gestationis bull",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/34/29216\" title=\"picture 3B\">",
"      Pemphigoid gestationis ext",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/13/11476\" title=\"picture 4\">",
"      Pemphigoid gestationis IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/20/1345\" title=\"picture 5\">",
"      PUPPP striae plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/25/37267\" title=\"picture 6A\">",
"      PUPPP abd thighs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/34/38434\" title=\"picture 6B\">",
"      PUPPP abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/30/15842\" title=\"picture 7\">",
"      PUPPP halo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/56/7045\" title=\"picture 8A\">",
"      Atopic dermatitis antecubit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/7/2163\" title=\"picture 8B\">",
"      Atopic dermatitis popliteal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/17/6418\" title=\"picture 9\">",
"      Atopic dermatitis papular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/39/22132\" title=\"picture 10\">",
"      Prurigo of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/27/16820\" title=\"picture 11\">",
"      Steroid induced acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/51/6963\" title=\"picture 12A\">",
"      Pustular psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/2/19493\" title=\"picture 12B\">",
"      Pustular psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/41/3740\" title=\"table 1\">",
"      Skin changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/11/5308\" title=\"table 2\">",
"      Vehicle selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/19/31035\" title=\"table 3A\">",
"      Amount of topical medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 3B\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/34/10795\" title=\"table 4\">",
"      Evaluation dermatoses pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=related_link\">",
"      The skin, hair, nails, and mucous membranes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29658="Hereditary angioedema: Prevention of attacks";
var content_f28_61_29658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary angioedema: Prevention of attacks",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29658/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Albert L Sheffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/61/29658/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/61/29658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE or inherited C1-inhibitor deficiency) is a rare genetic disorder resulting from deficiency (type I) or dysfunction of C1 inhibitor (type II). It is characterized by recurrent episodes of well-demarcated angioedema without pruritus or urticaria, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although swelling resolves spontaneously in two to four days in the absence of treatment, laryngeal edema may cause fatal asphyxiation.",
"   </p>",
"   <p>",
"    Effective prophylactic therapies for hereditary angioedema either replace inhibitor through an exogenous source or increase the patient's intrinsic production of inhibitor.",
"   </p>",
"   <p>",
"    The general management of adults and children with hereditary angioedema and the various prophylactic therapies that are used to prevent attacks will be reviewed here. The management of acute attacks and the clinical manifestations, pathogenesis, and diagnosis of this condition are discussed elsewhere:",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is another form of hereditary angioedema, type III, in which patients have normal C1 inhibitor. This disorder affects mainly women, some of whom have defects in factor XII. It is exacerbated by estrogens in many patients. Type III HAE is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5080?source=see_link\">",
"     \"Type III hereditary angioedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;General care measures for HAE include education, identification and avoidance of possible triggers, and planning for acute attacks. An international committee formulated a consensus report for the management of patients with hereditary angioedema in 2010, which was updated in 2012, and is based upon the available literature and practices worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The authors agree with this report, and the recommendations made in this review are consistent with it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important intervention for a patient who has been newly diagnosed with hereditary angioedema is education about the disease. Both the affected individual and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family members should be involved, and all first-degree relatives of the patient should be offered diagnostic testing for HAE. The disease is transmitted in an autosomal dominant fashion, although approximately 25 percent of cases result from new mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link&amp;anchor=H20557177#H20557177\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\", section on 'Subtypes and genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients can access detailed, patient-oriented information through the United States Hereditary Angioedema Association (",
"    <a class=\"external\" href=\"file://www.haea.org/\">",
"     www.haea.org",
"    </a>",
"    ) and the International Patient Organization for C1 Inhibitor Deficiencies (",
"    <a class=\"external\" href=\"file://www.haei.org/\">",
"     www.haei.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trigger avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triggers vary among patients, although the following measures are important for most:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoidance of trauma, particularly to the face and upper respiratory tract.",
"     </li>",
"     <li>",
"      Recognition and prompt treatment of oral and dental infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Triggers, including medications that exacerbate HAE, (eg, estrogens and ACE inhibitors) are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link&amp;anchor=H19#H19\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Triggers and exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Planning for acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be equipped with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A medical information bracelet or necklace identifying the condition.",
"     </li>",
"     <li>",
"      A written plan for treatment of acute attacks for use in emergency department care. This document (also available in a wallet card) should briefly explain the patient's diagnosis, outline the indicated treatment for acute attacks, and provide contact information for the supervising clinician (",
"      <a class=\"graphic graphic_form graphicRef70252 \" href=\"UTD.htm?37/57/38804\">",
"       form 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_form graphicRef62004 \" href=\"UTD.htm?7/38/7777\">",
"       form 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"       \"Hereditary angioedema: Treatment of acute attacks\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Baseline studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline studies are recommended to assess hepatic and other organ function (due to the potential need for chronic medications) and to screen for blood borne illnesses (due to the possible need for blood products). The following tests are suggested: liver function tests (including alanine aminotransferase, total bilirubin, alkaline phosphatase); albumin; creatine kinase; lactic dehydrogenase; blood urea nitrogen; creatinine; complete blood count and differential; pregnancy testing (if applicable); urinalysis; and screening tests for HIV, hepatitis B, and hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be vaccinated against hepatitis B in case they require blood-derived products in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17326295\">",
"    <span class=\"h2\">",
"     Gynecologic and obstetric care",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international expert panel produced guidelines on the gynecologic and obstetric care of women with HAE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-tolerated options for contraception include progesterone-based methods, such as progesterone-only oral contraceptives, other progesterone-delivering methods, and intrauterine devices [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect of pregnancy on a given patient&rsquo;s frequency and pattern of attacks is difficult to predict, although abdominal attacks usually become more frequent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/5\">",
"       5",
"      </a>",
"      ]. Disease activity during one pregnancy does not necessarily predict disease activity during subsequent pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/6\">",
"       6",
"      </a>",
"      ]. Labor and delivery generally do not precipitate attacks and the rate of cesarean deliveries is not elevated compared with the overall population. However, C1INHRP should be available during delivery in case acute symptoms develop and for at least 48 hours afterwards.",
"     </li>",
"     <li>",
"      Lactation can cause an increase in attacks in some women. C1INHRP is preferred during lactation because the effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      and androgens on infants are not known.",
"     </li>",
"     <li>",
"      The impact of menopause on HAE severity is variable.",
"     </li>",
"     <li>",
"      Other issues, such as the management of polycystic ovary syndrome; infertility; and breast, uterine, and cervical cancers are also discussed in the guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis may be administered short term in anticipation of a procedure or period of stress, or long term for the reduction of attack rates. Prophylaxis is also indicated for patients traveling to remote areas or countries in which they may not be able to access healthcare readily [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term prophylaxis should always be administered if intubation, oral surgery, or general surgery is planned. It is often administered prior to lesser dental procedures. Other minimally traumatic procedures, such as colonoscopy, may not require prophylaxis, although it is best to provide prophylaxis if the patient&rsquo;s tolerance to a procedure is unknown.",
"   </p>",
"   <p>",
"    Available evidence indicated that without short-term prophylaxis, approximately 40 percent of medical and dental procedures result in angioedema, which typically begins within 48 hours of the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, one of these studies focused on tooth extractions, which are more likely than many dental procedures to cause swelling.",
"   </p>",
"   <p>",
"    None of the therapies for short-term prophylaxis confers complete protection from an attack, and procedures should be performed in a setting in which emergency intubation is possible (such as a hospital-based dental clinic) if the patient is felt to be at significant risk for a laryngeal attack based upon the clinician's clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7611659\">",
"    <span class=\"h3\">",
"     Dental work and oral surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral surgery is one of the most predictable triggers for attacks of HAE and is typically a more potent stimulus for upper respiratory tract angioedema than abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/8\">",
"     8",
"    </a>",
"    ]. Dental work is also a frequent trigger for both cutaneous (facial) and laryngeal attacks in patients with HAE. The requirement for prophylaxis varies based upon the dental procedure performed, the patient's individual susceptibility to attacks, and the availability of acute therapies (ie, C1-inhibitor replacement therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    in the United States). Information about previously-tolerated procedures can be used to guide subsequent prophylaxis. General guidelines are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylaxis is recommended for all patients undergoing dental work that involves cutting of tissue or injections of anesthetic.",
"     </li>",
"     <li>",
"      With minor procedures such as routine dental cleaning, prophylaxis should be administered if the patient's susceptibility to an attack is unknown. By comparison, prophylaxis for routine cleaning may not be necessary in patients who have previously tolerated the procedure without an attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term prophylaxis is given to decrease the overall number of attacks. In countries where on demand therapies (ie, C1 inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    ) are available, most clinicians advocate the optimization of on demand therapies first, with long-term prophylaxis added for those patients whose disease is not satisfactorily controlled by on demand therapy alone or for whom access to on demand therapy is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, there is no consensus regarding when other therapies should be added to on demand therapies, and the approach will obviously vary depending upon the availability of demand therapies, access to emergency care, the likelihood of side effects from long-term prophylactic therapies, and the patient's preferences. Each case must be considered individually. One of the authors (MC) initiates androgen therapy (or another prophylactic therapy if androgens are contraindicated) when a patient is requiring more than five administrations of on demand therapy per month.",
"   </p>",
"   <p>",
"    Specific prophylactic regimens are discussed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Overview of available agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     STUDYING PROPHYLACTIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the efficacy of various agents in short-term prophylaxis is complicated by the unpredictability of HAE attacks. Procedures that have triggered attacks in a given patient do not necessarily do so reproducibly, and major interventions that would be expected to precipitate attacks may not, even in the absence of prophylaxis. Thus, relatively large numbers of patients or interventions are required to adequately assess short-term therapies, something that is difficult to achieve with a rare disease. Accordingly, there are few studies addressing the efficacy of short-term prophylaxis. In contrast, the efficacy of long-term therapies is more easily evaluated, and there are multiple studies for analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OVERVIEW OF AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the agents that can be used for short- and long-term prophylaxis is provided here, with mechanisms of action, availability, efficacy, adverse effects, contraindications, and long-term monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Attenuated androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic 17-alpha alkylated androgens (\"attenuated\" androgens) include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , stanozolol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"     oxymetholone",
"    </a>",
"    , tibolone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3652?source=see_link\">",
"     methyltestosterone",
"    </a>",
"    . These agents are used in short- and long-term prophylaxis and are believed to work either by increasing levels of aminopeptidase P, an enzyme that inactivates kinins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/11\">",
"     11",
"    </a>",
"    ], by increasing hepatic production of C1 inhibitor, or by additional undetermined mechanisms.",
"   </p>",
"   <p>",
"    The choice of agent is based largely upon availability, since differences among drugs have not been well characterized.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is widely available throughout the world. Although stanozolol is not produced commercially in the United States, it is available by prescription and can be compounded by individual pharmacies. Tibolone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"     oxandrolone",
"    </a>",
"    may be less virilizing than other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/36/3652?source=see_link\">",
"     Methyltestosterone",
"    </a>",
"    is another alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuated androgens are highly effective for both short- and long-term prophylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Short-term prophylaxis",
"      </strong>",
"      &mdash; Small, uncontrolled studies and individual case reports suggest that androgens are effective for short-term prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. As an example, attacks were completely prevented in 12 patients with a history of angioedema after dental procedures who were administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      four days before and four days after various procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Long-term prophylaxis",
"      </strong>",
"      &mdash; In a double-blind, placebo-controlled study of nine patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      dramatically reduced the risk of at least one acute episode during a one-month treatment period from 94 to 2 percent, and reduced attack rates from monthly to 1 every 10 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/18\">",
"       18",
"      </a>",
"      ]. Other small, controlled studies and multiple observational studies also concluded that androgens prevented attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/14,19-23\">",
"       14,19-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adverse effects and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen therapy is well tolerated by most postpubertal males, and by many female patients as well. However, there are important side effects and contraindications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &mdash; Short-term treatment with androgens (ie, one or two weeks) is well tolerated by most patients because the side effects are of minor significance. However, elevations in transaminases have been observed when large doses were given (eg, 4 to 16 mg of stanozolol daily in adults) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/24\">",
"       24",
"      </a>",
"      ]. These doses are not routinely used. Children can be treated short term with androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/25\">",
"       25",
"      </a>",
"      ], and this may be helpful during stressful periods, such as the beginning of school terms or during family crises. However, consultation with a pediatric endocrinology specialist should be pursued.",
"      <br/>",
"      <br/>",
"      Adverse effects with long-term androgen administration may include lipid abnormalities, virilization, abnormalities in serum transaminases, menstrual irregularities, weight gain, vasomotor symptoms, and depression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,23\">",
"       1,23",
"      </a>",
"      ]. Elevations of transaminases are most often seen with prolonged administration of higher doses (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      , 400 mg or more daily). There are also rare reports of hepatocellular adenomas and carcinoma with years of use [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Because of these concerns, daily doses greater than 200 mg a day are not recommended for long-term use [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/6\">",
"       6",
"      </a>",
"      ]. Although androgen-related adverse effects are more common with higher doses, they are not always dose-dependent, and some patients experience side effects at low doses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/24\">",
"       24",
"      </a>",
"      ]. A yearly measurement of alpha fetoprotein was also suggested by the 2010 consensus guidelines as a possible means of detecting liver neoplasms, although not all experts agree that this is helpful.",
"     </li>",
"     <li>",
"      The following are prominent studies reporting the side effects with long-term androgen use in patients with HAE:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One study examined the side effects with long-term androgen use (22 to 273 months, median 10.6 years) by comparing treated and untreated patients with HAE [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/19\">",
"       19",
"      </a>",
"      ]. Dose-related menstrual irregularities in premenopausal women and weight gain in both men and women were the most common side effects. Hypertension developed in 9 of 36 patients receiving androgens, compared with 1 of 33 never-treated patients.",
"     </li>",
"     <li>",
"      Another series of 37 patients treated for HAE because of monthly or more frequent attacks demonstrated that treatment with stanozolol was relatively well tolerated at doses of 2 mg per day or lower [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/28\">",
"       28",
"      </a>",
"      ]. Six patients were able to discontinue the drug over time, and the other 22 received therapy for 20 to 40 years. The most common side effects were hirsutism, postmenopausal bleeding, lipid abnormalities, and weight gain.",
"      <br/>",
"      <br/>",
"      A third study examined the effects of long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      therapy on the lipid profiles of HAE patients compared with untreated HAE patients and healthy controls. Total cholesterol levels were similar among the groups; however, high density lipoproteins (HDL) and apolipoprotein A-1 levels were significantly lower, and low density lipoproteins (LDL) and apolipoprotein B-100 levels were significantly higher in the treated patients compared with both control groups. Patients who received danazol had an 11.6 (95% CI 2.7-49.7) times higher risk for abnormally low HDL levels and a 4.4 (95% CI 1.2-16.0) times lower risk for high LDL concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Contraindications",
"      </strong>",
"      &mdash; There are no absolute contraindications to short-term prophylaxis with attenuated androgens except possibly pregnancy, since androgens can cause virilization of female fetuses. Androgens were successfully used in pregnant women with HAE in the past, with the close collaboration with an obstetrician. However, with the alternative therapies now available, androgen use in pregnancy is not recommended.",
"      <br/>",
"      <br/>",
"      Contraindications to long-term androgen use include childhood, pregnancy and lactation, liver disease, nephrotic syndrome, and breast or prostate cancer, although rare exceptions are made. The main concern about androgen use in prepubertal children is the potential of these agents to cause premature epiphyseal closure and decreased growth [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201135792\">",
"    <span class=\"h3\">",
"     Monitoring androgen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of long-term therapy is to decrease or eliminate attacks, and success should be measured by this clinical outcome rather than by laboratory parameters. Normalizing C4 or C1-INH antigenic levels is",
"    <strong>",
"     not",
"    </strong>",
"    necessary or even desirable. Attacks usually subside at levels of C1 inhibitor which are still significantly below normal. Higher levels do not confer benefit, and the greater doses of androgens required to achieve this are accompanied by increased toxicity. C4 levels rise more than C1-INH levels, although often not to within the normal range. C1-INH levels usually increase only with very high androgen doses. There are also some patients who do well clinically, in whom neither C4 nor C1-INH levels rise significantly. Conversely, some patients will continue to develop symptoms even when C4 is in the normal range (MC personal experience). Thus, monitoring therapy with laboratory parameters is",
"    <strong>",
"     not",
"    </strong>",
"    routinely necessary.",
"   </p>",
"   <p>",
"    Although monitoring C4 or C1-INH antigenic levels is not necessary in most patients, it can be helpful if a patient appears not to be responding to androgen therapy. For example, most patients demonstrate an increase in C4 levels while on standard doses of androgens, and failure to show an increase may help identify those patients who will not respond to this treatment. Also, a correlation between clinical improvement and a specific level of C4 (usually well below normal) is detectable in most cases, and can be useful in determining if a patient is taking an effective dose or is compliant with therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laboratory values",
"      </strong>",
"      &mdash; The 2010 consensus guidelines recommend obtaining a complete blood count, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, lipid profile, and urinalysis (to detect hematuria that can result from androgen use), every six months in patients taking long-term androgen therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ultrasonography &mdash;",
"      </strong>",
"      The risk of hepatic neoplasms may be increased with the long-term use of androgen therapy, both for patients with hereditary angioedema and other diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/7,27,31\">",
"       7,27,31",
"      </a>",
"      ]. This risk appears to be small, although there is insufficient data to quantitate magnitude. In addition, it is not clear how best to detect focal neoplastic lesions, which may not necessarily result in elevations in serum transaminases [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/32\">",
"       32",
"      </a>",
"      ]. As a result, not all of the authors of this review agree with the below suggestions.",
"      <br/>",
"      <br/>",
"      In the absence of consensus, the 2010 guidelines suggest that ultrasonography of the liver be performed every six months for adult patients receiving more than 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (or the equivalent of another androgen) and for all prepubertal patients receiving maintenance androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"       1",
"      </a>",
"      ]. Yearly screening may be sufficient for adults receiving 200 mg or less of danazol daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     C1-inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1 esterase inhibitor replacement protein (C1INHRP), purified and concentrated from pooled human plasma, is administered intravenously for purposes of short- and long-term prophylaxis. Two products are available in the United States, Cinryze (ViroPharma Inc.) and Berinert (CSL Behring). C1INHRP has been available for years throughout Europe, the United Kingdom, Canada, and Argentina as Berinert P [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. C1INHRP is the treatment of choice for short- and long-term prophylaxis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recombinant human C1-inhibitor preparation (rhC1INH, conestat alfa) (Ruconest, Pharming Technologies BV in Europe, Rhucin in other countries) is available within the EU. The dosing and potential adverse effects are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2297494#H2297494\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Recombinant C1-inhibitor (EU only)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Efficacy of plasma derived C1-INH",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Short-term prophylaxis",
"      </strong>",
"      &mdash; C1INHRP as a single prophylactic agent is generally accepted as effective based upon retrospective series and observational studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. In the largest series, 33 adults and eight children received 1000 units of C1INHRP within the 24 hours preceding 91 dental and medical procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/34\">",
"       34",
"      </a>",
"      ]. Angioedema did not occur in 98 percent of procedures. There have been no controlled studies comparing C1INHRP with androgens or other agents for short-term prophylaxis.",
"     </li>",
"     <li>",
"      <strong>",
"       Long-term efficacy",
"      </strong>",
"      &mdash; There are two approaches to the use of C1INHRP for long-term treatment: it may be administered by intravenous infusion at the first sign of an attack (\"on demand\" therapy) or at regularly-scheduled intervals. Although on demand therapy is not technically prophylactic because treatment is given after symptoms have appeared, it is an approach to long-term management. Several studies have demonstrated that C1INHRP is highly effective for long-term prophylaxis, when given either on demand or on a regular schedule [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. These estimates of efficacy may be understated, since the patients enrolled in these studies were refractory to other treatments and represented the severe end of the disease spectrum.",
"      <br/>",
"      <br/>",
"      In one study, 28 patients with refractory disease self-administered C1INHRP at home, on demand, over approximately two years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/38\">",
"       38",
"      </a>",
"      ]. Their clinical courses were compared before and after the addition of on demand C1INHRP. Prior to C1INHRP on demand, severe attacks were occurring in these individuals at an average frequency of one per 17 days, despite treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      in 94 percent or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      in 16 percent. Treatment for these attacks was C1INHRP, administered by a professional, in a hospital or clinic. Self-administration at home allowed the patients to reduce the amount of time from onset of symptoms to administration of C1INHRP from 3.4 to 1.4 hours. The overall use of C1INHRP was not significantly increased, and no adverse events requiring medical attention were reported. Similar findings were reported in a cohort of children and adolescents self-infusing or having a caretaker infuse at home [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/40\">",
"       40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There are a small number of studies evaluating the efficacy of regularly administered C1INHRP for long-term prophylaxis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The study described above also included 10 patients with frequent severe attacks of HAE (more than one attack per 10-day interval) who self-administered C1INHRP approximately weekly [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/38\">",
"       38",
"      </a>",
"      ]. Individual patients were receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (58 percent),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      (50 percent), or both for prophylaxis and still experiencing attacks, or were unable to tolerate prophylactic medications. After adding regular infusions of C1INHRP, seven patients were completely free of attacks, and five had occasional attacks (fewer than one per six-month period).",
"     </li>",
"     <li>",
"      A second study included 24 patients randomized to C1INHRP (1000 units every three to four days) or placebo infusions for 12 weeks, after which the groups crossed over for another 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients were not allowed to change their baseline androgen or antifibrinolytic medications for one month before or during the trial. Subjects receiving C1INHRP experienced approximately one-half as many attacks as those in the placebo group, and attacks were significantly shorter and less severe.",
"     </li>",
"     <li>",
"      The efficacy of C1 inhibitor as a single prophylactic therapy was evaluated in a controlled trial of six patients with refractory HAE attacks. These patients received either C1 inhibitor (25 plasma units per kilogram of body weight intravenously) as a single therapy or placebo, every third day for 17 days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/37\">",
"       37",
"      </a>",
"      ]. Compared with placebo, prophylactic infusions of C1 inhibitor resulted in significantly lower daily symptom scores for the severity of edema of the extremities, larynx, abdomen, and genitourinary tract, with an overall reduction in disease activity of over 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8055333\">",
"    <span class=\"h3\">",
"     Efficacy of recombinant C1-INH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An industry-sponsored pilot study evaluated the use of recombinant C1 inhibitor (rhC1INH) (50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    once weekly) in 25 patients with a history of HAE attacks occurring more frequently than every two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/41\">",
"     41",
"    </a>",
"    ]. Mean attack rate was reduced from 0.9",
"    <span class=\"nowrap\">",
"     attacks/week",
"    </span>",
"    to 0.4 attacks per week (95% CI 0.28-0.56).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1-inhibitor concentrates are quite costly (eg, 500 units cost about 500 euros in much of Europe and in the US, between 1700 and 2500 dollars). Cost is an issue when considering use of this agent for long-term prophylaxis. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Long-term prophylactic therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adverse effects and contraindications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Adverse effects",
"      </strong>",
"      &mdash; Side effects are rare and include headache, fever, and anaphylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/42\">",
"       42",
"      </a>",
"      ]. The formation of low levels of autoantibodies to C1 inhibitor has been reported in patients with HAE, although this was observed in patients who had never been exposed to C1INHRP, as well as those who received it regularly [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A paper based on an FDA database for adverse reactions to drugs, reports 10 cases of thrombosis related to LTP with Cinryze. Although the exact risk for this adverse event needs to be better defined, LTP with Cinryze requires careful evaluation of the indication and treatment monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/44\">",
"       44",
"      </a>",
"      ]. In addition, until more information is available, the use of indwelling infusion ports should be avoided in patients receiving Cinryze.",
"      <br/>",
"      <br/>",
"      Rare patients have been reported who experience an increase in the frequency of attacks during periods in which C1INHRP was administered for treatment of acute attacks",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for long-term prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Although C1INHRP infusion continued to be successful in treating the acute symptoms, the number of attacks,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the amount of C1INHRP needed to prevent attacks, gradually increased over years of prophylactic use. The mechanism responsible for this paradoxical response is not known. In one case report of two patients, both had elevated levels of anti-C1-INH antibodies and were treated successfully for acute attacks with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      instead.",
"     </li>",
"     <li>",
"      <strong>",
"       Theoretical risk of disease transmission",
"      </strong>",
"      &mdash; C1INHRP treatment confers a theoretical risk of disease transmission. Before the introduction of virucidal methods (from 1980 to 1985), a high percentage of HAE patients were infected with hepatitis C virus through a lyophilized preparation manufactured by Immuno Vienna (later Baxter). In response to this, C1INHRP was subsequently vapor heated to inactivate viruses, and the source of plasma was changed to carefully screened donors and continually monitored for pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/47\">",
"       47",
"      </a>",
"      ]. Since vapor heated C1INHRP became standard, only hepatitis G transmission has been reported, and the pathogenic significance of hepatitis G infection is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/48\">",
"       48",
"      </a>",
"      ]. Production of the Baxter C1-INH product was subsequently discontinued in 2004. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=see_link\">",
"       \"GB virus C (hepatitis G) infection\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The preparation currently in use in most of the world is Berinert P, (Berinert in the US) manufactured by CSL-Behring, which is virus inactivated by pasteurization. Postmarketing surveillance for Berinert P from 1985 until the present has revealed no case of viral transmission despite the administration of hundreds of millions of units. Current processing also removes prions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/49\">",
"       49",
"      </a>",
"      ]. Still, patients must be informed that there is a theoretical risk of transmission of unidentified pathogens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Monitoring long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic testing for hepatitis C and HIV is recommended for patients regularly receiving C1INHRP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Antifibrinolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytics are protease inhibitors that inhibit the conversion of plasminogen to plasmin and also inhibit activated plasmin. These steps in fibrinolysis are also inhibited by C1 inhibitor (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"UTD.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ), and the utility of antifibrinolytics in treating HAE may be due to a \"sparing effect\" on the natural inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents are used in short- and long-term prophylaxis. Antifibrinolytics are generally preferred over androgens for long-term prophylaxis in pregnant women, children, and patients who do not tolerate androgens. They should not be used in patients with increased risk for thrombosis. Because pregnancy itself is a relative risk factor for thrombosis, C1-inhibitor replacement therapy is a better choice for prophylaxis in pregnancy. However, one of the authors (MC) has some experience with using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    successfully in pregnant women, and it could be considered if C1-inhibitor replacement therapy is not feasible. Of note, Cinryze has been associated with a small number of cases of thrombosis as well. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Adverse effects and contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The antifibrinolytic medications currently in use are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (TA) and epsilon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (EACA). TA is more potent than EACA, and has a superior side effect profile, making it the antifibrinolytic drug of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/51\">",
"     51",
"    </a>",
"    ]. In the United States, an oral preparation of TA became available in 2009, when it was approved by the US Food and Drug Administration for the treatment of menorrhagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Short-term prophylaxis",
"      </strong>",
"      &mdash; Successful use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      for short-term prophylaxis has been reported in small series and case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/52-54\">",
"       52-54",
"      </a>",
"      ]. This agent does not appear to be as reliable as C1INHRP or androgen therapy, and the 2010 Consensus report removed TA from the list of agents recommended for short-term prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Long-term prophylaxis",
"      </strong>",
"      &mdash; In observational studies of TA, attack frequency and severity are reduced somewhat in about 70 percent of patients, although the effect is dramatic in only about 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/51,55,56\">",
"       51,55,56",
"      </a>",
"      ]. TA has been used successfully for long-term prophylaxis in pediatric patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytics carry the potential risk of intravascular thrombosis, although the true prothrombotic effects of these medications have not been quantified [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. It has also been proposed that long-term use of these agents may predispose to arteriosclerosis due to plasmin inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/55,60\">",
"     55,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional side effects associated with these agents include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      (TA) uncommonly causes gastrointestinal distress, headache, and anal pruritus, which can occur early in therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/51,61\">",
"       51,61",
"      </a>",
"      ]. There are also reports of retinal damage with prolonged use of higher doses of TA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epsilon",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      (EACA) is associated with painful myositis, quadriceps weakness, gastrointestinal distress, postural hypotension, disturbed color vision, rash, anal pruritus, and (at doses over 24",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in adults or 12",
"      <span class=\"nowrap\">",
"       grams/day",
"      </span>",
"      in children) myonecrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/55,63\">",
"       55,63",
"      </a>",
"      ]. EACA is rarely used because of this unfavorable side effect profile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Monitoring long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic success is determined clinically and each patient should be maintained on the lowest dose that adequately prevents attacks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laboratory values",
"      </strong>",
"      &mdash; Dosages are adjusted for decreased renal function, so blood urea nitrogen and serum creatinine should be measured yearly. The 2010 consensus algorithm suggests creatinine kinase, tests of liver and renal function, and urinalysis be performed every six months, although some experts feel yearly evaluation is sufficient. Annual assessment of ocular pressure should be considered for detection of glaucoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Ophthalmologic exam",
"      </strong>",
"      &mdash; Periodic ophthalmologic exams for patients on long-term therapy are suggested by some drug information databases because of early reports of ophthalmologic tumors in animals treated with high doses of TA, although this has never been reported in humans. The authors have not performed ophthalmologic exams as part of monitoring therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Plasma products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human plasma contains C1 inhibitor, as well as a full array of complement proteins, and can be used for short-term prophylaxis. Replacement plasma is available in two forms: fresh frozen plasma (FFP) and",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treated plasma",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    plasma). FFP is the only plasma preparation currently available in the United States.",
"   </p>",
"   <p>",
"    Plasma products are only used in short-term prophylaxis. Long-term administration has not been considered a viable approach because of both unknown efficacy, as well as the cumulative risk of disease transmission and need for multiple units per week that would be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of FFP for short-term prophylaxis is suggested by several case reports and observational series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. In a review of the literature, 148 cases were identified in which FFP was administered prophylactically [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/64\">",
"     64",
"    </a>",
"    ]. Angioedema occurred in six cases. No controlled trials have been performed.",
"   </p>",
"   <p>",
"    The efficacy data on",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma are only anecdotal, and studies are needed to demonstrate that it is an equivalent substitute for FFP, as",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treatment is known to remove some plasma components, and the effect on C1-inhibitor concentration has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;FFP has been associated acutely with urticaria, anaphylactic shock, and hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Risk of disease transmission",
"      </strong>",
"      &mdash; The primary concern with plasma products is disease transmission, and the risks of this must be presented to the patient.",
"      <span class=\"nowrap\">",
"       Solvent/detergent",
"      </span>",
"      treatment inactivates enveloped viruses (such as HIV, HTLV, and hepatitis B and C), but not prions or nonenveloped viruses (eg, hepatitis A, parvovirus).",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      plasma is currently not available in the United States.",
"      <br/>",
"      <br/>",
"      FFP does not undergo processing to remove infectious agents; however, it is obtained from single-donor units rather than pooled plasma, and each unit undergoes serological testing for viral markers. The risk of infection for a unit of FFP is identical to that of red blood cells, which are also obtained from single donors. The issue of disease transmission from red blood cells (and therefore FFP) is presented in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"       \"Transfusion transmitted HIV infection and AIDS\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Ineffective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and in vitro data suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be as effective as prophylactic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/68\">",
"     68",
"    </a>",
"    ]. However, a well-designed placebo-controlled, randomized study reported that injected or inhaled heparin failed to prevent attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SHORT-TERM PROPHYLACTIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choice of prophylactic treatment depends upon the procedure that the patient is to undergo, what therapies (if any) the patient is already taking or is known to tolerate, and the availability of the different agents. Among procedures, a distinction is made between minor (eg, routine dental work) and major procedures (eg, oral surgery, general surgery, or intubation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095156\">",
"    <span class=\"h2\">",
"     Relative effectiveness of different agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no controlled trials directly comparing the effectiveness of various agents for short-term prophylaxis in a head-to-head manner, although retrospective analyses provide relative comparisons. Overall, C1-inhibitor products are likely the most effective, followed by androgens and antifibrinolytics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/8\">",
"     8",
"    </a>",
"    ]. The efficacy of plasma is less clear. Studies of the effectiveness of individual agents were reviewed previously. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Overview of available agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2699915\">",
"    <span class=\"h2\">",
"     Acute therapy on demand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of the prophylactic regimen, it is always essential that patients undergoing any procedure that could precipitate angioedema have prompt access to one of the treatments that has been proven effective for treatment of acute attacks. These are: C1INHRP (available worldwide),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    (available in the United States), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    (available in the European Union and the US). Mechanism of action, efficacy, dosing, and administration of acute therapies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Medication options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Minor procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;For minor procedures, such as routine dental work (cleanings, filling of cavities, crown placement, restorative work, etc), the patient's past response to such procedures can guide the decision to give prophylaxis. Patients who have developed swelling in similar situations in the past should receive prophylaxis. Those who have tolerated these procedures in the past are likely to continue to do so. Communication between the patient, dentist, and allergist (or other HAE expert) is critical. Patients should be advised that swelling often occurs a day or so",
"    <strong>",
"     after",
"    </strong>",
"    the procedure, and a specific plan of treatment should be in place for symptoms that arise during this period.",
"   </p>",
"   <p>",
"    For minor manipulations, the most commonly used approach to short-term prophylaxis is either C1INHRP on demand or premedication with androgens, or a combination of both interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    may also be given if symptoms develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Androgen premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several approaches to dosing androgens for short-term prophylaxis, and no comparative data exist to recommend one regimen over another. For patients already on long-term androgens, the doses may be increased temporarily to those described below.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is used in the following examples, although equivalent doses of other attenuated androgens, as well as similar timeframes, are also appropriate. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Attenuated androgens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      , at a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 600",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or an equivalent androgen at a comparable dose (eg, 2.5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"       oxandrolone",
"      </a>",
"      is equivalent to 200 mg of danazol), may be given for five days before and five days after a procedure (",
"      <a class=\"graphic graphic_table graphicRef83117 \" href=\"UTD.htm?16/51/17212\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other regimens with which the authors of this topic have experience are (although doses are not necessarily equivalent):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39364?source=see_link\">",
"       Oxandrolone",
"      </a>",
"      (5 mg daily) for five days before and after",
"     </li>",
"     <li>",
"      Stanozolol (4 to 6 mg daily) for five days before and after",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients already taking androgens regularly, the dose may be increased by 50 to 100 percent for five days before and five days after a procedure.",
"   </p>",
"   <p>",
"    These recommendations are based upon the assumption that, for the individual patient in question, a dose of this magnitude or less has been effective for the patient in the past. If not, a higher effective dose must be determined for that patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Major procedures or intubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two principal options for prophylaxis prior to major procedures, such as surgery and intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1INHRP given one hour prior to procedure, with two additional doses on demand (see",
"      <a class=\"local\" href=\"#H38\">",
"       'C1-inhibitor dosing'",
"      </a>",
"      below). Of note,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      (a kallikrein inhibitor) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      (a bradykinin receptor antagonist) are",
"      <strong>",
"       not",
"      </strong>",
"      used in this manner, because these two agents act by inhibiting or interfering with bradykinin production or action, and are only used once an attack has commenced. Their utility as prophylactic agents has not been defined.",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Androgens given before the procedure, administered as described in the previous section, with C1INHRP on demand (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      ) to be given if symptoms develop. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Short-term prophylactic therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines and uncontrolled studies recommend the first approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,8\">",
"     1,8",
"    </a>",
"    ], while the authors generally prefer the second approach, especially for patients who tolerate and have experience taking androgens.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma or FFP are second-line options for short-term prophylaxis, if none of the other therapies is available. The usual dose of FFP is two units for adults, given one to two hours before the procedure. Optimal dosing has not been studied. Again, not all clinicians agree that this is needed if androgen prophylaxis has been given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     C1-inhibitor dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing for C1INHRP is based upon weight. The recommended dose for treatment of acute attacks (20",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    rounded up to the nearest 500 units) is also used in this prophylactic setting. Clinical trials comparing different doses for prophylaxis have not been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1000 units (if weight is &lt;50 kg [110 pounds])",
"     </li>",
"     <li>",
"      1500 units (if weight is &gt;50 kg [110 pounds] and &lt;100 kg [220 pounds])",
"     </li>",
"     <li>",
"      2000 units (if weight is &gt;100 kg [220 pounds])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    C1INHRP is usually given one hour prior to or immediately before the major procedure. If necessary, dosing can be given further in advance of the procedure. One small study found that up to 24 hours before was sufficient to prevent attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/34\">",
"     34",
"    </a>",
"    ], and the half-life of a weight-based dose of C1INHRP is 30 to 39 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, a dose of C1INHRP could conceivably be consumed within 24 hours in some patients, and the median time to maximal serum concentrations is 0.5 to 1 hour [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/71\">",
"     71",
"    </a>",
"    ]. For these reasons, it is preferable to administer C1INHRP as close in time to the procedure as possible. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Efficacy of plasma derived C1-INH'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    One or two additional doses (of C1INHRP or another acute therapy) should be immediately available at the time of the procedure in case symptoms appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     LONG-TERM PROPHYLACTIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consensus guidelines provide several options for long-term prophylaxis to prevent attacks of HAE, with which the authors agree, although their own practices differ slightly, as noted in the text below [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Options include (",
"    <a class=\"graphic graphic_table graphicRef83115 \" href=\"UTD.htm?11/63/12285\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attenuated androgens administered regularly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      (TA) administered regularly",
"     </li>",
"     <li>",
"      C1INHRP or other acute therapies (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      ) \"on demand\" (ie, administered at the first sign of an attack)",
"     </li>",
"     <li>",
"      C1INHRP administered regularly, which is usually reserved for patients who are not experiencing adequate control with one of the other options",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages and disadvantages of each therapy must be fully discussed with the patients and their preferences considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5941890\">",
"    <span class=\"h2\">",
"     Choice of agent in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to long-term prophylaxis in adults differs somewhat around the world, because the previous differences in availability of treatments led to differences in clinicians&rsquo; experience and comfort with specific agents. The consensus guidelines, which largely reflect the European experience with HAE treatment, suggest that most adults (with the important exception of pregnant women) be initially treated with full dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (ie, 3 grams per day, as described in the next section). If TA does not result in sufficient improvement, it should be stopped and androgen therapy initiated. However, for patients with frequent or severe attacks, androgens are recommended as initial therapy instead, because they are more reliably effective.",
"   </p>",
"   <p>",
"    The American authors of this review (JPA and ALS) are both of the view that androgens are an effective and well-tolerated choice for long-term therapy in nearly all cases, and that once stabilized, most patients do not require high doses to keep the disease under control. For the few patients who are intolerant of androgens, require relatively high doses to prevent attacks, or are noncompliant with androgens because of perceived or actual side effects, it is their preference to change to regularly administered C1INHRP when possible. Thus, they view the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    as limited.",
"   </p>",
"   <p>",
"    It is all of the authors&rsquo; experience that most adult patients respond to and tolerate either androgens or TA. When this does not occur, patient compliance with the therapy should be examined, as this is the usual cause for treatment failure. Once stabilized with androgens or TA, most patients will require one of the acute therapies (C1INHRP,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    ) for breakthrough attacks only sporadically, and typically less than once a year. Patients who require acute therapies only occasionally can either learn to self-administer at home (C1INHRP or icatibant) or have a caretaker infuse, or can receive the infusion in a medical facility. Patients who require regular infusions of C1INHRP usually prefer to infuse at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8056100\">",
"    <span class=\"h2\">",
"     Choice of agent in prepubescent children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent years, the expanded availability of on demand therapies for acute attacks has greatly reduced the numbers of children who require long-term prophylaxis. However, data reflecting the impact of modern therapies of the management of children and adolescents are still limited. In general, prepubertal children can usually be managed with on demand therapies and rarely require long-term prophylaxis.",
"   </p>",
"   <p>",
"    Before the newer therapies became available, management options in children consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    and androgens, while Berinert P was usually reserved for life-threatening attacks. One group published outcomes of a cohort of 48 children (23 boys and 25 girls), followed from diagnosis to age 18, in which tranexamic acid was the initial agent given for long-term prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/61\">",
"     61",
"    </a>",
"    ]. Overall, a relatively low percentage of children (19 percent) required long-term prophylaxis initially, compared with adult populations. However, by the age of 18 years, 43 percent required prophylaxis, with most needing to start long-term prophylaxis around the time of puberty. Some patients were adequately controlled with intermittent use of long-term prophylaxis during times when more attacks were anticipated (eg, during school exams, flu season, winter months, family crises, or puberty). If symptoms were not controlled by tranexamic acid, it was stopped and replaced with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (starting at 100 mg every other day). Only 2 of 48 patients required significant use of C1-inhibitor concentrate. Using this approach, serious side effects of danazol were avoided in children of both sexes.",
"   </p>",
"   <p>",
"    Based on previous experience and on the present situation of drug availability, we suggest that for those children who require long-term prophylaxis despite on demand therapy, androgens should be avoided.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    or regularly scheduled C1-INH infusions are better options. Tranexamic acid is easier to administer, while C1-INH is expected to be far more effective. Available data do not indicate major risks with either drug. Therefore, one approach would be a course with tranexamic acid (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily up to 3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    initially. If this does not control symptoms sufficiently, then it should be discontinued and regular infusions of C1-INH given instead. These suggestions are based on clinical experience and may change as more information about the newer therapies becomes available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8056161\">",
"    <span class=\"h2\">",
"     Choice of agent in pregnant and lactating women",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1INHRP is the agent of choice for long-term prophylaxis in pregnant and lactating women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HAE are controlled with doses ranging from 50 to 200 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , either daily or every other day (or an equivalent dose of another androgen, eg, stanozolol 1 to 2 mg daily or every other day). We suggest either of the following two ways of administering androgens for long-term prophylaxis: Starting with a high dose and then tapering or starting with a low dose and gradually increasing (",
"    <a class=\"graphic graphic_table graphicRef83115 \" href=\"UTD.htm?11/63/12285\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Initial high dose",
"      </strong>",
"      &mdash; This protocol is based on the strategy of initiating androgen therapy with high doses that are subsequently tapered as tolerated. This approach is favored for rapid control of attacks. Using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      as an example, therapy is begun with 400 to 600 mg daily until new attacks have ceased (sometimes this is apparent in less than one month). One of the authors (ALS) tapers the dose over several weeks to 200 mg daily. The guidelines suggest tapering more slowly (eg, by 100 mg daily per month or by one-third of the dose per month if there are no breakthroughs). When 200 mg daily is attained, therapy is tapered by 50 mg every two months and by every three months when below 100 mg per day. The minimum dose is 50 mg daily for five days every week for most patients. For those in whom a breakthrough attack occurs, remission can be reinduced by resuming the last effective dose and then using a higher maintenance dose.",
"      <br/>",
"      <br/>",
"      The equivalent dosing for stanozolol is 2 to 4 mg daily for the first month, and then gradual tapering to the minimal effective dose, which is generally in the range of 0.5 to 2 mg daily.",
"     </li>",
"     <li>",
"      <strong>",
"       Initial low dose",
"      </strong>",
"      &mdash; This regimen involves the initiation of therapy with low doses, with increases in the dose as necessary. This approach minimizes medication side effects. Using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      as an example, therapy is initiated at a dose of 200 mg daily for one month. If there is no response, the dose is increased to 300 mg daily for two to four weeks. If there is still no response, the dose is increased to 400 mg daily for two to four weeks. However, if the initial dose of 200 mg daily controls symptoms, the dose is reduced to 100 mg per day for one month. If 100 mg per day also controls the disease, the dose is decreased to 50 mg daily or 100 mg every other day. If there are prodromal symptoms of attack, the guidelines suggest doubling the dose for several days. As discussed previously, patients may demonstrate a rise in C4 (although usually well below normal), but direct correlation with control of attacks is weak. (See",
"      <a class=\"local\" href=\"#H201135792\">",
"       'Monitoring androgen therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General observations regarding the use of attenuated androgens for long-term prophylaxis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In postpubertal females androgenic effects may be troublesome, and regulation of periods and use of other hormones can become issues. We suggest that treatment decisions be made with the cooperation of the patient's",
"      <span class=\"nowrap\">",
"       obstetrician/gynecologist.",
"      </span>",
"     </li>",
"     <li>",
"      Some patients have reported that increasing the dose of androgen in response to prodromal symptoms or at the first sign of swelling seems to help prevent progression to more severe symptoms. As an example, a patient taking 200 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      daily for prophylaxis could increase the dose to 400 mg three times daily and maintain the higher dose until there is some indication of clinical improvement or an attack ensues. Although there are anecdotal reports of efficacy, this intervention has not been studied, and opponents of the practice counter that androgens should not be able to stimulate production quickly enough to be effective when used in this manner [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1,29\">",
"       1,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Tranexamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;TA is administered for long-term prophylaxis at a dose of 1 to 3 grams per day, or 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given two to three times per day. This dosing is appropriate for both children and adults. As stated above, an initial dose of 3 grams per day is suggested for adults, as only a minority of patients responds sufficiently well that the dose can be tapered. The dose of TA must be reduced for patients with renal impairment. TA is preferred over androgens for long-term prophylaxis in growing children and in women who are pregnant or planning to become pregnant in the near future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6468030\">",
"    <span class=\"h2\">",
"     Therapies for acute attacks used as prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapies available for acute symptoms are C1INHRP,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    (US), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    . These therapies may also be used for long-term control of angioedema symptoms, either by stopping attacks with early administration (on demand treatment), or by giving C1INHRP at regular intervals to prevent attacks:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6468045\">",
"    <span class=\"h3\">",
"     On demand treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;On demand treatment, when used, is usually administered in conjunction with prophylactic therapy. When deciding how best to integrate the various preventative and on demand therapies, the clinician must consider each patient&rsquo;s situation, including proximity to care, ability to self-administer medications, and preferences.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1INHRP may be administered at the first sign of an attack as an approach to long-term management. This is appropriate for the small percentage of patients who continue to have regular attacks despite treatment with androgens or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      (TA), and for those with contraindications (childhood, pregnancy) or intolerable side effects from androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"       1",
"      </a>",
"      ]. Most patients remain on either TA or androgens, and C1INHRP on demand is added. Patients keep a small supply of inhibitor at home, to be self-administered or given by a caregiver through a peripheral intravenous line, at the first sign of symptoms. Practices regarding self-infusion versus infusion by a nurse in the home setting differ by country. Dosing and side effects are discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'C1-inhibitor dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"      (a bradykinin B2 receptor antagonist) may be administered at the first sign of an attack as an approach to long-term management. This drug can be self-administered at home as a subcutaneous injection. Dosing and side effects are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2297196#H2297196\">",
"       \"Hereditary angioedema: Treatment of acute attacks\", section on 'Bradykinin B2 receptor antagonist'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the US,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      (a kallikrein inhibitor) is available but is not approved by the US Food and Drug Administration (FDA) for self-administration because of a risk of hypersensitivity reactions. Instead, it must be given by a trained provider in a supervised setting or by a nurse in the patient&rsquo;s home. Thus, on demand ecallantide would only be appropriate for patients who live near a healthcare facility or can have a nurse travel promptly to their home, such that they could receive treatment early in the attack. The risk of allergic reaction will be better defined as the medication is increasingly used, although between 2008 and 2011 the US FDA adverse event reporting system database registered 71 adverse events related to HAE treatments, none of which were caused by ecallantide [",
"      <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/44\">",
"       44",
"      </a>",
"      ]. Dosing and side effects are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H7#H7\">",
"       \"Hereditary angioedema: Treatment of acute attacks\", section on 'Kallikrein inhibitor (US only)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6468181\">",
"    <span class=\"h3\">",
"     Continuous C1-INH replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;C1INHRP can also be infused at regular intervals (continuous replacement therapy) for patients who have frequent symptoms that cannot be controlled by on demand treatment and who do not respond or tolerate androgens or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. In a randomized trial of 24 patients, C1INHRP was given at a dose of 1000 units every three to four days, during which patients did not change their baseline androgen or antifibrinolytic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/61/29658/abstract/39\">",
"     39",
"    </a>",
"    ]. Subjects receiving C1INHRP experienced approximately one-half as many attacks as those in the placebo group, and attacks were significantly shorter and less severe. Cinryze is the product currently available in the US with FDA approval for regular prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can access detailed, patient-oriented information through the United States Hereditary Angioedema Association (",
"    <a class=\"external\" href=\"file://www.haea.org/\">",
"     www.haea.org",
"    </a>",
"    ) and the International Patient Organization for C1 Inhibitor Deficiencies (",
"    <a class=\"external\" href=\"file://www.haei.org/\">",
"     www.haei.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hereditary angioedema (HAE) should be educated about medical and dental procedures, periods of stress, and other exposures that can precipitate symptoms. Clinicians should help patients avoid medications that can increase attacks, such as estrogens and ACE inhibitors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Education'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Trigger avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be offered a medical identification bracelet and a written plan for treatment of acute attacks for use in emergency department care (",
"      <a class=\"graphic graphic_form graphicRef70252 \" href=\"UTD.htm?37/57/38804\">",
"       form 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_form graphicRef62004 \" href=\"UTD.htm?7/38/7777\">",
"       form 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Planning for acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Short-term prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term prophylaxis is administered prior to a",
"    <span class=\"nowrap\">",
"     dental/medical",
"    </span>",
"    procedure or conditions that may precipitate symptoms. The preferred options for short-term prophylaxis are androgens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C1INHRP. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Short-term prophylactic therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      None of the available therapies confers complete protection from an attack, and the supervising clinician must be prepared to recognize and manage angioedema. In addition, therapies for treatment of acute attacks must be immediately available. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Studying prophylactic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Procedures are considered high- or low-risk based upon how likely that procedure is to trigger symptoms. However, patients vary in their susceptibility to attacks, and if a patient has had symptoms with a given procedure, then it should be considered high risk for that patient and prophylaxis should be administered for future similar procedures. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing high-risk procedures (eg, major dental procedures, surgery, intubation), we recommend administering prophylactic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). There are several options for short-term prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef83117 \" href=\"UTD.htm?16/51/17212\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest giving C1INHRP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose is based upon the patient&rsquo;s weight, and it should be infused as close in time to the procedure as is feasible (preferably within the hour before the procedure). (See",
"      <a class=\"local\" href=\"#H38\">",
"       'C1-inhibitor dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If C1INHRP is not available, we suggest premedication with androgens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A representative regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (2.5 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day to a maximum of 600",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      beginning five days before and extending for five days after the procedure. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Major procedures or intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another option, favored by the American experts, is to premedicate with androgens in nearly all patients, and have at least one dose of C1INHRP,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      (US only) available for infusion if symptoms develop.",
"     </li>",
"     <li>",
"      In an emergent situation in which prophylaxis is indicated, but no acute therapies are available and there is not enough time for androgen pretreatment, plasma products (FFP or",
"      <span class=\"nowrap\">",
"       S/D",
"      </span>",
"      plasma) may be given. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Plasma products'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing low-risk procedures, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      administering androgens in advance, provided C1INHRP,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      (US), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      is immediately available to treat any symptoms that arise (",
"      <a class=\"graphic graphic_table graphicRef83117 \" href=\"UTD.htm?16/51/17212\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If one of these acute therapies is not immediately available, we would administer androgen premedication unless the individual tolerated that specific procedure in the past. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Minor procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Long-term prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In countries where on demand therapies (ie, C1 inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      ) are available, most clinicians advocate the optimization of on demand therapies first, with long-term prophylaxis added for those patients whose disease is not satisfactorily controlled by on demand therapy alone. However, the decision of how best to combine on demand and long-term prophylactic therapies must consider various factors (access to therapies, the likelihood of side effects from long-term prophylactic therapies, and the patient's preferences). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When on demand therapy is not feasible, we recommend long-term prophylaxis for patients with more than one severe episode of angioedema per month, those with laryngeal attacks, or those unable to participate in normal activities more than five days per month because of symptoms of HAE (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three agents used for long-term prophylaxis are attenuated androgens,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      (TA), and regularly-infused C1INHRP. Attenuated androgens and C1INHRP are both highly effective, although androgens can have adverse effects in some patients and C1INHRP is expensive. Tranexamic acid is less effective but inexpensive and has a favorable side effect profile in most patients (",
"      <a class=\"graphic graphic_table graphicRef83115 \" href=\"UTD.htm?11/63/12285\">",
"       table 2",
"      </a>",
"      ). We suggest initiating long-term prophylactic therapy with either androgens or TA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Androgens are well tolerated in postpubertal males requiring long-term prophylaxis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      is preferred over androgens in growing children,",
"      <span class=\"nowrap\">",
"       pregnant/",
"      </span>",
"      lactating women, and patients with breast or prostate cancers. Tranexamic acid should be initiated at the relatively high dose of 3 grams per day (divided into two or three doses daily) and then tapered if symptoms are controlled. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Long-term prophylactic therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Antifibrinolytics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41\">",
"       'Tranexamic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      is not effective, we recommend replacing it with androgen therapy in postpubertal children and adults. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Androgens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients achieve adequate control of symptoms with either androgens or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      and require infrequent treatment for acute attacks; one or two attacks per year are typical. For these occasional attacks despite prophylactic therapy, C1INHRP or other available acute treatments (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       ecallantide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       icatibant",
"      </a>",
"      ) can be given at the first sign of symptoms (&ldquo;on demand&rdquo;). (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Long-term prophylactic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those few patients who continue to have frequent attacks despite on demand therapies and prophylactic androgens or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      , or who have contraindications to these agents, we recommend regular infusions of C1INHRP (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Long-term prophylactic therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/1\">",
"      Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/2\">",
"      Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/3\">",
"      Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/4\">",
"      Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008; 199:484.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/5\">",
"      Martinez-Saguer I, Rusicke E, Ayg&ouml;ren-P&uuml;rs&uuml;n E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010; 203:131.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/6\">",
"      Craig T, P&uuml;rs&uuml;n EA, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012; 5:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/7\">",
"      Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/8\">",
"      Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey. Allergy 2012; 67:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/9\">",
"      Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/10\">",
"      Frank MM. 8. Hereditary angioedema. J Allergy Clin Immunol 2008; 121:S398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/11\">",
"      Drouet C, D&eacute;sormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008; 121:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/12\">",
"      Ott HW, Mattle V, Hadziomerovic D, et al. Treatment of hereditary angioneurotic oedema (HANE) with tibolone. Clin Endocrinol (Oxf) 2007; 66:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/13\">",
"      Fox M, Minot AS, Liddle GW. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962; 22:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/14\">",
"      Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/15\">",
"      Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med 1977; 86:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/16\">",
"      Farkas H, Gyeney L, Gid&oacute;falvy E, et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 1999; 57:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/17\">",
"      Hardie J, Ringland T, Yang WH, Wagner V. Potentially fatal hereditary angioedema: a review and case report. J Can Dent Assoc 1990; 56:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/18\">",
"      Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/19\">",
"      Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/20\">",
"      Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/21\">",
"      Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/22\">",
"      Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of impeded androgen (oxymetholone) therapy of hereditary angioedema. J Allergy Clin Immunol 1979; 64:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/23\">",
"      Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/24\">",
"      Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/25\">",
"      Farkas H, Harmat G, Gyeney L, et al. Danazol therapy for hereditary angio-oedema in children. Lancet 1999; 354:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/26\">",
"      Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/27\">",
"      Crampon D, Barnoud R, Durand M, et al. Danazol therapy: an unusual aetiology of hepatocellular carcinoma. J Hepatol 1998; 29:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/28\">",
"      Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007; 120:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/29\">",
"      Sz&eacute;plaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005; 115:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/30\">",
"      Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies. Eur J Pediatr 2012; 171:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/31\">",
"      Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/32\">",
"      O'Neil KM. Complement deficiency. Clin Rev Allergy Immunol 2000; 19:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/33\">",
"      Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/34\">",
"      Grant JA, White MV, Lee HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/35\">",
"      Leimgruber A, Jaques WA, Spaeth PJ. Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol 1993; 101:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/36\">",
"      Langston D, Weiner J, Fary W. C1-esterase inhibitor concentrate prevents upper airways obstruction in hereditary angio-oedema. Med J Aust 1994; 164:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/37\">",
"      Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/38\">",
"      Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/39\">",
"      Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/40\">",
"      Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/41\">",
"      Reshef A, Moldovan D, Obtulowicz K, et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013; 68:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/42\">",
"      Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003; 29:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/43\">",
"      Varga L, Sz&eacute;plaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate na&iuml;ve patients. Mol Immunol 2007; 44:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/44\">",
"      Gandhi PK, Gentry WM, Bottorff MB. Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmacotherapy 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/45\">",
"      Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009; 122:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/46\">",
"      Bouillet L, Boccon-Gibod I, Dumestre-Perard C, et al. Efficacy of icatibant treatment in patients with hereditary angio-oedema type I resistant to treatment with C1 inhibitor concentrate. Br J Dermatol 2011; 164:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/47\">",
"      Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion 1995; 35:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/48\">",
"      De Filippi F, Castelli R, Cicardi M, et al. Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. Transfusion 1998; 38:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/49\">",
"      Gr&ouml;ner A, Nowak T, Sch&auml;fer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012; 52:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/50\">",
"      Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/51\">",
"      Agostoni A, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/52\">",
"      Sheffer AL, Fearon DT, Austen KF, Rosen FS. Tranexamic acid: preoperative prophylactic therapy for patients with hereditary angioneurotic edema. J Allergy Clin Immunol 1977; 60:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/53\">",
"      Crosher R. Intravenous tranexamic acid in the management of hereditary angio-oedema. Br J Oral Maxillofac Surg 1987; 25:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/54\">",
"      Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/55\">",
"      Gwynn CM. Therapy in hereditary angioneurotic oedema. Arch Dis Child 1974; 49:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/56\">",
"      Agostoni A, Marasini B, Cicardi M, et al. Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. Allergy 1978; 33:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/57\">",
"      Farkas H, Varga L, Sz&eacute;plaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120:e713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/58\">",
"      Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/59\">",
"      Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol 2002; 68:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/60\">",
"      Champion RH, Lachmann PJ. Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol 1969; 81:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/61\">",
"      Farkas H, Csuka D, Zotter Z, et al. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol 2013; 131:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/62\">",
"      Snir M, Axer-Siegel R, Buckman G, Yassur Y. Central venous stasis retinopathy following the use of tranexamic acid. Retina 1990; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/63\">",
"      Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972; 286:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/64\">",
"      Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/65\">",
"      Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/66\">",
"      Degroote DF, Smith GL, Huttula GS. Acute airway obstruction following tooth extraction in hereditary angioedema. J Oral Maxillofac Surg 1985; 43:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/67\">",
"      Phillips KM, Glick M, Cohen SG. Hereditary angioedema: report of case. Spec Care Dentist 1989; 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/68\">",
"      Weiler JM, Stechschulte DJ, Levine HT, et al. Inhaled heparin in the treatment of hereditary angioedema. Complement Inflamm 1991; 8:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/69\">",
"      Weiler JM, Quinn SA, Woodworth GG, et al. Does heparin prophylaxis prevent exacerbations of hereditary angioedema? J Allergy Clin Immunol 2002; 109:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/70\">",
"      Bernstein JA, Ritchie B, Levy RJ, et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/61/29658/abstract/71\">",
"      Martinez-Saguer I, Rusicke E, Ayg&ouml;ren-P&uuml;rs&uuml;n E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8100 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29658=[""].join("\n");
var outline_f28_61_29658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trigger avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Planning for acute treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Baseline studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17326295\">",
"      Gynecologic and obstetric care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7611659\">",
"      - Dental work and oral surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      STUDYING PROPHYLACTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OVERVIEW OF AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Attenuated androgens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adverse effects and contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H201135792\">",
"      - Monitoring androgen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      C1-inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Efficacy of plasma derived C1-INH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8055333\">",
"      - Efficacy of recombinant C1-INH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cost",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adverse effects and contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Monitoring long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Antifibrinolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Monitoring long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Plasma products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ineffective therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SHORT-TERM PROPHYLACTIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095156\">",
"      Relative effectiveness of different agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2699915\">",
"      Acute therapy on demand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Minor procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Androgen premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Major procedures or intubation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - C1-inhibitor dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      LONG-TERM PROPHYLACTIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5941890\">",
"      Choice of agent in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8056100\">",
"      Choice of agent in prepubescent children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8056161\">",
"      Choice of agent in pregnant and lactating women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Tranexamic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6468030\">",
"      Therapies for acute attacks used as prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6468045\">",
"      - On demand treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6468181\">",
"      - Continuous C1-INH replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Short-term prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Long-term prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8100|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/51/41791\" title=\"figure 1\">",
"      HAE pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8100|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?37/57/38804\" title=\"form 1\">",
"      HAE emergency care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?7/38/7777\" title=\"form 2\">",
"      HAE wallet card",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/51/17212\" title=\"table 1\">",
"      Short-term prophylaxis for HAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/63/12285\" title=\"table 2\">",
"      Long-term preventative tx of HAE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=related_link\">",
"      GB virus C (hepatitis G) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5080?source=related_link\">",
"      Type III hereditary angioedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_61_29659="ACC AHA selection mitral valve";
var content_f28_61_29659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Criteria for selection of a mitral valve in patients undergoing mitral valve replacement (MVR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement for the choice of a mechanical or bioprosthetic valve in",
"patients undergoing MVR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; A bioprosthetic valve in patients who will not take or are incapable of taking warfarin or have a major contraindication to warfarin therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of the choice of a mechanical or bioprosthetic",
"valve in patients undergoing MVR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A bioprosthesis in patients &ge;65 years of age who do not have risk factors for thromboembolism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Among patients less than 65 years of age:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. A mechanical valve in patients with long-standing atrial fibrillation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. A bioprosthetic valve may be chosen in patients in sinus rhythm who elect this valve for lifestyle considerations after a detailed discussion of the risks of warfarin therapy compared to the likelihood of repeat MVR in the future.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29659=[""].join("\n");
var outline_f28_61_29659=null;
var title_f28_61_29660="Symptoms of miliary TB";
var content_f28_61_29660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms in patients with miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maartens, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kim, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gelb, 1973",
"       </td>",
"       <td class=\"subtitle1\">",
"        Munt, 1971",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proudfoot, 1969",
"       </td>",
"       <td class=\"subtitle1\">",
"        Biehl, 1957",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever and/or night sweats",
"       </td>",
"       <td>",
"        96*",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness or malaise",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory (cough, dsypnea, pleuritic chest pain)",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        91",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GI (abdominal pain, nausea, vomiting, diarrhea)",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache or central nervous  system",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All of the numbers recorded are percentages.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nesli Basgoz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29660=[""].join("\n");
var outline_f28_61_29660=null;
var title_f28_61_29661="Fiber in foods PI";
var content_f28_61_29661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52349&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of fiber in different foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Food",
"      </td>",
"      <td class=\"subtitle1\">",
"       Serving",
"      </td>",
"      <td class=\"subtitle1\">",
"       Grams of fiber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Fruits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Apple (with skin)",
"      </td>",
"      <td>",
"       1 medium apple",
"      </td>",
"      <td>",
"       4.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Banana",
"      </td>",
"      <td>",
"       1 medium banana",
"      </td>",
"      <td>",
"       3.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Oranges",
"      </td>",
"      <td>",
"       1 orange",
"      </td>",
"      <td>",
"       3.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prunes",
"      </td>",
"      <td>",
"       1 cup, pitted",
"      </td>",
"      <td>",
"       12.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Juices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Apple, unsweetened, w/ added ascorbic acid",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Grapefruit, white, canned, sweetened",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Grape, unsweetened, w/added ascorbic acid",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Orange",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Cooked",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Green beans",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Carrots",
"      </td>",
"      <td>",
"       .5 cups sliced",
"      </td>",
"      <td>",
"       2.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Peas",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       8.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Potato (baked, with skin)",
"      </td>",
"      <td>",
"       1 medium potato",
"      </td>",
"      <td>",
"       3.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Raw",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Cucumber (with peel)",
"      </td>",
"      <td>",
"       1 cucumber",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Lettuce",
"      </td>",
"      <td>",
"       1 cup shredded",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Tomato",
"      </td>",
"      <td>",
"       1 medium tomato",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Spinach",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Legumes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Baked beans, canned, no salt added",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       13.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Kidney beans, canned",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       13.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Lima beans, canned",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       11.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Lentils, boiled",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       15.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Breads, pastas, flours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bran muffins",
"      </td>",
"      <td>",
"       1 medium muffin",
"      </td>",
"      <td>",
"       5.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Oatmeal, cooked",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       White bread",
"      </td>",
"      <td>",
"       1 slice",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Whole-wheat bread",
"      </td>",
"      <td>",
"       1 slice",
"      </td>",
"      <td>",
"       1.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"3\">",
"       Pasta and rice, cooked",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Macaroni",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rice, brown",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       3.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rice, white",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       0.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Spaghetti (regular)",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Nuts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Almonds",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       17.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Peanuts",
"      </td>",
"      <td>",
"       1 cup",
"      </td>",
"      <td>",
"       12.4",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    To learn how much fiber and other nutrients are in different foods, visit the United States Department of Agriculture (USDA) National Nutrient Database at: file://www.nal.usda.gov/fnic/foodcomp/search/.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Created using data from the USDA National Nutrient Database for Standard Reference. Available at file://www.nal.usda.gov/fnic/foodcomp/search/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29661=[""].join("\n");
var outline_f28_61_29661=null;
var title_f28_61_29662="IV contrast media";
var content_f28_61_29662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravascular contrast media",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Osmolality (m0sm/kg H",
"        <sub>",
"         2",
"        </sub>",
"        O)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iodine (mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nonionic",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodixanol&nbsp;",
"       </td>",
"       <td>",
"        Visipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        270",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;290",
"       </td>",
"       <td>",
"        &nbsp;270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodixanol",
"       </td>",
"       <td>",
"        Visipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        -320",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;290",
"       </td>",
"       <td>",
"        &nbsp;320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopromide",
"       </td>",
"       <td>",
"        Ultravist",
"        <sup>",
"         &reg;",
"        </sup>",
"        150",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;328",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioversol 34%",
"       </td>",
"       <td>",
"        Optiray&trade; 160",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;355",
"       </td>",
"       <td>",
"        160",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iohexol",
"       </td>",
"       <td>",
"        Omnipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        180",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;388&nbsp;",
"       </td>",
"       <td>",
"        180&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopamidol 40.8%",
"       </td>",
"       <td>",
"        Isovue",
"        <sup>",
"         &reg;",
"        </sup>",
"        -200",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;413",
"       </td>",
"       <td>",
"        200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopromide&nbsp;",
"       </td>",
"       <td>",
"        Ultravist",
"        <sup>",
"         &reg;",
"        </sup>",
"        240",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;483",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioversol 51%&nbsp;",
"       </td>",
"       <td>",
"        Optiray&trade; 240",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;502",
"       </td>",
"       <td>",
"        240&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iohexol 51.8%",
"       </td>",
"       <td>",
"        Omnipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        240",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;520",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopamidol 51%",
"       </td>",
"       <td>",
"        Isovue",
"        <sup>",
"         &reg;",
"        </sup>",
"        -250",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;524",
"       </td>",
"       <td>",
"        250",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioxilan 62.3%&nbsp;",
"       </td>",
"       <td>",
"        Oxilan",
"        <sup>",
"         &reg;",
"        </sup>",
"        300",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;607",
"       </td>",
"       <td>",
"        300&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopromide&nbsp;",
"       </td>",
"       <td>",
"        Ultravist",
"        <sup>",
"         &reg;",
"        </sup>",
"        300",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;607&nbsp;",
"       </td>",
"       <td>",
"        300&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopamidol 61.2%",
"       </td>",
"       <td>",
"        Isovue",
"        <sup>",
"         &reg;",
"        </sup>",
"        300",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;616",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioversol 64%&nbsp;",
"       </td>",
"       <td>",
"        Optiray&trade; 300",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;651&nbsp;",
"       </td>",
"       <td>",
"        300&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iohexol 64.7%",
"       </td>",
"       <td>",
"        Omnipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        -300",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;672",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioxilan 72.7%",
"       </td>",
"       <td>",
"        Oxilan",
"        <sup>",
"         &reg;",
"        </sup>",
"        350",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;695",
"       </td>",
"       <td>",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioversol 68%",
"       </td>",
"       <td>",
"        Optiray&trade; 320",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;702",
"       </td>",
"       <td>",
"        320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopromide",
"       </td>",
"       <td>",
"        Ultravist",
"        <sup>",
"         &reg;",
"        </sup>",
"        370&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;774",
"       </td>",
"       <td>",
"        370",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ioversol 74%",
"       </td>",
"       <td>",
"        Optiray&trade; 350&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        na&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;792&nbsp;",
"       </td>",
"       <td>",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iopamidol 75.5%&nbsp;",
"       </td>",
"       <td>",
"        Isovue",
"        <sup>",
"         &reg;",
"        </sup>",
"        -370",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;796&nbsp;",
"       </td>",
"       <td>",
"        370",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iohexol 75.5%",
"       </td>",
"       <td>",
"        Omnipaque",
"        <sup>",
"         &reg;",
"        </sup>",
"        -350",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        na",
"       </td>",
"       <td>",
"        &nbsp;844",
"       </td>",
"       <td>",
"        350",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ionic&nbsp;",
"        </strong>",
"       </td>",
"       <td>",
"        <sup>",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Conray&trade; 30",
"       </td>",
"       <td>",
"        &nbsp;Iothalamate",
"       </td>",
"       <td>",
"        &nbsp;Meglumine",
"       </td>",
"       <td>",
"        &nbsp;600",
"       </td>",
"       <td>",
"        &nbsp;141",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Hexabrix&trade;",
"       </td>",
"       <td>",
"        &nbsp;Ioxaglate",
"       </td>",
"       <td>",
"        &nbsp;Meglumine&nbsp;sodium&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;&asymp;600",
"       </td>",
"       <td>",
"        &nbsp;320",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Cholografin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;Iodipamide",
"       </td>",
"       <td>",
"        &nbsp;Meglumine",
"       </td>",
"       <td>",
"        &nbsp;&nbsp;664",
"       </td>",
"       <td>",
"        &nbsp;257",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Conray&trade; 43",
"       </td>",
"       <td>",
"        &nbsp;Iothalamate",
"       </td>",
"       <td>",
"        &nbsp;Meglumine",
"       </td>",
"       <td>",
"        &nbsp;1000",
"       </td>",
"       <td>",
"        &nbsp;202",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Conray&trade;",
"       </td>",
"       <td>",
"        &nbsp;Iothalamate",
"       </td>",
"       <td>",
"        &nbsp;Meglumine",
"       </td>",
"       <td>",
"        &nbsp;1400",
"       </td>",
"       <td>",
"        &nbsp;282",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <sup>",
"         &nbsp;MD-76&trade; R",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;Diatrizoate",
"       </td>",
"       <td>",
"        &nbsp;Meglumine&nbsp;sodium",
"       </td>",
"       <td>",
"        &nbsp;1551",
"       </td>",
"       <td>",
"        &nbsp;370",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;Conray&trade; -325",
"       </td>",
"       <td>",
"        &nbsp;Iothalamate",
"       </td>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;325",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The lowest osmolality agents are iso-osmolal agents, which are isotonic relative to serum (approximately 290 mosmol/kg). Low&nbsp;osmolal contrast material (LOCM) agents have osmolalities between 500 and 900 mosm/kg. High osmolal contrast material (HOCM) agents have osmolalities &ge;1400 mosm/kg.",
"    <div class=\"footnotes\">",
"     %: percent. na: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"     From: American College of Radiology Manual on Contrast Media, Version 8, 2012. Reprinted with permission of the American College of Radiology. No other representation of this material is authorized without expressed, written permission from the ACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29662=[""].join("\n");
var outline_f28_61_29662=null;
var title_f28_61_29663="Aspiration shoulder effusion";
var content_f28_61_29663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspiration of shoulder effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the anterior approach to aspiration of a shoulder effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_61_29663=[""].join("\n");
var outline_f28_61_29663=null;
